

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
15 March 2001 (15.03.2001)

PCT

(10) International Publication Number  
**WO 01/18035 A2**

(51) International Patent Classification<sup>7</sup>: **C07K 7/00**

(21) International Application Number: PCT/EP00/08761

(22) International Filing Date:  
7 September 2000 (07.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
9921242.5 8 September 1999 (08.09.1999) GB  
99402237.4 10 September 1999 (10.09.1999) EP  
60/187,215 3 March 2000 (03.03.2000) US

(71) Applicants: **TRANSGENE S.A.** [FR/FR]; 11, rue de Molsheim, F-67082 Strasbourg Cedex (FR). **IMPERIAL CANCER RESEARCH TECHNOLOGY, LTD.** [GB/GB]; Sardinia House, Sardinia Street, London WC2A 3NL (GB).

(72) Inventors: **TAYLOR-PAPADIMITRIOU, Joyce**; 9 Cedar Road, Berkhamstead, Hertfordshire\_HP4 1BL

(GB). **HEUKAMP, Lukas, Carl**; 144 Osborne Road, London E7 0PN (GB). **OFFRINGA, Rienk**; Stieltjesstraat 63, NL-2313 SJ Leiden (NL). **MELIEF, Cornelis, Johanna, Maria**; Wilhelminapark 33, NL-2012 KC Haarlem (NL). **ACRES, Bruce**; 10, rue Jean Hermann, F-67000 Strasbourg (FR). **THOMAS, Mireille**; 7, rue du Vieux Marché aux Poissons, F-67000 Strasbourg (FR).

(74) Agent: **VOSSIUS & PARTNER**; Siebertstr. 4, 81675 München, Germany (DE).

(81) Designated States (*national*): AU, CA, JP.

(84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

**Published:**

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **MUC-1 DERIVED PEPTIDES**

(57) Abstract: Described are peptides and polypeptides derived from the MUC-1 polypeptide which are able to activate Cytotoxic T Lymphocyte (CTL) response, analogues of such peptides and polypeptides nucleotide sequences encoding such peptides and polypeptides and therapeutic uses thereof. Moreover, indications for selecting appropriate minimal antigenic MUC-1 polypeptides with reference to the HLA-type of the patient to be treated or tested are described.

WO 01/18035 A2



## MUC-1 derived peptides

The present invention relates to MHC class I restricted epitopes and T cells which can be used to prevent or treat cancer or cause immunosuppression; and to the use of the epitopes to diagnose cancer.

In particular, the present invention relates to antigenic polypeptides of the MUC-1 protein which are able to activate Cytotoxic T Lymphocytes (CTL) response and to nucleotide sequences encoding such polypeptides. Furthermore, the present invention relates to vectors comprising such nucleotide sequences, host cells comprising the same and their use in the production of the antigenic polypeptides. In addition, the present invention relates to compositions comprising the polypeptides, nucleotide sequences, vector or host cells of the present invention and to therapeutic and diagnostic uses of such compositions.

Generally speaking, there are two major types of immune response: the humoral response which is characterized by the production of antibodies by B lymphocytes, and the cell-mediated immune response. Antibodies are able to recognize antigens in their three dimensional form, either soluble or bound to an insoluble support such as a cell, while T cells recognize processed antigen fragments which are bound and presented by glycoproteins encoded by the major histocompatibility complex (MHC) notably MHC-I genes which are expressed at the cell surface of almost all vertebrate cells or MHC-II genes which are expressed on antigen presenting cells (APC).

A cell-mediated immune response usually necessitates the cooperation of helper T lymphocytes and effector cells. This cooperation takes place, in particular, as a result of interleukin-2 and/or various other cytokines which are secreted by helper T lymphocytes after their activation by antigenic fragments presented by APC in association with MHC-II. Cytotoxic T Lymphocytes (CTL) are activated, induced to proliferate and to exert their antigen-specific cytotoxic function upon exposure to antigenic polypeptides complexed with

autologous MHC-I, co-stimulatory molecules on the surface of the APC and cytokines, often derived from helper T cells. T cell derived cytokines can also trigger and drive the proliferation and antigen processing capacity of APC as well as activation and induction of proliferation in other cells, including other T cells.

Thus, cytotoxic T lymphocytes (CTL) recognise epitopes bound to MHC class I molecules on the surface of cells. Recognition of such epitopes on the surface of target cells by CTL leads to the killing of the target cells by the CTL. The epitopes which are displayed on the cell are fragments from proteins which have been processed in the class I antigen processing pathway of the cell. In this pathway proteins (generally from the cytoplasm) are broken down in the cytoplasm into small peptides. The small peptides are then transported through the endoplasmic reticulum (where they bind to the MHC molecules) to the surface of the cell.

Said antigen presentation by MHC-I molecules has been characterized (see for example Groettrup et al., 1996, *Immunology Today* 17, 429-435): a full-sized protein or glycoprotein antigen is digested into shorter antigenic polypeptides (of about 7 to 13 amino acids in length). Said polypeptides are associated with MHC-I molecules and  $\beta$ -2 microglobulin leading to a ternary complex which is further presented on the cell surface.

It is not possible to predict which proteins will enter the antigen processing pathway, which fragments will be produced, or which fragments will bind to MHC molecules and be presented at the surface of the cell. Additionally it is not possible to predict which fragments T cells will recognise and whether the T cells which recognise the fragments will be protective.

MHC-I specificity towards antigens can vary greatly depending on the considered MHC-I molecule (HLA-A, HLA-B, ...) and on the allele (HLA-A2, HLA-A3, HLA-A11, ...) since genes encoding the MHC molecules are greatly variable between individuals among a species (reviewed in George et al., 1995, *Immunology Today*, 16, 209-212).

Most tumor cells express antigens at their surface which differ either qualitatively or quantitatively from the antigens present at the surface of the corresponding normal cells. These antigens are specific when they are expressed only by tumor cells. When they are present on both normal and tumor cells, these antigens are said to be associated with the tumor; in this case, they are present either in larger amounts or in a different form in the tumor cells.

It is now well known that patients suffering from a cancer may develop an immune response to their tumor. This has been revealed, in particular, by demonstrating that the serum of some patients contain anti-tumor antigen antibodies, and that their serum was capable of inhibiting

the growth of cancer cells in vitro. Nevertheless, inasmuch as spontaneous tumor regressions are extremely rare, it appears that the immune response observed in vitro remains ineffective in vivo.

Hellstrom et al. (1969, Adv.Cancer Res.12, 167-223) have shown that antigen-specific CTL can be effective mediators in a tumor-specific immune response. However, this natural immune response is not always effective enough to limit tumor growth. Although an immune response may develop against a tumor, it is not known whether it is of real benefit to the patient. Seemingly uncontrolled tumor growth would suggest that a tumor eludes the body's mechanisms of immune surveillance. Tumor-derived molecules are considered to play a significant part in modifying or diverting the immune response in favor of the tumor rather in favor of the individual.

In the light of the complexity of the immune response against tumors and the modest state of current knowledge in this field, the use of an anticancer vaccine is not obvious. Animal studies have shown that immunization using living or killed cancer cells could lead to rejection of a subsequent tumor graft, however attempts at immunization using acellular products, for example administration of the complete antigenic protein, with polypeptide fragments of such protein DNA fragment encoding all or part of tumor-associated proteins, have generally been less successful.

Recently, Toes et al. (1997, Proc. Natl. Acad. Sci. 94, 14660-14665) have developed an alternative approach based on minimal antigenic polypeptide fragments selection which might be specifically recognized by the CTL. According to said method, the minimal antigenic fragments are expressed in the host cells where they can be associated with MHC-I molecules and then be presented on the cell surface, inducing a specific immune reaction. More specifically, it has been shown that intra-cellular expression of "minigens" encoding very short epitopes (from 7 to 13 amino acids in length) can induce a cellular immune response. Moreover, Whitton et al. (1993, J. of Virology 67, 348-352) have proposed the use of a vector, called "string of beads" construct, which co-expresses several minigens and can induce a synergetic CTL immune response.

Another recent and important use for such polypeptides is in association with soluble complexes of MHC-I,  $\beta$ -2 microglobulin and a fluorescent or otherwise visually detectable reagent. These, so called "Tetramers" ( eg, as described in Altman et al, 1996, Science, 274:94-96) can be used to identify by flow cytometry or histology, antigen specific CTL ex vivo.

MUC-1 is a glycosylated mucin polypeptide found on the apical surface of mucin-secreting epithelial cells in various tissues, including breast, lung, pancreas, stomach, ovaries, fallopian tubes, and intestine (Peat et al., 1992, *Cancer Res.* 52:1954-60 - Ho et al., 1993, *Cancer Res.* 53:641-51). Malignant transformation of breast, ovary, pancreas and probably other epithelial tissues, results in over expression of MUC-1 polypeptide in tumor cells (Hareuveni et al., 1990, *Eur. Journ. Biochem.* 189:475-86 ; Layton et al., 1990, *Tumor Biol.* 11:274-86). In addition, abnormal glycosylation of MUC-1 polypeptide in breast, and probably other MUC-1-expressing tumour cells results in the exposure of tumor-associated antigenic epitopes on the protein core of MUC-1 (Burchell et al., 1987, *Cancer Res.* 47:5476-82; Devine et al., 1990, *J. Tumor Marker Oncol.* 5:11-26; Xing et al., 1989, *Immun.Cell Biol.* 67:183-95) as well as on the glycosyl side chains (Samuel et al., 1990, *Cancer Res.* 50:4801-8).

Monoclonal antibodies specific for these epitopes have been described which can identify more than 90% of breast and pancreatic tumors. Non major-histocompatibility-complex (MHC) restricted cytotoxic T cell responses to the MUC-1 tumor specific protein epitope by T cells from breast and pancreatic cancer patients have also been reported (Jerome et al., 1991, *Cancer Res.* 51:2908-16) in addition to MHC restricted, MUC-1-specific CTL (Reddish et al., 1995, *Int. J. Cancer* 10:817-823). Moreover, proliferation of T cells to purified MUC-1 has been seen (Keydar et al., 1989, *Proc.Natl. Acad. Sci. USA* 86:1362-6). These various observations suggest that MUC-1 may be an effective target antigen for active immunotherapy in breast, as well as other cancers. Hareuveni et al. (1991, *Vaccine* 9:618-27) expressed the MUC-1 antigen in vaccinia virus and showed that rat immunized with VV-MUC-1 rejected MUC-1-bearing tumor cells at a rate of 60-80 % (Hareuveni et al., 1990, *Proc. Natl. Acad. Sci. USA* 87:9498-502).

The inventors have now identified epitopes which can be used to induce a MHC class I restricted response which is protective against a tumor challenge. The epitopes are from the MUC1 protein. Since activated T cells express MUC1, these epitopes can also be used to induce an immune response against such T cells or be used to obtain products which are capable of targeting activated T cells.

Thus, the present invention concerns immuno-reactive polypeptides identified from the MUC-1 polypeptide sequence and their uses in cancer therapy and diagnosis. The invention could also be used to follow MUC-1 specific immune responses in patients during the course of disease

and/or treatment. The invention also concerns nucleotide sequences encoding these polypeptides, vectors useful for transferring and expressing said nucleotide sequences into target cells, and uses of said nucleotide sequences in cancer gene therapy vaccination and diagnosis.

Accordingly, in a first aspect the present invention relates to polypeptides consisting of or comprising at least one amino acid sequence of at most 20 consecutive amino-acids defined in SEQ ID NO: 1, wherein said polypeptide is different from SEQ ID NO : 2 and is capable of binding with at least one MHC-I molecule.

"Capable of binding with" means that the considered polypeptide is capable to interact and to bind with MHC-I molecules. In a preferred embodiment of the invention, this binding results in cell surface presentation of these polypeptides by MHC class I molecules in order to elicit a specific immune response or for the detection of a specific immune response, eg, by Tetramer analysis (as described, e.g., in Altman et al., 1996, Science 274:94-96).

According to a preferred embodiment, said amino acid sequence is selected from the group consisting of SEQ ID NO: 3 to SEQ ID NO: 33, SEQ ID NO: 65 and SEQ ID NO: 66. Data to explain why these sequences have been selected are shown in Figures 1 to 7.

According to a preferred embodiment of the invention, said polypeptide presents at least one of the following properties :

- (a) the amino acid sequence is selected from the group consisting of SEQ ID NO:3 to SEQ ID NO:6, SEQ ID NO: 65, SEQ ID NO: 66, and said polypeptide binds the HLA A2 glycoprotein of MHC-I;
- (b) the amino acid sequence is selected from the group consisting of SEQ ID NO:7 to SEQ ID NO: 15, and said polypeptide binds the HLA B7 glycoprotein of MHC-I;
- (c) the amino acid sequence is selected from the group consisting of SEQ ID NO: 16 to SEQ ID NO: 19, and said polypeptide binds the HLA A3 glycoprotein of MHC-I;
- (d) the amino acid sequence is selected from the group consisting of SEQ ID NO: 19 to SEQ ID NO: 21, and said polypeptide binds the HLA A11 glycoprotein of MHC-I;
- (e) the amino acid sequence is selected from the group consisting of SEQ ID NO: 22 to

- SEQ ID NO: 25, and said polypeptide binds the HLA A24 glycoprotein of MHC-I;
- (f) the amino acid sequence is selected from the group consisting of SEQ ID NO: 26 to SEQ ID NO: 29, and said polypeptide binds the HLA A1 glycoprotein of MHC-I; and
- (g) the amino acid sequence is selected from the group consisting of SEQ ID NO: 30 to SEQ ID NO: 33, and said polypeptide binds the HLA B8 glycoprotein of MHC-I.

In a particular preferred embodiment the polypeptide is a peptide that comprises a MHC class I restricted T cell epitope, the epitope being contained in or represented by any one of SEQ ID NO: 1 to 33, 65 or 66, preferably SEQ ID NO: 4, 3, or 5. These latter epitopes lie outside the immunogenic variable non tandem repeat (VNTR) region.

In general, the amino acid sequence present in the polypeptide of the invention may be any stretch of at most 20 contiguous amino acids (such a stretch is in the following referred to as "epitope") of the sequence represented by SEQ ID NO: 1, preferably a sequence represented by any one of SEQ ID NOs: 3 to 33, 65 or 66 below or the amino acid sequence of an epitope present within these sequences (such as the fragments of the sequences shown in the brackets shown below, e.g., for SEQ ID NO: 3 to 5 or for SEQ ID NO: 6, 65 and 66)

SEQ ID NO: 3 - ALGSTAPPV (LGSTAPPV)

SEQ ID NO: 4 - FLSFHISNL (LSFHISNL)

SEQ ID NO: 5 - TLAPATEPA (LAPATEPA)

SEQ ID NO: 6 - SLSYTNPAV (SLSYTNPA or LSYTNPAV)

SEQ ID NO: 65 - LLLTVLTVV (LLLTVLTV or LLTVLTVV)

SEQ ID NO: 66 - ALGSTTPPA (LGSTTPPA)

In one embodiment the polypeptide of the invention has the same sequence as the "epitope". The peptide typically comprises 1, 2, 3 or more copies of each of 1, 2 or more, or all of the above defined "epitopes".

Typically in the polypeptide, a 'linker' sequence may or may not separate the "epitopes" and/or there may or may not be additional (non-"epitope") sequences at the N terminal or C terminal of the polypeptide. Typically the peptide comprises 1, 2, 3 or more linkers. The linkers are typically 1, 2, 3, 4 or more amino acids in length and may comprise amino acid sequence encoded by a polynucleotide sequence that comprises enzyme restriction sites or amino acids

that constitute proteosomal cleavage sites. Thus, in the polypeptide 1, 2 or more, or all of the "epitopes" may be contiguous with each other or separated from each other. The "epitope" sequences may overlap with each other. The polypeptide is typically 8 to 2000 amino acids in length, such as 9 to 1000, 10 to 500, 11 to 200, 12 to 100 or 15 to 50 amino acids.

The peptide may be a natural protein, a fragment thereof, a non-natural protein, or a fusion protein (typically) comprising sequences from different proteins.

The peptide may or may not comprise or be a fragment of MUC1, which fragment may or may not include the MUC1 VNTR. In a preferred embodiment such a fragment only comprises sequences from outside the VNTR. Figure 12 shows a representation of the MUC1 amino acid sequence in which only a single perfect copy of the tandem repeat sequence is shown by amino acids 129 to 148 inclusive. In a particularly preferred embodiment the polypeptide of the invention comprises fragments of the MUC1 sequence shown in Figure 12 or in SEQ ID NO: 2, which fragments do not include any sequence from amino acids 97 to 184, e.g. fragments which do not include sequence from amino acids 90 to 190 (as shown in Figure 12).

SEQ ID NOs: 4, 3 and 5 can be seen at amino acid positions 264 to 272 (inclusive), 167 to 175 (inclusive) and 79 to 87 (inclusive) of Figure 12. In one embodiment the polypeptide only contains a MUC1 sequence that lies close to the epitopes, such as only sequences from or within positions 258 to 276, 253 to 281, 161 to 179, 156 to 184, 72 to 91 or 67 to 96 of Figure 12.

The polypeptide may also comprise a sequence which aids the stimulation of a CTL response directed to the epitope. Such sequence may act as adjuvant or may target the polypeptide to antigen presenting cells (APCs) or to compartments in the antigen processing pathway. The sequence may stimulate a T helper response, such as a Th1 response, and thus may comprise a T helper (e.g. Th1) cell epitope. The polypeptide may also comprise the sequence of any of the proteins mentioned herein.

The polypeptide may be free from modifications. In one embodiment the polypeptide is modified, for example by a natural post-translational modification (e.g. glycosylation) or an artificial modification. Thus, the sequence in the polypeptide may or may not comprise the modification(s) that are present when the sequence is expressed in a normal or cancer cell. The polypeptide may comprise the modifications that occur when it is expressed in a eukaryotic (e.g. human) or prokaryotic (e.g. E. coli) cell. In a further embodiment the polypeptide lacks glycosylation.



The modification may provide a chemical moiety (typically by substitution of a hydrogen, e.g. the hydrogen of a C-H bond), such as an amino, acetyl, hydroxy or halogen (e.g. fluorine) group or carbohydrate group. Typically the modification is present on the N or C terminus.

The present invention also relates to analogues of the polypeptides of the invention which are capable of inhibiting the binding of the polypeptide or of an epitope contained in said polypeptide to a T cell receptor either by directly binding to the same T cell receptor or by binding to the same T cell receptor after being processed.

The analogue of the invention is capable of inhibiting the binding of any of the above-mentioned polypeptides (epitopes) to a T cell receptor, either directly or after the analogue is processed. Therefore, certain analogues of the invention can be processed to provide other analogues (that can bind the T cell receptor directly). The term 'analogue' as used here includes both of these types of analogue.

The term 'processed' refers to being processed by the class I antigen presentation pathway (generally this will be hydrolysis, e.g. proteolysis).

Typically the amount of polypeptide (epitope) which can bind the T cell receptor in the presence of the analogue is decreased. This is because the analogue is able to bind the T cell receptor and therefore competes with the epitope for binding to the T cell receptor. The binding of the analogue to the T cell receptor is a specific binding. Generally during the binding discussed above the polypeptide (epitope) or analogue is bound to an MHC class I molecule, such as HLA-A\*0201.

The inhibition of binding can be determined using techniques known in the art or any of the techniques or under any of the conditions discussed herein. The T cell receptor used binds specifically to the polypeptide (epitope). T cells with such receptors can be produced by stimulating antigen naive T cells with any of the polypeptides (epitopes) of the invention, for example using the stimulation protocol described in Plebanski et al. (Eur. J. Immunol. 25 (1995), 1783-1787).

Typically an analogue is capable of causing antigen specific functional activation of a T cell which recognises the polypeptide (epitope) (which can be measured using any of the techniques discussed herein). Generally the analogue causes such activation when it is presented to the T cell associated with an MHC class I molecule, such as HLA-A\*0201 (for example on the surface of a cell).

The analogue is typically capable of stimulating a MHC class I restricted T cell response directed to the polypeptide (epitope), for example when administered to a human or animal (such as in any of the forms or with any of the adjuvants mentioned herein). Such a response may be protective against a tumor challenge in an animal model or of therapeutic benefit in a human patient.

The analogue typically has a shape, size, flexibility or electronic configuration which is substantially similar to the polypeptide of the invention. It is typically a derivative of the polypeptide.

As well as binding the T cell receptor discussed above the analogue may also be able to bind other specific binding agents that bind the polypeptide (epitope). Such an agent may be HLA-A\*0201. The analogue typically binds to antibodies specific for the polypeptide and, thus, inhibits binding of the polypeptide to such an antibody. The analogue is either a peptide or non-peptide or may comprise both peptide and non-peptide portions. Such a peptide or peptide portion may have homology with the polypeptide of the invention.

The analogue may be at least 30% homologous to the polypeptide, preferably at least 50, 70, 80 or 90% and more preferably at least 95%, 97% or 99% homologous thereto, for example over a region of about 20, preferably at least 30, for instance at least 40, 60 or 100 or more contiguous amino acids. Methods of measuring protein homology are well known in the art and it will be understood by those skilled in the art that in the present context, homology is calculated on the basis of amino acid identity (sometimes referred to as "hard homology"). For example the UWGCG Package provides the BESTFIT program which can be used (e.g. on its default setting) to calculate homology (Devereux et al., Nucl. Acids Res. 12 (1984), 387-395). The homologous peptide typically differs from the epitope present in the polypeptide of the present invention by substitution, insertion or deletion, for example from 1, 2, 3, 4 or more substitutions and/or 1, 2, 3, 4 or more deletions and/or 1, 2, 3, 4 or more insertions over its length. The substitutions are preferably 'conservative'. These are defined according to the following Table. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:

Table 1

ALIPHATIC	Non-polar	G A P
		I L V
	Polar - uncharged	C S T M
		N Q
	Polar - charged	D E
		K R
AROMATIC		H F W Y

Typically the amino acids in an analogue which has homology with the polypeptide which are equivalent to amino acids in the epitope sequence (such as those which contribute to binding the MHC molecule or are responsible for the recognition by the T cell receptor) are the same or are conservatively substituted.

Typically in the analogue the amino acid in position 2 (based on the numbering used for epitopes bound to MHC molecules) is a L or M and/or the amino acid in position 6 is a V and/or the amino acid in position 9 is V or L.

The analogue (including the homologous peptide discussed above) may comprise 1, 2, 3, 4 more non-natural amino acids, for example amino acids with a side chain different from natural amino acids. Generally, the non-natural amino acid will have an N terminus and/or a C terminus. The non-natural amino acid may be an L-amino acid.

Typically the analogue is a peptide which comprises one or more modifications. The sequence of the peptide may be the same as the epitope or homologous peptide discussed above. The modification may be any of the modifications mentioned above which can be present on the polypeptide of the invention.

The modification can be present on any of the amino acids of the polypeptide, such as any of the the amino acids responsible for binding the MHC molecule or which contact the T cell receptor during recognition by a T cell.

The analogue is typically designed or selected by computational means and then synthesised using methods known in the art. Alternatively, the analogue can be selected from a library of compounds. The library may comprise peptides which have an HLA-A\*0201 binding motif. The library may be a combinatorial library or a display library, such as a phage display library. The library of compounds may be expressed in the display library in the form of being bound to a MHC class I molecule, such as HLA-A\*0201.

Analogues can be selected from the library based on any of the characteristics mentioned above, such as their ability to mimic the binding characteristics of the original epitopes. Thus, they may be selected based on the ability to bind a T cell receptor, HLA-A\*0201 or antibody which recognises the epitope. They may be selected based on their ability to cause antigen specific functional activity of a T cell that recognises the epitope (for example using any of the techniques or methods of the invention mentioned herein, e.g. CTL assays, ELISPOT assays or by measuring the production of cytokines inside the T cell).

The analogue which is capable of inhibiting the binding of the polypeptide (epitope) to the T cell receptor after being processed is capable of being processed in the class I antigen processing pathway of a cell to provide a second analogue which can directly inhibit the binding of the polypeptide (epitope) to the T cell receptor.

Such a cell is typically a mammalian or avian cell, such as a human or rodent (e.g. mouse or rat cell). The cell may be a muscle cell or a professional APC (such as a dendritic cell, macrophage, Langerhans cell or B cell). Typically the cell will provide the epitope or analogue on its surface bound to a MHC class I molecule.

The invention also relates to polynucleotides comprising a nucleic acid sequence encoding at least one polypeptide or analogue of the present invention. Based on the amino acid sequences provided with in the present application and by using the genetic code those skilled in the art can easily identify said nucleic acid sequences. According to a preferred embodiment, the nucleic acid sequence of the invention is selected from the group consisting of SEQ ID NO: 34 to SEQ ID NO: 64, and their complementary sequences.

The term "polynucleotide" as used in the scope of the present invention means a DNA and/or RNA fragment, single or double-stranded, linear or circular, natural or synthetic, modified or not (see US-A-5,525,711, US-A-4,711,955, US-A-5,792,608 or EP-A-0 302 175 for modification examples) defining a fragment or a portion of a nucleic acid, without size limitation. It may be, *inter alia*, a genomic DNA, a cDNA, an mRNA. "Polynucleotides" and "nucleic acids" are synonyms with regard to the present invention. The nucleic acid may be in the form of a linear polynucleotide, and preferably in the form of a plasmid. A wide range of plasmids is commercially available and well known by one skilled in the art. These available plasmids are easily modified by the molecular biology techniques (Sambrook et al., 1989, Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York).

Plasmids derived from pBR322 (Gibco BRL), pUC (Gibco BRL), pBluescript (Stratagene), pREP4, pCEP4 (Invitrogen) and also p Poly (Lathe et al., 1987, Gene 57, 193-201) are illustrative of these modifications. According to the invention, the nucleic acid can be a naked polynucleotide (Wolff et al., Science 247 (1990), 1465-1468) or is formulated with at least one compound such as a polypeptide, preferably viral polypeptides, oligonucleotides or cationic lipids, or cationic polymers which can participate in the uptake of the nucleic acid into the cells (see Ledley, Human Gene Therapy 6 (1995), 1129-1144 for a review) or a protic polar compound (examples are provided below in the present specification or in EP-A-0 890362). "Polynucleotide" also designates nucleic acid of viral origin (viral vector) which encodes at least for the polypeptide of the invention. Such viral vector preferably derives from a virus selected among poxvirus (vaccine virus, MVA, canarypox....), adenovirus, retrovirus, herpes virus, alpha virus, foamy virus or adeno associated virus. Said viral vectors and their uses are widely disclosed in gene therapy literature.

Preferably, said nucleic acid includes at least one therapeutically useful gene sequence that can be transcribed and translated to generate a polypeptide of interest and the elements enabling its expression. The genetic information necessary for expression by a target cell comprises all the elements required for transcription of DNA into RNA and, if necessary, for translation of mRNA into a polypeptide. Transcriptional promoters suitable for use in various vertebrate systems are well known. For example, suitable promoters include viral promoters like RSV, MPSV, SV40, CMV or 7.5k, vaccinia promoter, inducible promoters, tissue specific promoters, synthetic promoters, etc or combination thereof. The nucleic acid can also include intron sequences, targeting sequences, transport sequences, sequences involved in replication or integration. Said sequences have been reported in the literature and can be readily obtained by those skilled in the art. The nucleic acid can also be modified in order to be stabilized with specific components as spermine.

The polynucleotide of the invention is capable of expressing 1, 2, 3 or more (different) compounds, each of which is a polypeptide or analogue of the invention (for example any combination of a polypeptide and an analogue). The polynucleotide is typically DNA or RNA, and is single or double stranded. The polynucleotide generally comprises 1, 2, 3 or more coding sequences which may be the same or different. At least one of the coding sequences

encodes a polypeptide or an analogue of the invention. The coding sequence is typically operably linked to a control sequence capable of providing for expression of the polynucleotide. Thus, typically the polynucleotide comprises 5' and 3' to the coding sequence sequences which aid expression, such as aiding transcription and/or translation of the coding sequence. Typically the polynucleotide comprises a promoter, enhancer, transcription terminator, polyadenylation signal, polyA tail, intron, translation initiation codon or translation stop codon.

The polynucleotide may in particular be capable of expressing a polypeptide or analogue of the invention in a mammalian or avian cell, such as in any of the cells discussed herein. The polynucleotide may furthermore be capable of expressing the polypeptide or analogue in the cellular vector discussed below.

The polynucleotide may form or be part of a vector, such as a plasmid or cosmid vector. In one embodiment the polynucleotide is present in a virus or cellular vector, such as a virus which is capable of stimulating a MHC class I restricted T cell response (e.g. a vaccinia virus).

The introduction or transfer process of an anionic substance of interest into a cell is by itself well known. "Introduction or transfer" means that the polynucleotide is transferred into the cell and is located, at the end of the process, inside said cell or within or on its membrane. It is also called "transfection" or "infection" depending of the nature of the vector.

The invention is therefore further directed to a vector, e.g. of viral or plasmid origin, comprising at least a nucleic acid sequence of the invention.

According to a preferred embodiment, the vector of the invention comprises one or more nucleotide sequences selected from the group consisting of:

- the sequences encoding a polypeptide as defined in (a) in addition to one or more of the sequences encoding a polypeptide as defined in (b), (c), (d), (e), (f) or (g),
- the sequences encoding a polypeptide as defined in (b) in addition to one or more of the sequences encoding a polypeptide as defined in (a), (c), (d), (e), (f) or (g),
- the sequences encoding a polypeptide as defined in (c) in addition to one or more of the sequences encoding a polypeptide as defined in (a), (b), (d), (e), (f) or (g),
- the sequences encoding a polypeptide as defined in (d) in addition to one or more of

- the sequences encoding a polypeptide as defined in (a), (b), (c), (e), (f) or (g),
- the sequences encoding a polypeptide as defined in (e) in addition to one or more of the sequences encoding a polypeptide as defined in (a), (b), (c), (d), (f) or (g),
  - the sequences encoding a polypeptide as defined in (f) in addition to one or more of the sequences encoding a polypeptide as defined in (a), (b), (c), (d), (e) or (g), and
  - the sequences encoding a polypeptide as defined in (g) in addition to one or more of the sequences encoding a polypeptide as defined in (a), (b), (c), (d), (e) or (f).

Said constructs are named "string of beads" (Whitton et al. 1993, loc. cit.)

Furthermore, the present invention relates to host cells comprising at least one polynucleotide or at least one vector according to the invention. Preferably such a host cell is a prokaryotic cell or a eukaryotic cell, such as a yeast cell, more preferably an animal cell, most preferably a mammalian cell.

The present invention also relates to a composition (iv) that comprises two or more different compounds wherein each of the compounds is (i) a polypeptide or (ii) an analogue or (iii) a polynucleotide of the invention as defined above.

In the composition (iv) 1, 2, 3, 4, 5 or more different compounds may be present, wherein each of these compounds is (i), (ii) or (iii). Thus, the composition may comprise all the epitopes of the invention (present in the form of the polypeptide of the invention), or instead of any of these epitopes the equivalent analogue. The composition may comprise 1, 2, 3, 4, 5 or more polynucleotides which together are capable of being expressed to provide 1, 2, 3, 4, 5 or more different epitopes, analogues or polypeptides of the invention, or all the epitopes (or instead of any of the epitopes the equivalent analogue) of the invention (e.g. in the form of polypeptide of the invention).

In particular, (i), (ii), (iii) or (iv) are provided for use in a method of vaccination against cancer or for use in a method of immunosuppression. 1, 2, 3, 4, 5, or more different epitopes of the invention (or all of the epitopes of the invention) may be used (or instead of any of these epitopes the equivalent analogue). As discussed above if more than one epitope/analogue is used then the combination of epitopes/analogues may be present in the form of the polypeptide of the invention or in the form of the composition of the invention. Similarly 1, 2, 3, 4, 5 or

more different polynucleotides may be used which together are capable of being expressed to provide any of the combinations of epitopes, analogues, polypeptides or compositions mentioned herein.

However, in one embodiment each epitope/analogue or one or more groups of epitopes/analogues within the combination are administered to the host separately or sequentially. The epitopes/analogues in each group are typically together in the form of a single peptide of the invention or in the form of the composition of the invention. Similarly, different polypeptides or polynucleotides of the invention may be administered separately or sequentially, for example polynucleotides capable of expressing individual or groups of epitopes and/or polypeptides and/or analogues and/or compositions.

Thus, the invention provides a combination of 1, 2, 3, 4, 5 or more different epitopes and/or analogues and/or polypeptides and/or compositions and/or polynucleotides of the invention for simultaneous, separate or sequential use in a method of treatment of the human or animal body by therapy, for example in a method of vaccination against cancer or in a method of immunosuppression.

The method of vaccination against cancer or the method of immunosuppression typically leads to a MHC class I restricted T cell response, the T cells of which are specific for an epitope of the invention.

Thus, (i), (ii), (iii), (iv) can be used in a form or manner in which they stimulate such a MHC class I restricted T cell response. Such methods are known in the art. Generally a MHC class I restricted T cell response can be obtained by vaccinating using an appropriate dose, route of administration, adjuvant or delivery system. Thus, the vaccine of the invention may comprise one or more components (for example, as discussed herein in relation to the vaccine of the invention) in addition to (i), (ii), (iii) or (iv). The components of the vaccine may be administered simultaneously, separately or sequentially to the host.

Thus, the invention also provides a vaccine comprising (i), (ii), (iii) or (iv), which vaccine is capable of stimulating a MHC class I restricted T cell response directed to an epitope (polypeptide) of the invention. Typically such a vaccine comprises an adjuvant or delivery system which stimulates a MHC class I restricted T cell response.

The adjuvant may be capable of causing or augmenting a MHC class II restricted T cell (typically CD4) response which is favourable to the production of a MHC class I restricted T cell response, such as a Th1 response. Thus, the adjuvant may comprise a MHC class II



restricted T cell epitope (or a precursor which can be processed *in vivo* to provide such an epitope). The adjuvant may be a cytokine, such as a cytokine which stimulates a MHC class I restricted T cell response or favourable MHC class II restricted T cell response (e.g. IL-2, IL-7, IL-12 or IFN- $\gamma$ ). The adjuvant may be, for example, CFA (Golding and Scott, Ann. N.Y. Acad. Sci. 754 (1995), 126-137), a muramyl dipeptide (e.g. of a mycobacterial cell wall), monophosphoryl lipid A, lipopolysaccharide (e.g. from *B. abortus*), liposomes, SAF-1 (Golding and Scott, Ann. N.Y. Acad. Sci. 754 (1995), 126-137), a saponin (e.g. Quil A), keyhole limpet hemocyanin, yeast TY particle, beta 2-microglobulin or mannan (e.g. oxidised mannan).

The delivery system is typically capable of providing (i), (ii), (iv) or an epitope or analogue expressed from (iii) or (iv) to an APC, such as a professional APC.

As mentioned above the particular route of administration used may aid the stimulating of a MHC class I restricted T cell response and, thus, (i), (ii), (iii), (iv) or the vaccine of the invention may be provided in a form suitable for administering by such a route. Intraperitoneal or intravenous routes are preferred. In one embodiment these substances are delivered by biolistic means.

Generally a low dose of antigen favours the development of a MHC class I restricted T cell response. Thus, in the method a suitable low dose of a compound of the invention can be given. The vaccine may be provided in an amount and concentration that is suitable for administering to provide an appropriate low dose. In one embodiment (iv) is administered in the form of "naked DNA".

The invention also relates to a composition, preferably a pharmaceutical composition, which is particularly useful for the delivery of polynucleotides of the invention to cells or tissues of a subject in the scope of a gene therapeutic method, especially in case of cancer treatment. The term "gene therapy method" is preferably understood as a method for the introduction of a polynucleotide into cells either *in vivo* or by introduction into cells *in vitro* followed by re-implantation into a subject. "Gene therapy" in particular concerns the case where the polynucleotide is expressed in a target tissue, especially tissue comprising cell expressing MHC-I molecules.

Preferably, the composition, in particular pharmaceutical composition, furthermore comprises

a pharmaceutically acceptable carrier or diluent. The carrier or diluent is non toxic to recipients at the dosages and concentrations employed. Representative examples of carrier or diluent for injectable solutions include water, isotonic saline solutions which are preferably buffered at the physiological pH (such as phosphate buffered saline or Tris-buffered saline), mannitol, dextrose, glycerol and ethanol, as well as polypeptides or protein such as human serum albumin. This carrier or diluent is preferably isotonic, hypotonic or weakly hypertonic and has a relatively low ionic strength. Furthermore, it may contain any relevant solvents, aqueous or partly aqueous liquid carriers comprising sterile, pyrogen-free water, dispersion media, coatings, and equivalents. The pH of the pharmaceutical preparation is suitably adjusted and buffered.

The invention more particularly pertains to a composition, in particular pharmaceutical composition, comprising at least one of the complexes described above and also incorporating at least one adjuvant capable of improving the transfection capacity of said complex. Adjuvants may be selected from the group consisting of a chloroquine, protic polar compounds such as propylene glycol, polyethylene glycol, glycerol, EtOH, 1-methyl L -2-pyrrolidine or their derivatives, or aprotic polar compounds such as dimethylsulfoxide (DMSO), diethylsulfoxide, di-n-propylsulfoxide, dimethylsulfone, sulfolane, dimethylformamide, dimethylacetamide, tetramethylurea, acetonitrile and their derivatives.

In a preferred embodiment, the polynucleotide which is contained in the composition is a DNA. Other particular embodiments of the invention are compositions, in particular pharmaceutical compositions, wherein said polynucleotide is naked, associated with viral polypeptides or complexed with cationic components, more preferably with cationic lipids. In general, the concentration of polynucleotide in such a composition is from about 0.1 µg/ml to about 20 mg/ml.

The composition, in particular pharmaceutical composition, in accordance with the present invention can be administered into a vertebrate tissue. This administration may be made by intradermal, subdermal, intravenous, intramuscular, intranasal, intracerebral, intratracheal, intraarterial, intraperitoneal, intravesical, intrapleural, intracoronary or intratumoral injection, by means of a syringe or other devices. Transdermal administration is also contemplated, as

are inhalation, aerosol routes, instillation or topical application.

According to the present invention, the composition, in particular pharmaceutical composition, can be administered into target tissues of the vertebrate body including those of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, connective tissue, blood, etc. In a preferred embodiment, said composition will be administered into tumor.

Administration of such a composition to a patient allows to elicit an immune response based on the activation of cytotoxic lymphocytes by the polypeptides encoded by said nucleotide sequences. The composition of the invention is particularly suitable for the treatment or prevention of MUC-1-expressing cancers, such as breast cancer, ovary cancer, pancreas or lung cancer.

According to a special embodiment, the compositions of the present invention, i.e. containing polypeptide or polynucleotide sequences of the instant invention (see above), is suitable for the treatment or prevention of MUC1-expressing cancers, wherein said treatment or prevention comprises:

- a step a) consisting in administering to a patient a composition of the present invention,
- a step b) consisting in administering to the same patient in need a second composition, wherein said composition is either a composition of the present invention, or a composition containing a MUC-1 polypeptide, or a polynucleotide encoding such a MUC-1 polypeptide, wherein said MUC-1 polypeptide is the full length MUC-1 polypeptide of SEQ ID NO: 2, or a MUC-1 polypeptide as disclosed in US 4,963,848, US 5,053,489, WO 8805054 or US 5,861,381 corresponding to MUC-1 polypeptide presenting varying tandem repeat sequence.

According to this special embodiment, both administration steps a) and b) can be made independently of each other or in the same time. This special embodiment can result in boosting the immune response developed by the treated patient.

According to the invention, the term "cells" includes prokaryote cells and eukaryote cells, yeast cells, plant cells, human or animal cells, in particular mammalian cells. In particular, cancer cells should be mentioned. The invention can be applied *in vivo* to the interstitial or

luminal space of tissues in the lungs, the trachea, the skin, the muscles, the brain, the liver, the heart, the spleen, the bone marrow, the thymus, the bladder, the lymphatic system, the blood, the pancreas, the stomach, the kidneys, the ovaries, the testicles, the rectum, the peripheral or central nervous system, the eyes, the lymphoid organs, the cartilage, the endothelium. In preferred embodiments, the cell will be a muscle cell, a haematopoietic system stem cell or an airways cell, a tracheal or pulmonary cell, or a tumor cell.

The present invention also relates to a process for transferring a nucleic acid into cells wherein said process comprises contacting said cells with at least one polynucleotide according to the invention. This process may be applied by direct administration of said polynucleotide to cells of the animal *in vivo*, or by *in vitro* treatment of cells which were recovered from the animal and then re-introduced into the animal body (*ex vivo* process). In *in vitro* application, cells cultivated on an appropriate medium are placed in contact with a suspension consisting of polynucleotide of the invention. After an incubation time, the cells are washed and recovered. Introduction of the polynucleotide can be verified (eventually after lysis of the cells) by any appropriate method.

In the case of *in vivo* treatment according to the invention, in order to improve the transfection rate, the patient may undergo a macrophage depletion treatment prior to administration of the pharmaceutical preparations described above. Such a technique is described in the literature (refer particularly to Van Rooijen et al., 1997, TibTech 15, 178-184).

The present invention further concerns the use of a polypeptide or analogue or a polynucleotide, a vector or a host cell as defined above for the preparation of a composition intended for diagnostic, curative, preventive or vaccination treatment of man or animals, and more specifically for the treatment of cancer.

Moreover, the present invention relates to a diagnostic composition comprising at least one polypeptide as defined above. The use of a polypeptide of the invention in a diagnostic composition is illustrated by the following processes:

- a process which enables the detection and eventually the quantification of an antibody directed against said polypeptide consists in (i) contacting with said polypeptide a biological sample susceptible to containing said antibody and (ii) detecting the

- formation of an immune complex between said antibody and said polypeptide.
- a process which enables the detection and eventually the quantification of MUC-1-specific T lymphocytes according to the ELISPOT technique (Scheibenbogen et al., 1997, Clinical Cancer Research 3, 221-226); Tetramer analysis (e.g., as described in Altman et al., 1996, Science 274:94-96) or other techniques which allow the identification of specific T cells by virtue of specificity of their T cell receptor for the polypeptides of this invention.

The methods, compositions, uses of the invention can be used for the treatment of all kinds of cancer the treatment and/or diagnostic of which being related to or dependent on the immune properties of the polypeptides of the invention. The compositions, and uses of the present invention may be desirably employed in humans, although animal treatment is also encompassed by the uses described herein.

The present invention also relates to a T cell receptor which recognizes a polypeptide (epitope) of the invention or a fragment thereof which can recognize the polypeptide (epitope).

The T cell receptor of the invention recognises a polypeptide (epitope) of the invention. The fragment of the T cell receptor typically comprises the extracellular domain. The fragment may be a soluble fragment or a fragment capable of binding to a cell membrane. The T cell receptor or fragment may be modified, such as by any of the modifications described herein in relation to the polypeptide of the invention. The T cell receptor or fragment may be part of a fusion protein.

The T cell receptor or fragment is able to bind an MHC molecule (e.g. HLA-A\*0201) that comprises the polypeptide (epitope) in its peptide binding groove. Typically the MHC molecule will be present on the surface of a cell. The T cell receptor or fragment may or may not be able to cause antigen specific functional activity of a T cell upon which they are present. This activity may include cytotoxic activity (such as the killing of the cell that bears the MHC/epitope complex which is recognised) or the secretion of substance (such as IFN- $\gamma$ ) from the T cell. The activity may be measured by CTL assay, ELISPOT assay or by measuring the production of cytokine inside the T cell.

The T cell receptor may be present in a population (or composition) which comprises 2, 3, 4,

5 or more different T cell receptors of the invention which together recognise any of the combinations of a polypeptide or analogue of the invention.

Furthermore, the present invention relates to a T cell which comprises a T cell receptor according to the invention.

Such a T cell is preferably a MHC class I restricted cell, and is typically a CD8 T cell, although in one embodiment it is a MHC class I restricted CD4 cell. Generally when the T cell receptor of the T cell recognises the epitope antigen specific functional activity of the cell occurs (such as the functional activity mentioned above). The T cell may be an antigen naive or antigen experienced T cell. The T cell may be of a cell line, such as an immortalised cell line. The T cell may have been fused with another cell, which may or may not be a T cell.

The T cell is typically obtained from a host, such as a naive host, a host that has cancer or a host that has been immunised with a MUC1 based immunogen, such as any of the polypeptides, analogues or polynucleotides mentioned herein. The T cell may be replicated *in vitro* in an antigen specific (typically by contacting with an epitope or analogue of the invention) or a non-antigen specific manner. Thus, the invention provides a T cell of the invention that has been produced by replication *in vitro*.

The invention also provides a product that selectively binds a T cell receptor of the invention, typically in a reversible manner. Such a product is generally able to inhibit the binding of a polypeptide (epitope) of the invention (e.g. bound to an MHC molecule) to the T cell receptor. The product is typically able to cause antigen specific functional activity of a T cell with the T cell receptor of the invention.

The product typically comprises (a) an MHC molecule, or fragment thereof, comprising a polypeptide (epitope) or analogue of the invention in its peptide binding groove, or (b) an analogue of (a) which is capable of inhibiting the binding of (a) to a T cell receptor of the invention.

The MHC molecule of (a) is generally a class I molecule (e.g. HLA-A\*0201). Such molecules comprise an  $\alpha$  chain and a  $\beta$  chain. The fragment may comprise only the extracellular domain of the MHC molecule. The fragment may or may not be capable of binding a cell membrane. (b) may comprise a protein which has homology with a naturally occurring  $\alpha$  chain (or a fragment thereof) and/or a protein which has homology with a naturally occurring  $\beta$  chain (or a fragment thereof). The naturally occurring  $\alpha$  or  $\beta$  chain may be of an HLA-A molecule (e.g.

HLA-A\*0201). Any of the above homologous proteins or fragments may be present as part of fusion proteins.

(b) is typically a derivative of (a) and, thus, may be made by modifying (a) by any of the modifications mentioned herein.

The product may be designed, made or identified using methods known in the art. Thus, the invention provides use of a polypeptide (epitope or epitope sequence) of the invention to design or identify the product. The product may be designed by computational means or may be identified from a library of compounds.

Thus, the invention also provides a method of identifying a product of the invention comprising contacting a candidate substance with a T cell receptor or fragment of the invention and determining whether the candidate substance binds to the T cell receptor or fragment, the binding of the candidate substance to the T cell receptor or fragment indicating that the substance is such a product.

In the method the product may be present on the surface of a cell, such as a professional APC. The binding may be measured by contacting the candidate substance with a T cell of the invention and determining whether the candidate substance causes antigen specific functional activity of the T cell (such as by any means mentioned herein).

The product may be linked to a cytotoxic agent. In one embodiment the product is an antibody. In one embodiment 2, 3, 4 or more products are linked together in a multimer and, thus, the invention provides a multimer comprising 2 or more products of the invention. Such a multimer may be used in the same manner as the product is used in the different aspects of the invention and, thus, the term 'product' as used in the context of the other aspects of the invention includes the multimer.

The products in the multimer may be linked by a covalent bond or by non-covalent means. In a preferred embodiment the products are linked by a streptavidin - biotin interaction and, thus, typically the products comprise a biotin portion (typically chemically linked to or in a fusion protein with the product) which allows the products to be linked together by streptavidin.

The multimer generally has a higher binding affinity to the T cell receptor of the invention than the product, and in one embodiment is able to cause more antigen specific functional activity than the product. The multimer may also comprise a detectable label, such as a radioactive or a light detectable (e.g. fluorescent) label. The label may allow the multimer to be sorted by

flow cytometry (e.g. when the multimer is bound to a T cell receptor which is present on a T cell of the invention).

The multimer may be a soluble multimer or may be capable of associating with a cell membrane. In one embodiment the multimer is attached to a solid support, such as a microtitre plate.

The invention also provides a cell comprising a product of the invention. The cell may be any of the types of cells mentioned herein, such as a professional APC or T cell. The cell may be capable of stimulating antigen specific functional activation of a T cell of the invention. Thus, the cell may be used to stimulate a MHC class I restricted T cell response *in vitro* or *in vivo*, which response is directed to a polypeptide (epitope) of the invention. The cell may, therefore, be used in a method of treatment of the human or animal body by therapy, particularly in a method of treating or preventing cancer.

In one embodiment the cell may be made by providing a polypeptide, analogue, polynucleotide or composition of the invention to a cell which is able to process the polypeptide, analogue, polynucleotide or composition and present them on its surface (under conditions in which such processing occurs).

The invention furthermore provides a method of causing the replication of MHC class I restricted T cells which are specific for a cancer epitope comprising contacting a population of cells which comprises MHC class I restricted T cells with a polypeptide or analogue of the invention under conditions in which the polypeptide or analogue are presented to T cells in the population, or with a product or cell of the invention.

The invention includes use of a T cell of the invention (including a T cell replicated by the above method) *in vitro* or *in vivo* to kill a cell which presents the polypeptide (epitope) of the invention. Such a cell is typically a cancer cell, but in one embodiment is a T cell (typically a MUC1 expressing activated T cell). Thus, the invention provides a T cell of the invention, or a cell which has been replicated in the method of the invention for use in a method of treatment of the human or animal body by therapy. In particular for use in a method of preventing or treating cancer or a disease caused by an immune response, such as an inflammatory disorder, autoimmune disease, organ transplant rejection or graft versus host disease.



As mentioned above, the invention also provides a method of identifying a MHC class I restricted T cell response which is based on determining whether MHC class I restricted T cells from a host recognise a polypeptide or analogue of the invention (either of which may be provided by a polynucleotide of the invention), or a product or cell of the invention. In the method the polypeptide or analogue may be in the form of the composition of the invention. In one embodiment the determination of whether the T cells recognise the polypeptide or analogue is done by detecting a change in the state of the T cells in the presence of the polypeptide or analogue or determining whether the T cells bind the polypeptide or the analogue. The change in state is generally caused by antigen specific functional activity of the T cell after the T cell receptor binds the polypeptide or the analogue. Generally, when binding the T cell receptor the polypeptide or the analogue is bound to an MHC class I molecule, which is typically present on the surface of an APC.

The change in state of the T cell may be the start of or increase in the expression of a substance in the T cells and/or secretion of a substance from the T cell, such as a cytokine (e.g. IFN- $\gamma$ , IL-2 or TNF- $\alpha$ ). Determination of IFN- $\gamma$  expression or secretion is particularly preferred. The substance can typically be detected by allowing it to bind to a specific binding agent and then measuring the presence of the specific binding agent/substance complex. The specific binding agent is typically an antibody, such as polyclonal or monoclonal antibodies. Antibodies to cytokines are commercially available, or can be made using standard techniques.

Typically the specific binding agent is immobilised on a solid support (and thus the method may be based on the ELISPOT assay to detect secretion of the substance). After the substance is allowed to bind the solid support can optionally be washed to remove material which is not specifically bound to the agent. The agent/substance complex may be detected by using a second binding agent which will bind the complex. Typically the second agent binds the substance at a site which is different from the site which binds the first agent. The second agent is preferably an antibody and is labelled directly or indirectly by a detectable label.

Thus, the second agent may be detected by a third agent which is typically labelled directly or indirectly by a detectable label. For example, the second agent may comprise a biotin moiety, allowing detection by a third agent which comprises a streptavidin moiety and typically alkaline phosphatase as a detectable label.

Alternatively, the change in state of the T cell which can be measured may be the increase in

the uptake of substances by the T cell, such as the uptake of thymidine. The change in state may be an increase in the size of the T cells, or proliferation of the T cells, or a change in cell surface markers on the T cell.

The change in state may be the killing (by the T cell) of a cell which presents the polypeptide, the analogue or the product of the invention to the T cell (e.g. the killing of the cell of the invention). Thus, the determination of whether the T cells recognise the peptide may be carried out using a CTL assay.

In one embodiment the T cells which are contacted in the method are taken from the host in a blood sample, although other types of samples which contain T cells can be used. The sample may be added directly to the assay or may be processed first. Typically the processing may comprise diluting of the sample, for example with water or buffer. Typically the sample is diluted from 1.5 to 100 fold, for example 2 to 50 or 5 to 10 fold.

The processing may comprise separation of components of the sample. Typically mononuclear cells (MCs) are separated from the sample. The MCs will comprise the T cells and APCs. Thus, in the method the APCs present in the separated MCs can present the peptide to the T cells. In another embodiment only T cells, (in one embodiment only CD8 T cells), can be purified from the sample. PBMCs, MCs and T cells can be separated from the sample using techniques known in the art.

The T cells used in the assay can be in the form of unprocessed or diluted samples, or are freshly isolated T cells (such as in the form of freshly isolated MCs or PBMCs) which are used directly *ex vivo*, i.e. they are not cultured before being used in the method. However, more typically the T cells are cultured before use, for example in the presence of the polypeptide or the analogue of the invention and, generally, also exogenous growth promoting cytokines. During culturing the polypeptide or the analogue are typically present on the surface of APCs, such as the APC used in the method. Pre-culturing of the T cells may lead to an increase in the sensitivity of the method.

The APC which is typically used in the method is from the same host as the T cell or from a different host. The APC can be a non-professional APC, but is typically a professional APC, such as any of the APCs mentioned herein. The APC may be an artificial APC. The APC is a cell which is capable of presenting the peptide to a T cell. It is typically separated from the same sample as the T cell and is typically co-purified with the T cell. Thus, the APC may be present in MCs or PBMCs. The APC is typically a freshly isolated *ex vivo* cell or a cultured

cell. It may be in the form of a cell line, such as a short term or immortalised cell line. The APC may express empty MHC class I molecules on its surface.

In one embodiment the method identifies a MHC class I restricted T cell response to any of the combinations of a polypeptide or an analogue of the invention discussed above in relation to the composition of the invention. Thus, in the method the T cells can be placed into an assay with the composition of the invention (which comprises the combination of the polypeptide or the analogue which are to be tested). Alternatively, the T cells can be divided and placed into separate assays each of which contains a group of polypeptides or analogues within the combination.

In one embodiment a polypeptide or an analogue *per se* is added directly to an assay comprising T cells and APCs. As discussed above the T cells and APCs in such an assay could be in the form of MCs.

In one embodiment the polypeptide or the analogue are provided to the APC in the absence of the T cell. The APC is then provided to the T cell, typically after being allowed to present the polypeptide or the analogue on its surface. The polypeptide or the analogue may have been taken up inside the APC and presented, or simply be taken up onto the surface without entering inside the APC.

The duration for which the polypeptide or the analogue are contacted with the T cells will vary depending on the method used for determining recognition of the peptide. Typically the concentration of T cells used is  $10^3/\text{ml}$  to  $10^9/\text{ml}$ , preferably  $10^5/\text{ml}$  to  $10^7/\text{ml}$ . In the case where peptide is added directly to the assay its concentration is typically from 0.1 to 1000  $\mu\text{g}/\text{ml}$ , preferably 10 to 100  $\mu\text{g}/\text{ml}$ .

Typically the length of time for which the T cells are incubated with the polypeptide or the analogue is from 4 to 24 hours, preferably 6 to 16 hours.

The determination of the recognition of the polypeptide or the analogue by the T cells may be done by measuring the binding the polypeptide or the analogue to the T cells. Typically, T cells which bind the polypeptide can be sorted based on this binding, for example using a FACS machine. The presence of T cells which recognise the polypeptide will be deemed to occur if the frequency of cells sorted using the polypeptide is above a 'control' value (i.e. above the frequency of antigen naive T cells which recognise the polypeptide or the analogue). The frequency of antigen-experienced T cells during a disease state can be up to 2.5% of the total CD8 T cells.

The polypeptide, the analogue, the polynucleotide, the composition, the product or the cell of the invention can be used to detect a MHC class I restricted T cell response to a polypeptide (epitope) of the invention *in vitro* (such as in a sample from a host) or *in vivo*. This can be done, for example, by using the method discussed above. The presence of a response generally indicates the presence of a cell which is expressing MUC1, such as a cancer cell or an activated T cell. Thus, the detection of the response may be used to diagnose cancer. Measurement of the level of the response may be used to monitor the severity of the cancer (i.e. the number of cancer cells present in the host), a larger response indicating a more severe cancer.

In the method of diagnosis of the invention the presence or absence of the MHC class I restricted T cell response is typically determined by the method of identifying a MHC class I restricted T cell response discussed above.

The antibodies mentioned herein may be produced by raising antibody in a host animal. Such antibodies will be specific to the peptide or to the substances mentioned above which bind antibodies. The peptide or substances are referred to as the 'immunogen' below. Methods of producing monoclonal and polyclonal antibodies are well-known. A method for producing a polyclonal antibody comprises immunising a suitable host animal, for example an experimental animal, with the immunogen and isolating immunoglobulins from the serum. The animal may therefore be inoculated with the immunogen, blood subsequently removed from the animal and the IgG fraction purified. A method for producing a monoclonal antibody comprises immortalising cells which produce the desired antibody. Hybridoma cells may be produced by fusing spleen cells from an inoculated experimental animal with tumour cells, for example as described in Köhler and Milstein (Nature 256 (1975), 495-497).

An immortalized cell producing the desired antibody may be selected by a conventional procedure. The hybridomas may be grown in culture or injected intraperitoneally for formation of ascites fluid or into the blood stream of an allogenic host or immunocompromised host. Human antibody may be prepared by *in vitro* immunisation of human lymphocytes, followed by transformation of the lymphocytes with Epstein-Barr virus.

For the production of both monoclonal and polyclonal antibodies, the experimental animal is suitably a goat, rabbit, rat or mouse. If desired, the immunogen may be administered as a conjugate in which the immunogen is coupled, for example via a side chain of one of the amino acid residues, to a suitable carrier. The carrier molecule is typically a physiologically

acceptable carrier. The antibody obtained may be isolated and, if desired, purified.

#### Administration

Any of the polypeptides, analogues or polynucleotides discussed above in any form or in association with any other agent discussed above is included in the termed "vaccination agent" below. An effective non-toxic amount of such a vaccination agent may be given to a human or non-human patient in need thereof. The condition of a patient suffering from a cancer can therefore be improved by administration of such a vaccination agent. The vaccination agent may be administered prophylactically to an individual who does not have a cancer in order to prevent the individual developing cancer.

Thus, the present invention provides the vaccination agent for use in a method of treating the human or animal body by therapy. The invention provides the use of the vaccination agent in the manufacture of a medicament for vaccinating against cancer. Thus, the invention provides a method of vaccinating an individual comprising administering the vaccination agent to the individual.

The vaccination agent is typically administered by any standard technique used for administering vaccines, such as by injection.

Typically after the initial administration of the vaccination agent a booster of the same or a different vaccination agent of the invention can be given. In one embodiment the subject is given 1, 2, 3 or more separate administrations, each of which is separated by at least 12 hours, 1 day, 2, days, 7 days, 14 days, 1 month or more.

The vaccination agent may be in the form of a pharmaceutical composition which comprises the vaccination agent and a pharmaceutically acceptable carrier or diluent. Suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline. Typically the composition is formulated for parenteral, intravenous, intramuscular, subcutaneous, transdermal, intradermal, oral, intranasal, intravaginal, or intrarectal administration.

The dose of vaccination may be determined according to various parameters, especially according to the substance used; the age, weight and condition of the patient to be treated; the route of administration; and the required regimen. A physician will be able to determine the required route of administration and dosage for any particular patient. A suitable dose may however be from 10µg to 10g, for example from 100 µg to 1g of the vaccination agent. These values may represent the total amount administered in the complete treatment regimen or may represent each separate administration in the regimen.

In the case of vaccination agents which are polynucleotides transfection agents may also be administered to enhance the uptake of the polynucleotides by cells. Examples of suitable transfection agents include cationic agents (for example calcium phosphate and DEAE-dextran) and lipofectants (for example lipofectam<sup>TM</sup> and transfectam<sup>TM</sup>).

When the vaccination agent is a polynucleotide which is in the form of a viral vector the amount of virus administered is in the range of from  $10^4$  to  $10^{12}$  pfu, preferably from  $10^7$  to  $10^{10}$  pfu (for example for adenoviral vectors), more preferably about  $10^8$  pfu for herpes viral vectors. A pox virus vector may also be used (e.g. vaccinia virus), typically at any of the above dosages. When injected, typically 1-2 ml of virus in a pharmaceutically acceptable suitable carrier or diluent is administered.

These and other embodiments are disclosed or are obvious from and encompassed by the description and examples of the present invention. Further literature concerning any one of the methods, uses and compounds to be employed in accordance with the present invention may be retrieved from public libraries, using for example electronic devices. For example the public database "Medline" may be utilized which is available on Internet, e.g. under <http://www.ncbi.nlm.nih.gov/PubMed/medline.html>. Further databases and addresses, such as <http://www.ncbi.nlm.nih.gov/>, <http://www.infobiogen.fr/>, [http://www.fmi.ch/biology/research\\_tools.html](http://www.fmi.ch/biology/research_tools.html), <http://www.tigr.org/>, are known to the person skilled in the art and can also be obtained using, e.g., <http://www.lycos.com>. An overview of patent information in biotechnology and a survey of relevant sources of patent information useful for retrospective searching and for current awareness is given in Berks, TIBTECH 12 (1994), 352-364.

The invention has been described in an illustrative manner, and it is to be understood that the terminology which has been used is intended to be in the nature of words of description rather than of limitation. Obviously, many modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that within the scope of the appended claims, the invention may be practised otherwise than as specifically described. Accordingly, those skilled in the art will recognize, or able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described specifically herein. Such equivalents are intended to be encompassed in

the scope of the following claims.

All of the above cited disclosures of patents, publications and database entries are specifically incorporated herein by reference in their entirety to the same extent as if each such individual patent, publication or entry were specifically and individually indicated to be incorporated by reference.

**Figures 1 to 7** show competition binding data from polypeptides whose sequences are from within the sequence of human MUC-1. Experiments were performed according to the method described in *van der Burg et al.* (1995, Hum. Immunol. 44:189-198). Polypeptides described as 'pp x' correspond to the SEQ ID NO. For example, pp 27 corresponds to SEQ ID NO 27. In some Figures the competition binding curves of some negative (therefore not claimed) polypeptide sequences are shown to demonstrate the specificity of the competition binding assay.

**Figures 8, 9 and 10** show ELISpot data from three experiments performed with PBMC, from patients immunized with VV-MUC-1-IL2, exposed to polypeptides from this invention. Spots per 10e6 PBMC indicate the number of CD8+ (CTL) T lymphocytes, per million PBMC, which are specific for that polypeptide. Black histograms represent the ELISpot responses of PBMC drawn from the patient 1 weeks after the injection of VV-MUC-1-IL2 (Figure 8) , 4 weeks after injection (Figure 9) or 4 weeks after the second injection (Figure 10). The white bars correspond to the ELISpot response of patient PBMC taken before VV-MUC-1 administration (Figure 8) 5 months after injection (Figure 9) or before the second injection (Figure 10).

**Figure 11** shows that MUC1 derived HLA-A\*0201 binding peptides induce peptide specific cytotoxic CTL responses. A2K<sup>b</sup> mice were immunised twice with 100µg of MUC1 peptide in IFA and 140µg of Th peptide on day -28 and -14. On day 0 single cell splenocyte suspensions were restimulated *in vitro* for one week with peptide loaded syngeneic LPS-elicited lymphoblasts and tested for cytotoxicity of peptide loaded Jurkat-A\*0201K<sup>b</sup>. Groups of A2K<sup>b</sup> mice were immunised with MUC1 peptides MUC1<sup>264-272</sup> (FLSFHISNL), MUC1<sup>460-468</sup> (SLSYTNPAV), MUC1<sup>13-21</sup> (LLLTVLTVV), MUC1<sup>167-175</sup> (ALGSTAPPV) or MUC1<sup>79-87</sup>

(TLAPATEPA). CTL bulk cultures were tested against Jurkat-A\*0201K<sup>b</sup> cells loaded with the cognate peptide (filled triangles) or irrelevant influenza matrix control peptide (open circles). Three representative graphs for each peptide are shown. The vertical axis shows % specific lysis.

**Figure 12** shows the amino acid sequence of one version of the MUC-1 protein.

The following examples serve to further illustrate the invention.

These examples show:

- 1) The identification of MUC-1 polypeptides which bind specifically to molecules of the human Major Histocompatibility Complex I (MHC-I); and
- 2) The utility of these polypeptides in a functional bioassay, known as ELISpot (Enzyme Linked Immuno Spot) assay.

### **Example 1**

#### **Competition Binding Assay**

**INTRODUCTION:** Polypeptide fragments 8 - 13 amino acids long, of proteins produced within a nucleated, vertebrate cell are associated with newly formed cellular proteins of the MHC-I complex. The complex of MHC-I protein and polypeptide fragment are further associated with a protein known as Beta-2 microglobulin. This trimolecular complex is then transported to the cell surface, anchored to the cell membrane and exposed to the extracellular milieu. Thymus-derived, or T lymphocytes of the CD8 category have specific 'antigen' receptors on their cell surface, which recognise the MHC-I-Beta-2-microglobulin-peptide complex. Individual CD8<sup>+</sup> T cells or clonal progeny of an individual T cell precursor express on their cell surface antigen receptors which recognise only one (or very few) such polypeptides within the context of the MHC-I-Beta-2-microglobulin-peptide complex. This is known as 'Antigen Specificity' of T lymphocytes. If the polypeptide is derived from a normal or 'self' protein, T lymphocytes are not 'stimulated' due either to the deletion of self-specific T cells from the immune repertoire or due to negative regulation of self-specific immune responses. If, however, the polypeptide is from a pathogenic organism, such as a virus, then specific T cells are activated to proliferate and to become cytotoxic such that CD8 'cytotoxic



effector cells' or CTL specifically recognise the infected cell and eliminate that cell in an effort to contain the pathogenic condition. Tumours can also produce 'tumour-specific' protein molecules or modifications of cellular proteins. In those cases, specific CD8 T cells can recognise a tumour cell as pathogenic and eliminate these cells by the same mechanism as is used to eliminate virus-infected cells. Often, the tumour-specific modification of a protein is merely quantitative in that a protein is over-produced in tumour cells. It has been shown that such proteins can also be recognised by specific Cytotoxic T Lymphocytes (CTL). For example see Disis *et al.*, Cancer Research, 54: 1071-1076 (1994); or Barnd *et al.*, Proc Natl Acad Sci USA, 86: 7159-7163 (1989).

It has been shown in numerous publications that the binding of said polypeptides to MHC-I molecules depends upon certain 'motifs' of amino acids at defined positions within the polypeptides. For example, the amino acids Leucine at position 2 and Valine at position 9 of a nine amino acid polypeptide will result in the binding of that polypeptide to HLA-A2. For a review, see Rammensee *et al.*, Immunogenetics, 41: 178-228 (1995). The knowledge of the required amino acid positions had been acquired by the extraction of polypeptides from MHC-I molecules and sequencing them. In addition to the 'anchoring' residues there are various other 'preferred' flanking amino acids, such that a polypeptide can be given a 'rank' of likelihood that it will bind to a particular MHC-I molecule, depending on its sequence. Such ranking of predicted binding of polypeptides can be determined by one of several computer programs. In accordance with the invention, the program 'BIMAS' has been consulted (BioInformatics & Molecular Analysis Section) 'HLA POLYPEPTIDE Binding Predictions' ([http://bimas.dcrt.nih.gov/molbio/hla\\_bind/](http://bimas.dcrt.nih.gov/molbio/hla_bind/)) for predictions of which polypeptides from the human MUC-1 sequence are likely to bind to various HLA types. This, of course, is only a computer prediction and binding must be ascertained with a biochemical assay. Then, whether the polypeptides selected by the binding assay must be tested in a biological assay.

About 200 of the top ranking MUC-1 polypeptides, as predicted by the BIMAS program, predicted to bind to HLA-A1, A2, A3, A11, A24, B7 and B8 were produced (NeoSytem, Strasbourg, France) and were screened for HLA binding by a competitive binding assay. This assay is described in van der Burg *et al.*, Human Immunology, 44:189-198 (1995). Briefly, EBV-transformed B lymphocyte cell lines, of a known HLA-type, are exposed to a polypeptide known to bind to that HLA type. Binding of the polypeptide is determined by flow cytometry

using a Fluorescence Activated Cell Sorter. Binding can be envisioned with this apparatus since the polypeptide known to bind is tagged with a fluorescence molecule. Thus cells binding the polypeptide become fluorescent. Each polypeptide to be screened for binding is mixed together with the reference fluorescent polypeptide, which is at a constant concentration of 150 nM. The test polypeptide is added at various concentrations and the mixture exposed to the same cells. A test polypeptide is considered 'positive' if the binding of the reference polypeptide is inhibited by 50 % at 20 µg/ml or less of the test polypeptide. In Figures 1 - 7 are shown data for the competitive binding of polypeptides deemed, by this assay, to be positive for binding to HLA-A2, B7, A3, A11, A24, A1, and B8 respectively. In each case, binding is compared to a negative control polypeptide, known not to bind to that HLA type and a positive control polypeptide, known to bind to that HLA type. For example, the positive control 'Flu' is a polypeptide with the sequence GILGFVFTL from the influenza virus matrix protein (Scheibenbogen et al. International Journal of Cancer, 71: 932-936 (1997)).

#### **MATERIALS:**

EBV-B cell lines were derived by cultivating human Peripheral Blood Mononuclear Cells (PBMC) in filtered culture supernatant which had been used to grow cells from the marmoset line B-958. These cells produce the Epstein Barr Virus. PBMC are cultured for 2-3 days in the presence of 1 µg/ml Cyclosporin A (to inhibit T cell reactivity to the virus) in the B-958 supernatant, then thereafter cultured in fresh culture medium. HLA-typed EBV-transformed human B cell lines were used for all tests. HLA types are described in Table 2.

Culture medium was Dulbecco's Modified Eagle's Medium (DMEM) +  $5 \times 10^{-5}$  M Beta-Mercaptoethanol (with the addition of 25 mM HEPES buffer for the step of polypeptide detachment and cell washing) plus either 2% or 10% Fetal bovine Serum. All tests were performed in 96 well, V-bottom microtitre plates (PS micro plate).  $\beta$ -2 microglobulin was purchased from Sigma. The buffer for the polypeptide detachment used was:

13.76 g citric acid (M MUC-1 210.14 g/L)

5.43 g  $\text{Na}_2\text{HPO}_4 \cdot 2\text{H}_2\text{O}$  (MMUC-1 177.9 g/L)

in 500 ml distilled  $\text{H}_2\text{O}$

pH initially adjusted to pH 4.0, but pH then re-adjusted depending upon which HLA type is

being tested (see Table 2).

Dulbecco's Phosphate Buffered Saline (PBS) was purchased as a powder from Sigma. Reference polypeptides labelled with fluorescence at the cysteine residue (Table 2) were prepared according to Van de Burg et al., 1995, Hum. Immunol., 44, 189-198. Test polypeptides were purchased from NeoSystem, Strasbourg or prepared according to standard methods. Positive control polypeptides were purchased from NeoSystem (Strasbourg, France). Details of the polypeptides used are described in Table 2.

Plastics, unless otherwise indicated, were purchased from Corning.

## METHODS:

Cells were cultivated in Corning T175 flasks in 20 of culture medium (10% FBS). The night before the assay, cells were re-suspended and 10 ml of fresh medium added. The day of the test cells were resuspended, counted, pelleted by centrifugation and resuspended in 5 ml complete medium with 10% FBS. Distribute cells into a 6 well plate,  $10^5$  cells per well in 5 ml culture medium. Cells were then cultured for 4 hours at 37°, 5% CO<sub>2</sub>. During that time polypeptides were prepared by dilution in 600 µg/ml in PBS. Two-fold serial dilutions from 600 - 4.68 (to have a final dilution of 100 to 0.78 µg/ml in the test plate) were first prepared in a separate 96 well 'polypeptide dilution' plate.

The test plate (96 well, V-bottom) was prepared as follows:

- negative control (no polypeptide): 50 µl PBS
- positive control (reference polypeptide only): 25 µl PBS + 25 µl Fl-reference polypeptide
- tests: 25 µl Fl-reference polypeptide at 150 nM (final) then 25 µl of test polypeptides (including positive and negative control polypeptides) at their various dilutions were added. Plates were then placed in a refrigerator in the dark.

After the 4 hour incubation of cells, the following were prepared, on ice:

- Two 15 ml conical bottom test tubes containing culture medium with 2% FBS.
- One 15 ml conical bottom test tube containing 10 ml culture medium with 2% FBS and

including 1.5 µg/ml β-2 microglobulin

- One 15 ml conical bottom test tube containing 2 ml acid 'peptide detachment' buffer at the pH for the particular HLA type as indicated in Table 2.

Cells in the 5 ml culture medium in the 6 well plate were resuspended and transferred to a 15 ml conical bottom test tube and then centrifuged for 5 minutes at 1500 rpm (500g). Resuspend the cells in PBS and centrifuge a second time (500g). Supernatant was removed and 2 ml detachment buffer while on ice. Cells were resuspended by gentle pipetting during the first 30 seconds of this 2 minute period. After 2 minutes, 14 ml culture medium with 2% FBS was added. Cells are mixed by inverting the tube twice, then centrifuged at 2000 rpm (800g) for 3 minutes at 4°C. Supernatant was removed and cells resuspended in 14 ml cold culture medium with 2% FBS and centrifugation repeated (3 minutes at 800g). Supernatant was removed and cells gently resuspended in 14 ml culture medium, 2 % FBS and 1.5 µg/ml β-2 microglobulin. One hundred µl cells from this suspension were added to each well of the 96 well plate, which already contained the polypeptides. The plate was wrapped in Saran Wrap and left 24 hours at 4°C. The next day, plates were centrifuged at 1000 rpm (200g), supernatant removed and cells resuspended in 100 µl PBS containing 0.1% Bovine Serum Albumin (BSA) and 0.02% sodium azide and cells pelleted by centrifugation at 200g. This step was repeated once more, then cells were resuspended in 1% paraformaldehyde and analysed for fluorescence by a FACScan (Becton Dickenson, Mountainview California).

The mean fluorescence intensity (MFI) of cells with the fluorescent reference polypeptide but with no competitor polypeptide (positive control) was taken as 0% inhibition. Similarly, the MFI of cells without the fluorescent reference polypeptide (negative control) was taken to be equal to 100 % inhibition. Percentage inhibition was calculated as:

$$\% \text{ inhibition} = \left( 1 - \frac{(\text{MFI with test polypeptide}) - (\text{MFI negative control})}{(\text{MFI with test polypeptide}) - (\text{MFI positive control})} \right) \times 100$$

High Affinity Binding was taken to be 50 % inhibition at  $\leq 10 \mu\text{M}$  polypeptide ( $\sim 10 \mu\text{g/ml}$ )

TABLE 2: Reference and Positive Control polypeptides used in the Competition Binding assay

Allele tested	elution pH	Reference Polypeptide			Positive Control Polypeptide	B-EBV Line	HLA Type
		sequence (origin)	Conc. pmol/ $\mu$ l	Final Conc. nM			
A1	pH 3.1	YLEPAC*AKY	183	150	CTELKLSDY (Influenza NP 44-52)	MAR	A01, A02, B08, B27, C01, C07
A2	pH 3.1	FLPSDC*FPSV (HBV core 18-27)	250	150	GILGFVFTL (Influenza matrix 58-66)	JY	A02, B07, C07
A3	pH 3	KVFPAC*ALINK	28 et 20	150	QVPLRPMTYK (HIV nef 73-82)	FRE	A03, A24, B35, B08, C04, C07
A11	pH 3	KVFPAC*ALINK	28 et 20	150		BVR	A11, B35, C04
A24	pH 3.1	RYLKC*QQLL (HIV gp41 583-591)	66 et 20	150	AYGLDFYIL (melanoma p15 10-18)	YT2	A24, B54, C01
B7	pH 3.1	APAPAPC*WPL (human p53 84-93)	29 et 20	150	RPPIFIRRL (EBNA-3A 379-387)	JY	A02, B07, C07
B8	pH 3.1	FLRGRAC*GI (EBNA-3 339-347)	20	150	YLKDQQLL (HIV gp41 591-598)	MAR	A01, A02, B08, B27, C01, C07

Where polypeptide origin is not indicated, HLA-A consensus sequences, as described in Sette *et al.*, Molecular Immunology, 31: 813-822 (1994) were used. C\* indicates that the flourescene molecule is coupled to a cysteine residue (as described in van der Burg *et al.*, Human Immunology, 44: 189-198 (1995)).

Positive control polypeptides are published in Rammensee *et al.*, 'MHC Ligands and polypeptide Motifs' Springer, New York (1995)

## RESULTS:

The competition for binding to selected HLA types between serial dilutions of selected peptides and the reference peptides (as described in Table 2) are shown in Figures 1-7. Binding of polypeptides, from the sequence of human MUC-1, to HLA -A2, B7,A3, A11, A24, A1 and B8 are shown in Figures 1,2,3,4,5,6, and 7 respectively. High affinity binding sequences were often, but not always, within the top 20 predicted binding polypeptide sequences as predicted by the BIMAS HLA Peptide Motif program (as described above).

### Example 2

#### ELISpot

The ELISpot is a technique which allows the identification of antigen-specific (in this case, MUC-1-specific) T cell recognician by the detection of antigen induced production of cytokines (IFN $\gamma$ , TNF $\alpha$ , IL-4, etc...) following an antigenic stimulation *in vitro*. More particularly, ELISpot allows the determination of the number of antigen specific T lymphocytes in a population of peripheral blood mononuclear cells (PBMC) (Scheibenbogen et al., 1997, Int. J. Cancer 71-1). In this case, the production of IFN $\gamma$  produced by CD8+ T cells (CTL) in responses to polypeptides as presented by autologous HLA molecules were examined.

Briefly, in an ELISpot, the cytokines are captured between two specific antibodies. The first antibody, specific for human IFN $\gamma$ , is adsorbed on a nitrocellulose membrane. Lymphocytes from human blood samples are added to the microtitre wells containing the attached antibody. Antigen, in the form of polypeptides, is also added to the wells. The principal is that polypeptides will attach to cell surface HLA molecules (together with  $\beta$ -2 microglobulin). Polypeptide specific T cells will recognize the complex of the polypeptide:HLA: $\beta$ -2 $\mu$ globulin. Upon recognition of antigen, the T cells become 'activated' to produce cytokines such as IFN $\gamma$ . Secreted IFN $\gamma$  is then captured by the antibody which is attached to the nitrocellulose. Cells are washed away leaving behind the areas of secreted IFN $\gamma$ . These areas are revealed by the second antibody (coupled to biotin) and then by a streptavidin-alkaline phosphatase conjugate. The enzyme substrate hydrolysis by the enzyme leads to a spot appearance. Thus each spot

represents the 'fingerprint' of a cytokine producing cell. The tests described below were performed using a commercially available kit (MABTECH, Nacka, Sweden)

## MATERIALS

### *Peripheral blood mononuclear cells :*

In Figures 8 and 9 patient PBMC (Peripheral Blood Mononuclear Cells) were obtained from breast cancer patients who had participated in a Phase I clinical trial carried out in the Institut Curie, Paris. In Figure 10, patient PBMC came from prostate cancer patients who had participated in a similar immunotherapy Phase I trial in Los Angeles, USA. In these trials, patients were immunized with a Vaccinia virus construct which expresses, upon infection, the both MUC-1 and IL2. The goal was to generate an immune response to MUC-1 which is an antigen over-expressed on both types of cancers. PBMC were isolated from peripheral blood by Hypaque-Ficol density centrifugation and resulting mononuclear cells frozen in aliquotes of 2 to  $4 \times 10^6$  cells in a 1 ml volume of culture medium containing 10% DMSO and stored in the vapour phase of liquid nitrogen until use.

**TABLE 3**

Patient Identification Code	Cancer	HLA-Type
Pt#4 SOM	Advanced Breast	HLA-A 01/02; B 44/08
Pt#5 LEC	Advanced Breast	HLA-A 02/24; B 07/44
A002	Prostate	HLA-A01/26; B38/08

### *Tissue typing :*

Breast cancer patient PBMC was HLA typed by serology and PCR at the Etablissement de Transfusion Sanguine, Strasbourg. Prostate cancer patients' PBMC were HLA typed by PCR at Transgene using the 'One Lamda' HLA typing kit (One Lamda, Canoga Park, CA, USA)

*Polypeptides :*

Polypeptides were produced at NeoSytem (Strasbourg, France)

*ELISPOT :*

The ELISPOT kit was purchased from and used according the instructions of MABTECH (Nacka, Sweden). The technique was carried out according to the manufacturer's instructions. Briefly, PBMC were cultured in 96 well microtitre plates for 48 hours in the presence of test or control polypeptides at 5 µg/ml and recombinant IL-2 at 30 units/ml. IFN $\gamma$  spots were revealed with a second antibody reagent, also specific for Human Interferon gamma, according to the manufacturer's instructions.

**RESULTS:**

The results from three experiments are shown in Figures 8, 9 and 10. Patient PBMC were taken from liquid nitrogen and thawed the day before the ELISpot assay. The controls and the polypeptides (numbered according to their SEQ ID N°) were added as described above. Duplicate or triplicate wells containing 1- 2 x 10<sup>5</sup> PBMC were used. The number of spots was determined and is represented as the number of spots per 10<sup>6</sup> cells.

These data shown in Figure 8 show that PBMC from patient #4 (who is HLA-A2) are able to respond to the polypeptide of SEQ ID NO: 4 in that PBMC from this patient are stimulated to produce IFN $\gamma$  in response to the presence of this polypeptide but not in the presence of the negative control polypeptide or polypeptide SEQ ID N° 3. The response is seen after vaccination (black histograms), but not before (white histograms). In Figure 9 is shown the results of an experiment in which PBMC from patient #5 (HLA-A2 and B7) are stimulated to produce IFN $\gamma$  ELISpots upon exposure to polypeptide 4 (SEQ ID N° 4) and polypeptide 10 (SEQ ID N° 10) but not to the negative control or to polypeptides 3 or 7. No PBMC from prior to vaccination were available, but the patient's T cell response, as determined by *in vitro* CD4+ T cell proliferation assay, to a longer (24 aa) MUC-1 polypeptide was discernable only in the weeks following vaccination but was undetectable 5 months afterwards. The transient nature of the T cell responses is verified in Figure 9 in that only PBMC taken 28 days after



vaccination (black histograms) were able to produce ELISpots over background, whereas PBMC taken 5 months after injection produced no ELISpot response to these peptide (white histograms).

These examples demonstrate the value of the invention in the diagnosis of a CD8+T cell immune response to MUC-1.

The invention could also be used in other diagnostic applications such as Tetramer analysis in which soluble MHC-I, beta-2-microglobulin and polypeptides of this invention are complexed together with a fluorescent reagent. The complex is then used to fluorescently tag T cells with an antigen receptor specific for that polypeptide. The quantification of the specific T cells is accomplished with a fluorescence activated flow cytometer and can be done by one practised in the art.

The polypeptides of the invention could also be use in therapeutic or vaccine composition in order to prevent or treat MUC-1-expressing cancers. Polypeptides could be administered alone or complexed with MHC-I and beta-2-microglobulin to stimulate a MUC-1-specific CD8+ (CTL) T cell immune response. The invention could also be used as a DNA-based vector in which oligonucleotide sequences coding for the polypeptides of this invention, incorporated into viral or synthetic vector, are used to vaccinate a patient for the treatment or prevention of MUC-1-expressing cancers.

### **Example 3**

#### **Prediction of peptides that bind HLA-A\*0201**

A computer program (D'Amaro et al., Hum. Immunol. 43 (1995), 13-18) was used to scan the MUC1 sequence with two tandem repeats for nine amino acid long peptides complying with the anchor residue motifs for HLA-A\*0201. A full set of ninemers with an eight amino acid overlap covering the tandem repeat as well as ninemers in the top 10% of the scoring data for HLA-A\*0201 were synthesised (90 peptides in total) by fmoc chemistry with a yield of 5-15 mg.

### Example 4

#### Testing the synthesised peptides in a binding assay

Peptide binding to HLA-A\*0201 was analysed using HLA-A\*0201<sup>+</sup> B lymphoblastoid JY cells in a semi-quantitative competition assay (van der Burg et al. (J. Immunol. 156 (1996), 3308-3314)). The assay is based on competitive binding of two peptides to acid stripped MHC class I molecules on a B cell line (JY). A test peptide competes with a fluorescently labelled reference peptide for the empty class I molecules on the cell surface. Mild-acid-treated JY cells were incubated with 150nM fluorescein (FL)-labelled reference peptide FLPSDC(-FL)FPSV and with several concentrations of competitor peptide for 24 hours at 37°C in the presence of 1.0µg/ml β2-microglobulin. Subsequently, the cells were washed, fixed with paraformaldehyde and analysed by flow cytometry. The mean fluorescence (MF) obtained in the absence of competitor peptide was regarded as maximal binding and equated to 0%; the MF obtained without reference peptide was equated to 100% inhibition. The percentage inhibition was calculated using the formula:

$$\{1 - (\text{MF 150nM reference and competitor peptide} - \text{MF no reference peptide}) / (\text{MF 150nM reference peptide} - \text{MF no reference peptide})\} \times 100\%$$

The binding capacity of competitor peptides is expressed as the concentration needed to inhibit 50% of binding of the FL-labelled reference peptide (IC<sub>50</sub>). All peptides were tested several times in two fold dilutions starting with a concentration of 100µM. The six peptides that showed any significant binding were further analysed. The IC<sub>50</sub> values of these peptides are shown in the table below together with the value for a flu peptide.

The peptides are defined in terms of the amino acid numbering used in Figure 12. The tandem repeat can be defined using the restriction enzyme SmaI which cuts at CCCGGG three times in the MUC1 sequence, once either side of the tandem repeat and once in the C-terminus. This leads to the tandem repeat being defined as amino acids 129 to 148 in Figure 12. The six peptides were analysed further as described below.

Peptide Position	Amino Acid Sequence	Motif Score *	IC <sub>50</sub> mM/ml
Flu Matrix <sup>58-66</sup>	GILGVVFTL	54	<5
MUC1 <sup>264-272</sup>	FLSFHISNL	59	3-5
MUC1 <sup>460-468</sup>	SLSYTNPAV	62	5-10
MUC1 <sup>13-21</sup>	LLTVLTVV	63	6-10
MUC1 <sup>167-175</sup>	ALGSTAPPV	64	10
MUC1 <sup>79-87</sup>	TLAPATEPA	58	10-15
MUC1 <sup>107-115</sup>	ALGSTTPPA	56	25

\* The algorithm used to define the motif score is described in (D'Amaro et al. (loc. cit.)).

### Example 5

#### Testing the peptides in a cytotoxic T lymphocyte (CTL) assay

##### Summary of assay

To show that the six peptides were functional *in vivo*, transgenic mice expressing the chimeric protein A\*0201K<sup>b</sup> (Vitiello et al. (J. Exp. Med. 173 (1991), 1007-1015)) underwent an immunization protocol with a MUC1-derived peptide and T helper epitope formulated with adjuvant. The mice were then sacrificed and the splenocytes restimulated by culturing with peptide-loaded, irradiated LPS-elicited B lymphoblasts. The restimulated cells were separated from the lymphoblasts and used in a CTL assay as effector cells. Effector cells were incubated with Na<sup>51</sup>CrO<sub>4</sub> loaded target cells at various E:T ratios and cell killing estimated by measuring the amount of <sup>51</sup>Cr released into the cell supernatant using a gamma radiation counter.

##### Immunisation of mice with MUC1-derived peptides

Transgenic mice expressing the chimeric protein A\*0201K<sup>b</sup> (Vitiello et al., loc. cit.) were immunised subcutaneously in the base of the tail with 100µg of MUC1-derived peptide and 140µg of H-2 I-A<sup>b</sup>-restricted HBV core antigen-derived T helper epitope (amino acid sequence; TPPAYRPPNAPIL) (Milich et al., Proc. Natl. Acad. Sci. USA 85 (1988), 1610-1614) emulsified in a 1:1 ratio with Incomplete Freund's Adjuvant (IFA) in a total volume of 200 µl. After a minimum of two weeks, the mice were boosted using the same protocol.

##### Preparation of LPS-elicited B lymphoblasts

Splenocytes from (unimmunized) transgenic mice expressing the chimeric protein A\*0201K<sup>b</sup> (Vitiello et al., loc. cit.) were prepared 72h prior to use as stimulator cells. The cells of several mice were pooled and resuspended in IMDM N medium (IMDM (Biowhittaker) supplemented with 2mM L-glutamine, 8% (v/v) heat inactivated foetal calf serum (FCS), 20μM 2-mercaptoethanol and 100 IU/ml penicillin) containing 25μg/ml LPS (Sigma) and 7μg/ml dextran sulphate (Pharmacia). A 30 ml culture of cellular concentration,  $1.5 \times 10^6$  cells per ml was incubated at 37°C for 72h.

Cells were then collected, resuspended in IMDM N, separated on a Ficoll gradient and adjusted to a cellular concentration of  $5 \times 10^6$  cells/ml. Cells were then irradiated for 8 min (the equivalent of 2500 RAD). Cells were then washed once and resuspended in IMDM to a cellular concentration of  $40 \times 10^6$  cells/ml.

Each MUC1 derived peptide, at a concentration of 100μg/ml, was incubated for 1h at 37°C with 1 ml LPS-elicited B lymphoblasts. The cells were then washed once and resuspended in IMDM N at a concentration of  $10 \times 10^6$  cells/ml.

#### Restimulation of splenocytes from peptide-immunized mice

Two weeks after the final immunization, the mice were sacrificed and the spleens removed. Splenocytes ( $30 \times 10^6$  cells in a 9 ml volume of IMDM N medium) were restimulated by incubation in complete medium with a 1ml volume of syngeneic, irradiated LPS-elicited B cell lymphoblasts (such that the ratio of splenocytes to blast cells is 3:1). On day 7 of culture the cells were separated on a Ficoll gradient, resuspended in IMDM N medium and counted to generate a preparation of effector cells of known concentration.

#### Preparation of target cells

The Jurkat-A\*0201K<sup>b</sup> cell line which is a stable transfectant of a human T cell leukaemia line expressing the product of the HLA-A\*0201K<sup>b</sup> chimeric gene construct was used as a source of target cells.

Cells growing in log phase were harvested, washed once, counted and  $10^6$  cells transferred to a microfuge tube. The cells were pelleted and resuspended in a 100μl volume of 1 mCi/ml Na<sup>51</sup>CrO<sub>4</sub> solution (Amersham) followed immediately by the addition of a 5μl volume of 1M HEPES pH 7.0 and gentle mixing of the cell suspension by pipetting. The tubes were incubated

for 1h at 37°C. The cells were then washed four times in IMDM N medium and resuspended in a 25 ml volume of IMDM N medium containing the relevant peptide. After a 20 min incubation the cells were plated out into wells already containing effector CTLs. The final concentration of peptide in each well was 2µg/ml.

#### <sup>51</sup>Cr release assay

Effector cells, prepared as above, were added in triplicate to wells of a 96 well plate (round bottom wells) such that the resulting ratio of Effector:Target cells was a range from 5:1 to 100:1. For each target cell line tested, six wells containing IMDM N or PBS with 2% (v/v) triton X-100 were prepared as controls to measure the spontaneous and maximal release of <sup>51</sup>Cr respectively.

A 50µl volume of the preparation of target cells (1000 or 2000 cells depending on preparation and number of effector cells) was then added to each well and the 96 well plates centrifuged for 2 min at 1200rpm. The plates were then incubated for 6 h at 37°C. The culture supernatants from each well were then harvested using Skatron harvesting frames according to the manufacturer's instructions and the <sup>51</sup>Cr in each supernatant measured using a Wallac gamma counter.

The data was presented as %age specific <sup>51</sup>Cr release which is defined as 100 x ([experimental cpm - spontaneous cpm]/[total cpm - spontaneous cpm]) where the experimental value was the average of three test wells, the spontaneous value, the average of six wells containing IMDM N and target cells and the total value is the average of six wells containing 2% (v/v) triton X-100 and target cells. Data is shown for peptides MUC1<sup>79-87</sup>, MUC1<sup>167-175</sup>, MUC1<sup>264-272</sup>, MUC1<sup>460-468</sup> and MUC1<sup>13-21</sup> in Figure 11.

### **Example 6**

#### **Protection assay**

Mice were inoculated subcutaneously with 10<sup>5</sup>, 5x10<sup>5</sup> and 10<sup>6</sup> B16-MUC1-A2K<sup>b</sup> cells (a melanoma cell line constitutively expressing MUC1 and the chimeric gene product HLA-A\*0201K<sup>b</sup>). Tumour growth was observed 20 days post inoculation and continued until sacrifice of the animal. An inoculation of 5x10<sup>5</sup> B16-MUC1-A2K<sup>b</sup> was defined as the optimal

dose for tumour challenge experiments.

To test whether the HLA-A\*0201 binding peptides that were previously identified could protect A2K<sup>b</sup> transgenic mice (Vitiello et al., loc. cit.) against subsequent tumour challenge with B16-MUC1-A2K<sup>b</sup>, groups of 6-8 animals were immunised with 100µg of peptide in IFA in the presence of 140µg of the H-2 I-A<sup>b</sup>-restricted HBV core antigen-derived T helper epitope (128-140; sequence TPPAYRPPNAPIL)(Milich et al., loc. cit.), on day -28, boosted on day -14 and challenged with 5x10<sup>5</sup> B16-MUC1-A2K<sup>b</sup> cells on day 0. Control mice were given IFA or PBS. A measurable tumour was defined as having a volume greater than 36 mm<sup>3</sup>.

Results from these experiments are shown in the tables below in the form of the percentage of mice surviving at a given day. For experiments 2 and 3 results using a vaccinia construct that expresses MUC1 (VV-MUC1) are also shown. In other experiments immunising with MUC1<sup>167-175</sup> and boosting with MUC1<sup>79-87</sup> or immunising with MUC1<sup>79-87</sup> and boosting with MUC1<sup>167-175</sup> gave a percentage survival of between 60 and 70% at day 30. Experiment 3 shows results from an experiment in which the mice were inoculated with 8x10<sup>5</sup> A2K<sup>b</sup> dendritic cells (DC) which had been pulsed with the peptides.

### **Experiment 1**

Day	0	21	22	23	26	32	34
IFA	100	38	0	0	0	0	0
MUC1 <sup>264-272</sup>	100	75	75	75	63	63	63
MUC1 <sup>167-175</sup>	100	63	63	63	63	63	63
MUC1 <sup>79-87</sup>	100	100	75	75	75	75	63
MUC1 <sup>460-468</sup>	100	25	25	25	25	25	25
MUC1 <sup>13-21</sup>	100	25	13	13	0	0	0
VV-MUC1	100	75	75	75	63	63	38

### **Experiment 2**

Day	0	13	24	26	28	33	38	46	52	53
IFA	100	100	70	50	50	40	40	30	30	30

MUC1 <sup>264-272</sup>	100	100	100	88	88	75	75	63	63	63
MUC1 <sup>167-175</sup>	100	100	88	63	63	63	63	38	38	38
MUC1 <sup>79-87</sup>	100	100	100	100	100	88	88	75	75	75
MUC1 <sup>460-468</sup>	100	100	100	75	75	50	50	38	38	38
MUC1 <sup>13-21</sup>	100	100	50	25	25	25	25	25	25	25
VV-MUC1	100	100	90	80	80	80	80	60	60	60

**Experiment 3**

Day	0	15	21	24	27	32	39	40	42	45	72
PBS	100	89	56	11	11	11	11	11	11	11	0
DC + Flu Matrix <sup>58-66</sup>	100	88	63	50	50	38	38	38	38	38	38
DC + MUC1 <sup>264-272</sup>	100	100	88	88	88	88	88	88	88	88	88
DC + MUC1 <sup>167-175</sup>	100	100	78	78	78	78	78	78	67	67	67
DC + MUC1 <sup>79-87</sup>	100	100	89	89	89	67	67	67	67	67	67
DC + MUC1 <sup>460-468</sup>	100	100	75	63	38	38	25	25	25	13	13
DC + MUC1 <sup>13-21</sup>	100	100	67	56	56	44	22	22	22	22	22

**CLAIMS**

1. A polypeptide consisting of or comprising at least one amino acid sequence of at most 20 consecutive amino-acids defined in SEQ ID NO: 1, said polypeptide binding at least one MHC-I glycoprotein, with the proviso that said polypeptide is different from SEQ ID NO: 2.
2. The polypeptide of claim 1, wherein the amino acid sequence is selected from the group consisting of the amino acid sequences shown in SEQ ID NO: 3 to SEQ ID NO: 33, SEQ ID NO: 65 and SEQ ID NO: 66.
3. The polypeptide of claim 1 or 2, wherein the amino acid sequence is selected from the group consisting of:
  - (a) SEQ ID NO: 3 to SEQ ID NO: 6 and SEQ ID NO: 65 and SEQ ID NO: 66, and said polypeptide binds the HLA A2 glycoproteins of MHC-I;
  - (b) SEQ ID NO: 7 to SEQ ID NO: 15, and said polypeptide binds the HLA B7 glycoproteins of MHC-I;
  - (c) SEQ ID NO: 16 to SEQ ID NO: 19, and said polypeptide binds the HLA A3 glycoprotein of MHC-I;
  - (d) SEQ ID NO: 19 to SEQ ID NO: 21, and said polypeptide binds the HLA A11 glycoproteins of MHC-I;
  - (e) SEQ ID NO: 22 to SEQ ID NO: 25, and said polypeptide binds the HLA A24 glycoproteins of MHC-I;
  - (f) SEQ ID NO: 26 to SEQ ID NO: 29, and said polypeptide binds the HLA A1 glycoproteins of MHC-I; and
  - (g) SEQ ID NO: 30 to SEQ ID NO: 33, and said polypeptide binds the HLA B8 glycoproteins of MHC-I.
4. An analogue of the polypeptide of any one of claims 1 to 3, which is capable of inhibiting the binding of the polypeptide or of an epitope contained in said polypeptide to a T cell receptor either by directly binding to the same T cell receptor or by binding to the same T cell receptor after being processed.



5. A polynucleotide encoding the polypeptide of any one of claims 1 to 3.
6. The polynucleotide of claim 5, comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 34 to SEQ ID NO: 64, and their complementary sequences.
7. A polynucleotide encoding the analogue of claim 4.
8. The polynucleotide of any one of claims 5 to 7, further containing elements allowing the expression of the polypeptide or analogue in a host cell.
9. The polynucleotide of claim 8, wherein said element for expression in a host cell is a promoter.
10. The polynucleotide of any one of claims 5 to 9, wherein said polynucleotide is associated with one or more compounds selected from the group consisting of transfecting agents, stabilizing agents and targeting agents.
11. A vector comprising at least one polynucleotide of any one of claims 5 to 10.
12. The vector of claim 11 comprising at least two different nucleotide sequences encoding at least two polypeptides as defined in claim 3.
13. The vector of claim 11 or 12 which is a plasmid.
14. The vector of claim 11 or 12, which is a viral vector.
15. A host cell comprising a polynucleotide of any one of claims 5 to 10 or a vector of any one of claims 11 to 14.
16. The host cell of claim 15, which is a prokaryotic cell, a yeast cell, or an animal cell, such as a mammalian cell.

17. A composition comprising a polypeptide of any one of claims 1 to 3, an analogue of claim 4, a polynucleotide of any one of claims 5 to 10, a vector of any one of claims 11 to 14, or a host cell of claim 15 or 16 or a combination of two or more of these different compounds.
18. The composition of claim 17, further comprising a pharmaceutical carrier.
19. Use of a polypeptide of any one of claims 1 to 3, of an analogue of claim 4, of a polynucleotide of any one of claims 5 to 10, of a vector of any one of claims 11 to 14, of a host cell of claim 15 or 16 or of a composition of claim 17 for the preparation of a medicament for effecting a CTL response in a subject.
20. A diagnostic composition comprising a polypeptide of any one of claims 1 to 3.
21. A vaccine comprising a polypeptide of any one of claims 1 to 3, an analogue of claim 4, a polynucleotide of any one of claims 5 to 10, a vector of any one of claims 11 to 14 or a host cell of claim 15 or 16, which vaccine is capable of stimulating a MHC class I restricted T cell response directed to an epitope as contained in a polypeptide of any one of claims 1 to 3.
22. The vaccine of claim 21 which comprises an adjuvant or a delivery system, which adjuvant or delivery system stimulates a MHC class I restricted response.
23. A T cell receptor which recognizes an epitope contained in a polypeptide of any one of claims 1 to 3 or a fragment of said T cell receptor which can recognize the epitope.
24. A T cell comprising the T cell receptor of claim 23.
25. The T cell of claim 24, which has been produced by replication *in vitro*.
26. A product that selectively binds a T cell receptor of claim 23.

27. The product of claim 26 which product comprises (a) an HLA molecule, or a fragment thereof, comprising a polypeptide of any one of claims 1 to 3 or an analogue of claim 4 in its peptide binding groove, or (b) an analogue of (a) which is capable of inhibiting the binding of (a) to a T cell receptor of claim 23.
28. A method of identifying a product of claim 26 or 27 comprising contacting a candidate substance with a T cell receptor or fragment of claim 23 and determining whether the candidate substance binds to the T cell receptor or fragment, the binding of the candidate substance to the T cell receptor or fragment indicating that the candidate substance is such a product.
29. A cell comprising a product of claim 26 or 27.
30. A method of identifying a MHC class I restricted T cell response, said method comprising contacting a population of cells comprising MHC class I restricted T cells with:  
the polypeptide of any one of claims 1 to 3 or with the analogue of claim 4 under conditions suitable for the presentation of the polypeptide or analogue to the T cells,  
or  
a product of claim 26 or 27 or cells of claim 29; and  
determining whether the CD8 T cells recognize the polypeptide, analogue, the product or the cell, recognition by the T cells indicating the presence of a MHC class I restricted T cell response.
31. The method of claim 30, in which the determination of the T cell recognition is done by detecting the expression of a substance by the T cells, the expression of the substance indicating that the T cells have recognized the polypeptide, the analogue, the product or the cell.
32. The method of claim 31, in which the substance which is detected is IFN- $\gamma$ .
33. A method of diagnosing cancer in a host said method comprising determining the presence or absence in the host of a MHC class I restricted T cell response to a

polypeptide of any one of claims 1 to 3, the presence of the MHC class I restricted T cell response indicating that the host has cancer.

34. The method of claim 33, in which the presence or absence of the MHC class I restricted T cell response is determined by the method of any one of claims 30 to 32.
35. A method of causing the replication of MHC class I restricted T cells which recognize an epitope of a cancer cell or an activated T cell, said method comprising contacting a population of cells which comprises MHC class I restricted T cells with the polypeptide of any one of claims 1 to 3 or with the analogue of claim 4 under conditions in which the polypeptide or the analogue are presented to T cells in the population, or with a product of claim 26 or 27 or with a cell of claim 29.
36. A pharmaceutical composition comprising a product of claim 26 or 27, a cell of claim 28, the T cell of claim 24 or 25, or a cell which has been replicated in the method of claim 35.
37. A kit for carrying out a method of any one of claims 30 to 35 comprising a polypeptide of any one of claims 1 to 3, an analogue of claim 4, a polynucleotide of any one of claims 5 to 10, a composition of claim 17 and/or a product of claim 26 or 27.

**HLA-A2:  
MUC1 Polypeptide Competition  
Binding Assay**




FIGURE 1

**HLA-B7:  
MUC1 Polypeptide  
Competition Binding Assay**




FIGURE 2

**HLA-A3:  
MUC1 Polypeptide  
Competition Binding Assay**




FIGURE 3

4/13

**HLA-A11:  
MUC1 Polypeptide  
Competition Binding Assay:**




FIGURE 4



**HLA-A24 :  
MUC1 Polypeptide  
Competition Binding Assay**




FIGURE 5

**HLA-A1:**  
**MUC1 Polypeptide Competition**  
**Binding Assay:**




FIGURE 6

7/13




FIGURE 7




FIGURE 8




FIGURE 9

10/13





FIGURE 10

11/13



E:T

FIGURE 11

12/13

Met Thr Pro Gly Thr Gln Ser Pro Phe Phe Leu Leu Leu Leu Leu Thr  
 1 5 10 15  
 Val Leu Thr Val Val Thr Gly Ser Gly His Ala Ser Ser Thr Pro Gly  
 20 25 30  
 Gly Glu Lys Glu Thr Ser Ala Thr Gln Arg Ser Ser Val Pro Ser Ser  
 35 40 45  
 Thr Glu Lys Asn Ala Val Ser Met Thr Ser Ser Val Leu Ser Ser His  
 50 55 60  
 Ser Pro Gly Ser Gly Ser Ser Thr Thr Gln Gly Gln Asp Val Thr Leu  
 65 70 75 80  
 Ala Pro Ala Thr Glu Pro Ala Ser Gly Ser Ala Ala Thr Trp Gly Gln  
 85 90 95  
 Asp Val Thr Ser Val Pro Val Thr Arg Pro Ala Leu Gly Ser Thr Thr  
 100 105 110  
 Pro Pro Ala His Asp Val Thr Ser Ala Pro Asp Asn Lys Pro Ala Pro  
 115 120 125  
 Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr  
 130 135 140  
 Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser  
 145 150 155 160  
 Ala Pro Asp Asn Arg Pro Ala Leu Gly Ser Thr Ala Pro Pro Val His  
 165 170 175  
 Asn Val Thr Ser Ala Ser Gly Ser Ala Ser Gly Ser Ala Ser Thr Leu  
 180 185 190  
 Val His Asn Gly Thr Ser Ala Arg Ala Thr Thr Thr Pro Ala Ser Lys  
 195 200 205  
 Ser Thr Pro Phe Ser Ile Pro Ser His His Ser Asp Thr Pro Thr Thr  
 210 215 220  
 Leu Ala Ser His Ser Thr Lys Thr Asp Ala Ser Ser Thr His His Ser  
 225 230 235 240  
 Thr Val Pro Pro Leu Thr Ser Ser Asn His Ser Thr Ser Pro Gln Leu  
 245 250 255  
 Ser Thr Gly Val Ser Phe Phe Phe Leu Ser Phe His Ile Ser Asn Leu  
 260 265 270  
 Gln Phe Asn Ser Ser Leu Glu Asp Pro Ser Thr Asp Tyr Tyr Gln Glu  
 275 280 285

FIGURE 12



13/13

Leu Gln Arg Asp Ile Ser Glu Met Phe Leu Gln Ile Tyr Lys Gln Gly  
 290 295 300  
 Gly Phe Leu Gly Leu Ser Asn Ile Lys Phe Arg Pro Gly Ser Val Val  
 305 310 315 320  
 Val Gln Leu Thr Leu Ala Phe Arg Glu Gly Thr Ile Asn Val His Asp  
 325 330 335  
 Val Glu Thr Gln Phe Asn Gln Tyr Lys Thr Glu Ala Ala Ser Arg Tyr  
 340 345 350  
 Asn Leu Thr Ile Ser Asp Val Ser Val Ser Asp Val Pro Phe Pro Phe  
 355 360 365  
 Ser Ala Gln Ser Gly Ala Gly Val Pro Gly Trp Gly Ile Ala Leu Leu  
 370 375 380  
 Val Leu Val Cys Val Leu Val Ala Leu Ala Ile Val Tyr Leu Ile Ala  
 385 390 395 400  
 Leu Ala Val Cys Gln Cys Arg Arg Lys Asn Tyr Gly Gln Leu Asp Ile  
 405 410 415  
 Phe Pro Ala Arg Asp Thr Tyr His Pro Met Ser Glu Tyr Pro Thr Tyr  
 420 425 430  
 His Thr His Gly Arg Tyr Val Pro Pro Ser Ser Thr Asp Arg Ser Pro  
 435 440 445  
 Tyr Glu Lys Val Ser Ala Gly Asn Gly Gly Ser Ser Leu Ser Tyr Thr  
 450 455 460  
 Asn Pro Ala Val Ala Ala Thr Ser Ala Asn Leu  
 465 470

FIGURE 12 (continued)

## SEQUENCE LISTING

&lt;110&gt; TRANSGENE SA et al.

&lt;120&gt; MUC-1 derived peptides

&lt;130&gt; D 2195 PCT

&lt;140&gt;

&lt;141&gt;

&lt;160&gt; 67

&lt;170&gt; PatentIn Ver. 2.1

&lt;210&gt; 1

&lt;211&gt; 1572

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (58)..(1542)

&lt;400&gt; 1

```

gaattccctg gctgcttgaa tctgttctgc cccctcccca cccatttcac caccacc      57

atg aca ccg ggc acc cag tct cct ttc ttc ctg ctg ctg ctc ctc aca      105
Met Thr Pro Gly Thr Gln Ser Pro Phe Phe Leu Leu Leu Leu Leu Thr
   1             5             10             15

gtg ctt aca gtt gtt aca ggt tct ggt cat gca agc tct acc cca ggt      153
Val Leu Thr Val Val Thr Gly Ser Gly His Ala Ser Ser Thr Pro Gly
           20           25           30

gga gaa aag gag act tcg gct acc cag aga agt tca gtg ccc agc tct      201
Gly Glu Lys Glu Thr Ser Ala Thr Gln Arg Ser Ser Val Pro Ser Ser
           35           40           45

act gag aag aat gct gtg agt atg acc agc agc gta ctc tcc agc cac      249
Thr Glu Lys Asn Ala Val Ser Met Thr Ser Ser Val Leu Ser Ser His
           50           55           60

agc ccc ggt tca ggc tcc tcc acc act cag gga cag gat gtc act ctg      297
Ser Pro Gly Ser Gly Ser Ser Thr Thr Gln Gly Gln Asp Val Thr Leu
   65           70           75           80

gcc ccg gcc acg gaa cca gct tca ggt tca gct gcc acc tgg gga cag      345
Ala Pro Ala Thr Glu Pro Ala Ser Gly Ser Ala Ala Thr Trp Gly Gln
           85           90           95

gat gtc acc tcg gtc cca gtc acc agg cca gcc ctg ggc tcc acc acc      393
Asp Val Thr Ser Val Pro Val Thr Arg Pro Ala Leu Gly Ser Thr Thr
           100          105          110

ccg cca gcc cac gat gtc acc tca gcc ccg gac aac aag cca gcc ccg      441
Pro Pro Ala His Asp Val Thr Ser Ala Pro Asp Asn Lys Pro Ala Pro
           115          120          125

ggc tcc acc gcc ccc ccg gcc cac ggt gtc acc tcg gcc ccg gac acc      489
Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr
           130          135          140

```

agg ccg ccc ccg ggc tcc acc gcc ccc gcc gcc cac ggt gtc acc tcg	537
Arg Pro Pro Pro Gly Ser Thr Ala Pro Ala Ala His Gly Val Thr Ser	
145 150 155 160	
gcc ccg gac acc agg ccg gcc ccg ggc tcc acc gcc ccc ccg gcc cac	585
Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His	
165 170 175	
ggt gtc acc tcg gcc ccg gac aac agg ccg gcc ttg ggc tcc acc gcc	633
Gly Val Thr Ser Ala Pro Asp Asn Arg Pro Ala Leu Gly Ser Thr Ala	
180 185 190	
cct cca gtc cac aat gtc acc tcg gcc tca ggc tct gca tca ggc tca	681
Pro Pro Val His Asn Val Thr Ser Ala Ser Gly Ser Ala Ser Gly Ser	
195 200 205	
gct tct act ctg gtg cac aac ggc acc tct gcc agg gct acc aca acc	729
Ala Ser Thr Leu Val His Asn Gly Thr Ser Ala Arg Ala Thr Thr Thr	
210 215 220	
cca gcc agc aag agc act cca ccc agc att ccc agc cac cac tct gat	777
Pro Ala Ser Lys Ser Thr Pro Pro Ser Ile Pro Ser His His Ser Asp	
225 230 235 240	
act cct acc acc ctt gcc agc cat agc acc aag act gat gcc agt agc	825
Thr Pro Thr Thr Leu Ala Ser His Ser Thr Lys Thr Asp Ala Ser Ser	
245 250 255	
act cac cat agc acg gta cct cct ctc acc tcc tcc aat cac agc act	873
Thr His His Ser Thr Val Pro Pro Leu Thr Ser Ser Asn His Ser Thr	
260 265 270	
tct ccc cag ttg tct act ggg gtc tct ttc ttt ttc ctg tct ttt cac	921
Ser Pro Gln Leu Ser Thr Gly Val Ser Phe Phe Phe Leu Ser Phe His	
275 280 285	
att tca aac ctc cag ttt aat tcc tct ctg gaa gat ccc agc acc gac	969
Ile Ser Asn Leu Gln Phe Asn Ser Ser Leu Glu Asp Pro Ser Thr Asp	
290 295 300	
tac tac caa gag ctg cag aga gac att tct gaa atg ttt ttg cag att	1017
Tyr Tyr Gln Glu Leu Gln Arg Asp Ile Ser Glu Met Phe Leu Gln Ile	
305 310 315 320	
tat aaa caa ggg ggt ttt ctg ggc ctc tcc aat att aag ttc agg cca	1065
Tyr Lys Gln Gly Gly Phe Leu Gly Leu Ser Asn Ile Lys Phe Arg Pro	
325 330 335	
gga tct gtg gtg gta caa ttg act ctg gcc ttc cga gaa ggt acc atc	1113
Gly Ser Val Val Val Gln Leu Thr Leu Ala Phe Arg Glu Gly Thr Ile	
340 345 350	
aat gtc cac gac gtg gag aca cag ttc aat cag tat aaa acg gaa gca	1161
Asn Val His Asp Val Glu Thr Gln Phe Asn Gln Tyr Lys Thr Glu Ala	
355 360 365	
gcc tct cga tat aac ctg acg atc tca gac gtc agc gtg agt cat gtg	1209
Ala Ser Arg Tyr Asn Leu Thr Ile Ser Asp Val Ser Val Ser His Val	
370 375 380	
cca ttt cct ttc tct gcc cag tct ggg gct ggg gtg cca ggc tgg ggc	1257
Pro Phe Pro Phe Ser Ala Gln Ser Gly Ala Gly Val Pro Gly Trp Gly	
385 390 395 400	

atc gcg ctg ctg gtg ctg gtc tgt gtt ctg gtt gcg ctg gcc att gtc 1305  
 Ile Ala Leu Leu Val Leu Val Cys Val Leu Val Ala Leu Ala Ile Val  
 405 410 415  
 tat ctc att gcc ttg gct gtc tgt cag tgc cgc cga aag aac tac ggg 1353  
 Tyr Leu Ile Ala Leu Ala Val Cys Gln Cys Arg Arg Lys Asn Tyr Gly  
 420 425 430  
 cag ctg gac atc ttt cca gcc cgg gat acc tac cat cct atg agc gag 1401  
 Gln Leu Asp Ile Phe Pro Ala Arg Asp Thr Tyr His Pro Met Ser Glu  
 435 440 445  
 tac ccc acc tac cac acc cat ggg cgc tat gtg ccc cct agc agt acc 1449  
 Tyr Pro Thr Tyr His Thr His Gly Arg Tyr Val Pro Pro Ser Ser Thr  
 450 455 460  
 gat cgt agc ccc tat gag aag gtt tct gca ggt aat ggt ggc agc agc 1497  
 Asp Arg Ser Pro Tyr Glu Lys Val Ser Ala Gly Asn Gly Gly Ser Ser  
 465 470 475 480  
 ctc tct tac aca aac cca gca gtg gca gcc act tct gcc aac ttg 1542  
 Leu Ser Tyr Thr Asn Pro Ala Val Ala Ala Thr Ser Ala Asn Leu  
 485 490 495  
 taggggcacg tcgccctctg agctgagtgg 1572

<210> 2  
 <211> 495  
 <212> PRT  
 <213> Homo sapiens

<400> 2  
 Met Thr Pro Gly Thr Gln Ser Pro Phe Phe Leu Leu Leu Leu Leu Thr  
 1 5 10 15  
 Val Leu Thr Val Val Thr Gly Ser Gly His Ala Ser Ser Thr Pro Gly  
 20 25 30  
 Gly Glu Lys Glu Thr Ser Ala Thr Gln Arg Ser Ser Val Pro Ser Ser  
 35 40 45  
 Thr Glu Lys Asn Ala Val Ser Met Thr Ser Ser Val Leu Ser Ser His  
 50 55 60  
 Ser Pro Gly Ser Gly Ser Ser Thr Thr Gln Gly Gln Asp Val Thr Leu  
 65 70 75 80  
 Ala Pro Ala Thr Glu Pro Ala Ser Gly Ser Ala Ala Thr Trp Gly Gln  
 85 90 95  
 Asp Val Thr Ser Val Pro Val Thr Arg Pro Ala Leu Gly Ser Thr Thr  
 100 105 110  
 Pro Pro Ala His Asp Val Thr Ser Ala Pro Asp Asn Lys Pro Ala Pro  
 115 120 125  
 Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr  
 130 135 140  
 Arg Pro Pro Pro Gly Ser Thr Ala Pro Ala Ala His Gly Val Thr Ser  
 145 150 155 160

Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His  
 165 170 175  
 Gly Val Thr Ser Ala Pro Asp Asn Arg Pro Ala Leu Gly Ser Thr Ala  
 180 185 190  
 Pro Pro Val His Asn Val Thr Ser Ala Ser Gly Ser Ala Ser Gly Ser  
 195 200 205  
 Ala Ser Thr Leu Val His Asn Gly Thr Ser Ala Arg Ala Thr Thr Thr  
 210 215 220  
 Pro Ala Ser Lys Ser Thr Pro Pro Ser Ile Pro Ser His His Ser Asp  
 225 230 235 240  
 Thr Pro Thr Thr Leu Ala Ser His Ser Thr Lys Thr Asp Ala Ser Ser  
 245 250 255  
 Thr His His Ser Thr Val Pro Pro Leu Thr Ser Ser Asn His Ser Thr  
 260 265 270  
 Ser Pro Gln Leu Ser Thr Gly Val Ser Phe Phe Phe Leu Ser Phe His  
 275 280 285  
 Ile Ser Asn Leu Gln Phe Asn Ser Ser Leu Glu Asp Pro Ser Thr Asp  
 290 295 300  
 Tyr Tyr Gln Glu Leu Gln Arg Asp Ile Ser Glu Met Phe Leu Gln Ile  
 305 310 315 320  
 Tyr Lys Gln Gly Gly Phe Leu Gly Leu Ser Asn Ile Lys Phe Arg Pro  
 325 330 335  
 Gly Ser Val Val Val Gln Leu Thr Leu Ala Phe Arg Glu Gly Thr Ile  
 340 345 350  
 Asn Val His Asp Val Glu Thr Gln Phe Asn Gln Tyr Lys Thr Glu Ala  
 355 360 365  
 Ala Ser Arg Tyr Asn Leu Thr Ile Ser Asp Val Ser Val Ser His Val  
 370 375 380  
 Pro Phe Pro Phe Ser Ala Gln Ser Gly Ala Gly Val Pro Gly Trp Gly  
 385 390 395 400  
 Ile Ala Leu Leu Val Leu Val Cys Val Leu Val Ala Leu Ala Ile Val  
 405 410 415  
 Tyr Leu Ile Ala Leu Ala Val Cys Gln Cys Arg Arg Lys Asn Tyr Gly  
 420 425 430  
 Gln Leu Asp Ile Phe Pro Ala Arg Asp Thr Tyr His Pro Met Ser Glu  
 435 440 445  
 Tyr Pro Thr Tyr His Thr His Gly Arg Tyr Val Pro Pro Ser Ser Thr  
 450 455 460  
 Asp Arg Ser Pro Tyr Glu Lys Val Ser Ala Gly Asn Gly Gly Ser Ser  
 465 470 475 480  
 Leu Ser Tyr Thr Asn Pro Ala Val Ala Ala Thr Ser Ala Asn Leu  
 485 490 495

<210> 3  
<211> 9  
<212> PRT  
<213> Homo sapiens

<220>  
<221> CDS  
<222> (58)..(1542)

<400> 3  
Ala Leu Gly Ser Thr Ala Pro Pro Val  
1 5

<210> 4  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 4  
Phe Leu Ser Phe His Ile Ser Asn Leu  
1 5

<210> 5  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 5  
Thr Leu Ala Pro Ala Thr Glu Pro Ala  
1 5

<210> 6  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 6  
Ser Leu Ser Tyr Thr Asn Pro Ala Val  
1 5

<210> 7  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 7  
Ser Val Pro Val Thr Arg Pro Ala Leu  
1 5

<210> 8

<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 8  
Gly Val Pro Gly Trp Gly Ile Ala Leu  
1 5

<210> 9  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 9  
Ala Pro Gly Ser Thr Ala Pro Pro Ala  
1 5

<210> 10  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 10  
Ala Val Ser Met Thr Ser Ser Val Leu  
1 5

<210> 11  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 11  
Ala Val Ala Ala Thr Ser Ala Asn Leu  
1 5

<210> 12  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 12  
Arg Pro Gly Ser Val Val Val Gln Leu  
1 5

<210> 13  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 13  
Val Pro Gly Trp Gly Ile Ala Leu Leu  
1 5

<210> 14  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 14  
Ser Ala Ser Gly Ser Ala Ser Thr Leu  
1 5

<210> 15  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 15  
Ser Ala Gly Asn Gly Gly Ser Ser Leu  
1 5

<210> 16  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 16  
Ala Leu Ala Val Cys Gln Cys Arg Arg  
1 5

<210> 17  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 17  
Gly Gln Leu Asp Ile Phe Pro Ala Arg  
1 5

<210> 18  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 18  
Thr Leu Val His Asn Gly Thr Ser Ala Arg  
1 5 10

<210> 19  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 19



Thr Thr Leu Ala Ser His Ser Thr Lys  
1 5

<210> 20  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 20  
Gly Val Thr Ser Ala Pro Asp Thr Arg  
1 5

<210> 21  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 21  
Gly Val Thr Ser Ala Pro Asp Asn Arg  
1 5

<210> 22  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 22  
Ile Tyr Lys Gln Gly Gly Phe Leu Gly Leu  
1 5 10

<210> 23  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 23  
Phe Phe Leu Ser Phe His Ile Ser Asn Leu  
1 5 10

<210> 24  
<211> 10  
<212> PRT  
<213> Homo sapiens

<220>  
<221> CDS  
<222> (58)..(1542)

<400> 24  
Gly Phe Leu Gly Leu Ser Asn Ile Lys Phe  
1 5 10

<210> 25  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 25  
Tyr Tyr Gln Glu Leu Gln Arg Asp Ile Ser  
1 5 10

<210> 26  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 26  
Ile Ser Glu Met Phe Leu Gln Ile Tyr  
1 5

<210> 27  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 27  
Asp Val Glu Thr Gln Phe Asn Gln Tyr  
1 5

<210> 28  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 28  
Ser Leu Glu Asp Pro Ser Thr Asp Tyr Tyr  
1 5 10

<210> 29  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 29  
Ile Ser Glu Met Phe Leu Gln Ile Tyr Lys  
1 5 10

<210> 30  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 30  
Asn Ile Lys Phe Arg Pro Gly Ser Val

1

5

<210> 31  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 31  
Thr Leu Ala Phe Arg Glu Gly Thr Ile  
1 5

<210> 32  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 32  
Gln Cys Arg Arg Lys Asn Tyr Gly Gln Leu  
1 5 10

<210> 33  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 33  
Glu Ala Ala Ser Arg Tyr Asn Leu Thr  
1 5

<210> 34  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 34  
gccttgggct ccaccgcccc tccagtc

27

<210> 35  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 35  
ttcctgtctt ttcacatttc aaacctc

27

<210> 36  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 36  
actctggccc cggccacgga accagct

27

<210> 37  
<211> 27  
<212> DNA  
<213> Homo sapiens  
  
<400> 37  
agcctctctt acacaaaccc agcagtg 27

<210> 38  
<211> 27  
<212> DNA  
<213> Homo sapiens  
  
<400> 38  
tcggtcccag tcaccaggcc agccctg 27

<210> 39  
<211> 27  
<212> DNA  
<213> Homo sapiens  
  
<400> 39  
ggggtgccag gctggggcat cgcgctg 27

<210> 40  
<211> 27  
<212> DNA  
<213> Homo sapiens  
  
<400> 40  
gccccgggct ccaccgcccc cccggcc 27

<210> 41  
<211> 27  
<212> DNA  
<213> Homo sapiens  
  
<400> 41  
gctgtgagta tgaccagcag cgtactc 27

<210> 42  
<211> 27  
<212> DNA  
<213> Homo sapiens  
  
<400> 42  
gcagtggcag ccacttctgc caacttg 27

<210> 43  
<211> 27  
<212> DNA  
<213> Homo sapiens  
  
<400> 43  
aggccaggat ctgtgggtgg acaattg 27

<210> 44  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 44  
gtgccaggct ggggcatcgc gctgctg 27

<210> 45  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 45  
tctgcatcag gctcagcttc tactctg 27

<210> 46  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 46  
tctgcaggta atggtggcag cagcctc 27

<210> 47  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 47  
gccttggctg tctgtcagt cgcgccga 27

<210> 48  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 48  
gggcagctgg acatctttcc agcccgg 27

<210> 49  
<211> 30  
<212> DNA  
<213> Homo sapiens

<400> 49  
actctggtgc acaacggcac ctctgccagg 30

<210> 50  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 50  
accacccttg ccagccatag caccaag 27

<210> 51  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 51  
ggtgtcacct cggccccgga caccagg

27

<210> 52  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 52  
ggtgtcacct cggccccgga caacagg

27

<210> 53  
<211> 30  
<212> DNA  
<213> Homo sapiens

<400> 53  
atttataaac aaggggggttt tctgggcctc

30

<210> 54  
<211> 30  
<212> DNA  
<213> Homo sapiens

<400> 54  
tttttcctgt cttttcacat ttcaaacctc

30

<210> 55  
<211> 30  
<212> DNA  
<213> Homo sapiens

<400> 55  
ggttttcttg gcctctccaa tattaagtgc

30

<210> 56  
<211> 30  
<212> DNA  
<213> Homo sapiens

<400> 56  
tactaccaag agctgcagag agacatttct

30

<210> 57  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 57  
atttctgaaa tgtttttgca gatttat

27

<210> 58  
<211> 30  
<212> DNA  
<213> Homo sapiens

<400> 58  
atttctgaaa tgtttttgca gatttataaa

30

<210> 59  
<211> 30  
<212> DNA  
<213> Homo sapiens

<400> 59  
tctctggaag atcccagcac cgactactac

30

<210> 60  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 60  
gacgtggaga cacagttcaa tcagtat

27

<210> 61  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 61  
aatattaagt tcaggccagg atctgtg

27

<210> 62  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 62  
actctggcct tccgagaagg taccatc

27

<210> 63  
<211> 30  
<212> DNA  
<213> Homo sapiens

<400> 63  
cagtgccgcc gaaagaacta cgggcagctg

30

<210> 64  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 64  
gaagcagcct ctcgatataa cctgacg

27

<210> 65  
 <211> 9  
 <212> PRT  
 <213> Homo sapiens

<400> 65  
 Leu Leu Leu Thr Val Leu Thr Val Val  
 1 5

<210> 66  
 <211> 9  
 <212> PRT  
 <213> Homo sapiens

<400> 66  
 Ala Leu Gly Ser Thr Thr Pro Pro Ala  
 1 5

<210> 67  
 <211> 475  
 <212> PRT  
 <213> Homo sapiens

<400> 1  
 Met Thr Pro Gly Thr Gln Ser Pro Phe Phe Leu Leu Leu Leu Leu Thr  
 1 5 10 15  
 Val Leu Thr Val Val Thr Gly Ser Gly His Ala Ser Ser Thr Pro Gly  
 20 25 30  
 Gly Glu Lys Glu Thr Ser Ala Thr Gln Arg Ser Ser Val Pro Ser Ser  
 35 40 45  
 Thr Glu Lys Asn Ala Val Ser Met Thr Ser Ser Val Leu Ser Ser His  
 50 55 60  
 Ser Pro Gly Ser Gly Ser Ser Thr Thr Gln Gly Gln Asp Val Thr Leu  
 65 70 75 80  
 Ala Pro Ala Thr Glu Pro Ala Ser Gly Ser Ala Ala Thr Trp Gly Gln  
 85 90 95  
 Asp Val Thr Ser Val Pro Val Thr Arg Pro Ala Leu Gly Ser Thr Thr  
 100 105 110  
 Pro Pro Ala His Asp Val Thr Ser Ala Pro Asp Asn Lys Pro Ala Pro  
 115 120 125  
 Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr  
 130 135 140  
 Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser  
 145 150 155 160  
 Ala Pro Asp Asn Arg Pro Ala Leu Gly Ser Thr Ala Pro Pro Val His  
 165 170 175  
 Asn Val Thr Ser Ala Ser Gly Ser Ala Ser Gly Ser Ala Ser Thr Leu  
 180 185 190  
 Val His Asn Gly Thr Ser Ala Arg Ala Thr Thr Thr Pro Ala Ser Lys



195	200	205
Ser Thr Pro Phe Ser Ile Pro Ser His His Ser Asp Thr Pro Thr Thr 210 215 220		
Leu Ala Ser His Ser Thr Lys Thr Asp Ala Ser Ser Thr His His Ser 225 230 235 240		
Thr Val Pro Pro Leu Thr Ser Ser Asn His Ser Thr Ser Pro Gln Leu 245 250 255		
Ser Thr Gly Val Ser Phe Phe Phe Leu Ser Phe His Ile Ser Asn Leu 260 265 270		
Gln Phe Asn Ser Ser Leu Glu Asp Pro Ser Thr Asp Tyr Tyr Gln Glu 275 280 285		
Leu Gln Arg Asp Ile Ser Glu Met Phe Leu Gln Ile Tyr Lys Gln Gly 290 295 300		
Gly Phe Leu Gly Leu Ser Asn Ile Lys Phe Arg Pro Gly Ser Val Val 305 310 315 320		
Val Gln Leu Thr Leu Ala Phe Arg Glu Gly Thr Ile Asn Val His Asp 325 330 335		
Val Glu Thr Gln Phe Asn Gln Tyr Lys Thr Glu Ala Ala Ser Arg Tyr 340 345 350		
Asn Leu Thr Ile Ser Asp Val Ser Val Ser Asp Val Pro Phe Pro Phe 355 360 365		
Ser Ala Gln Ser Gly Ala Gly Val Pro Gly Trp Gly Ile Ala Leu Leu 370 375 380		
Val Leu Val Cys Val Leu Val Ala Leu Ala Ile Val Tyr Leu Ile Ala 385 390 395 400		
Leu Ala Val Cys Gln Cys Arg Arg Lys Asn Tyr Gly Gln Leu Asp Ile 405 410 415		
Phe Pro Ala Arg Asp Thr Tyr His Pro Met Ser Glu Tyr Pro Thr Tyr 420 425 430		
His Thr His Gly Arg Tyr Val Pro Pro Ser Ser Thr Asp Arg Ser Pro 435 440 445		
Tyr Glu Lys Val Ser Ala Gly Asn Gly Gly Ser Ser Leu Ser Tyr Thr 450 455 460		
Asn Pro Ala Val Ala Ala Thr Ser Ala Asn Leu 465 470 475		

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
15 March 2001 (15.03.2001)

PCT

(10) International Publication Number  
**WO 01/18035 A3**

(51) International Patent Classification<sup>7</sup>: **C12N 15/12**,  
C07K 14/47, 7/06, A61K 38/17, 48/00, G01N 33/50,  
33/53, 33/68

(21) International Application Number: PCT/EP00/08761

(22) International Filing Date:  
7 September 2000 (07.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
9921242.5 8 September 1999 (08.09.1999) GB  
99402237.4 10 September 1999 (10.09.1999) EP  
60/187,215 3 March 2000 (03.03.2000) US

(71) Applicants: **TRANSGENE S.A.** [FR/FR]; 11, rue de  
Molsheim, F-67082 Strasbourg Cedex (FR). **IMPE-**  
**RIAL CANCER RESEARCH TECHNOLOGY, LTD.**  
[GB/GB]; Sardinia House, Sardinia Street, London WC2A  
3NL (GB).

(72) Inventors: **TAYLOR-PAPADIMITRIOU, Joyce**; 9  
Cedar Road, Berkhamstead, Hertfordshire\_HP4 1BL

(GB). **HEUKAMP, Lukas, Carl**; 144 Osborne Road,  
London E7 0PN (GB). **OFFRINGA, Rienk**; Stieltjesstraat  
63, NL-2313 SJ Leiden (NL). **MELIEF, Cornelis, Jo-**  
**hanna, Maria**; Wilhelminapark 33, NL-2012 KC Haarlem  
(NL). **ACRES, Bruce**; 10, rue Jean Hermann, F-67000  
Strasbourg (FR). **THOMAS, Mireille**; 7, rue du Vieux  
Marché aux Poissons, F-67000 Strasbourg (FR).

(74) Agent: **VOSSIUS & PARTNER**; Siebertstr. 4, 81675  
München, Germany (DE).

(81) Designated States (*national*): AU, CA, JP.

(84) Designated States (*regional*): European patent (AT, BE,  
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,  
NL, PT, SE).

**Published:**

— with international search report


(88) Date of publication of the international search report:  
8 November 2001

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: MUC-1 DERIVED PEPTIDES

(57) Abstract: Described are peptides and polypeptides derived from the MUC-1 polypeptide which are able to activate Cyto-  
toxic T Lymphocyte (CTL) response, analogues of such peptides and polypeptides nucleotide sequences encoding such peptides and  
polypeptides and therapeutic uses thereof. Moreover, indications for selecting appropriate minimal antigenic MUC-1 polypeptides  
with reference to the HLA-type of the patient to be treated or tested are described.

WO 01/18035 A3



# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 00/08761

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/47 C07K7/06 A61K38/17 A61K48/00  
G01N33/50 G01N33/53 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 50527 A (BIOMIRA INC (CA); AGRAWAL B; KRANTZ M.J; REDDISH M.A; LONGENECKER B.M.) 12 November 1998 (1998-11-12)	1-11, 13-22, 26,27, 29,30, 35-37
Y	page 8, line 9,10; figure 12A page 11, line 23,24 page 43; table III page 45, line 17; figure 9 page 47, line 5-18 claim 14 --- -/--	31,32



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \* & \* document member of the same patent family

Date of the actual completion of the international search

9 July 2001

Date of mailing of the international search report

23/07/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Macchia, G

## INTERNATIONAL SEARCH REPORT

International Application No

PLI/EP 00/08761

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	AGRAWAL B. ET AL.: "In vitro induction of MUC-1 peptide-specific type 1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors" JOURNAL OF IMMUNOLOGY, vol. 157, no. 5, 1 September 1996 (1996-09-01), pages 2089-2095, XP002078857 ISSN: 0022-1767 page 2090	31, 32
X	KAM J.L. ET AL.: "MUC1 synthetic peptide inhibition of intercellular adhesion molecule-1 and MUC1 binding requires six tandem repeats" CANCER RESEARCH, vol. 58, 1 December 1998 (1998-12-01), pages 5577-5581, XP002171171 page 5578; table 1 page 5580; figure 3B	1-7, 17, 18, 20, 37
X	AGRAWAL B. ET AL.: "The anti-MUC1 monoclonal antibody BCP8 can be used to isolate and identify putative major histocompatibility complex class I associated amino acid sequences" CANCER RESEARCH, vol. 58, 15 November 1998 (1998-11-15), pages 5151-5156, XP002171172 page 5152; table 1 page 5155 -page 5156	1-7, 17, 18, 20, 37
A	APOSTOLOPOULOS V. ET AL.: "MUC1 peptide epitopes associated with five different H-2 class I molecules" EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 27, October 1997 (1997-10), pages 2579-2587, XP001009768 page 2582 -page 2583; figures 2B, 4A, 5B, 6A; table 1 page 2585; table 3 page 2587	19
X	APOSTOLOPOULOS V. ET AL.: "Anti-MUC1 antibodies react directly with MUC1 peptides presented by class I H2 and HLA molecules" THE JOURNAL OF IMMUNOLOGY, vol. 161, 1998, pages 767-775, XP002171173 page 768, right-hand column -page 769; figure 1B	1-7, 17, 18, 20, 26, 27, 29, 30, 35-37

-/--

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 00/08761

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	APOSTOLOPOULOS V. ET AL.: "Induction of HLA-A2-restricted CTLs to the Mucin 1 human breast cancer antigen" THE JOURNAL OF IMMUNOLOGY, vol. 159, 1997, pages 5211-5218, XP002171238 page 5213, right-hand column, paragraph 2 page 5215; figure 3A ---	1-7, 17-22, 26,27, 29,30, 35-37
X	EP 0 369 816 A (UNIV MELBOURNE (AU); XING PEI-XIANG; MCKENZIE IAN FARQUHAR CAMPBELL) 23 May 1990 (1990-05-23) page 10, line 24-49, paragraph 2.4 page 15; table 2 page 4, column 37 -page 5, column 18 page 20; claims 22,24,25 ---	1-7, 17-22,37
X	XING PEI-XIANG ET AL.: "Synthetic peptides reactive with anti-human milk fat globule membrane monoclonal antibodies" CANCER RESEARCH, vol. 50, no. 1, 1 January 1990 (1990-01-01), pages 89-96, XP001010017 page 90; table 1 page 93, right-hand column -page 94; figures 5,6 page 93 -page 94; figures 5,6 ---	1-7,17, 18,20,37
X	DOMÉNECH N. ET AL.: "Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen Mucin" THE JOURNAL OF IMMUNOLOGY, vol. 155, 1995, pages 4766-4774, XP002171174 page 4767; figure 1 page 4770; table I ---	1-7,17, 18,20, 26,27, 29,30,37
X	NISHIMORI I. ET AL.: "N-Acetylgalactosamine glycosylation of MUC1 tandem repeat peptides by pancreatic tumor cell extracts" CANCER RESEARCH, vol. 54, 15 July 1994 (1994-07-15), pages 3738-3744, XP002171175 page 3741 -page 3742; figures 3,5 ---	1-7,17, 20
	---	
	-/--	

## INTERNATIONAL SEARCH REPORT

International Application No

PCI/EP 00/08761

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>WO 00 06723 A (YEDA RES DEV CO LTD WEIZMANN INST SCI (IL) BIO-TECHNOLOGY GEN CORP (US) 10 February 2000 (2000-02-10)</p> <p>SEQ ID NO:43,44,47 page 4, line 35,36 page 40, line 9 -page 42, line 38; figures 18-22; example 4 page 54 -page 59; claims</p>	<p>1-4, 17-22, 26,27, 29,30, 35-37</p>
P, X	<p>CARMON L. ET AL.: "Novel breast-tumor-associated Muc1-derived peptides: characterization in Db-/- X beta2 microglobulin (beta2m) null mice transgenic for a chimeric HLA-A2.1/Db-beta2 microglobulin single chain" INTERNATIONAL JOURNAL OF CANCER, vol. 85, no. 3, 1 February 2000 (2000-02-01), pages 391-397, XP001009767 page 393, left-hand column; table I</p>	<p>1-4, 17-22, 26,27, 29,30, 35-37</p>
P, X	<p>PIETERSZ G.A. ET AL.: "Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1" VACCINE, vol. 18, no. 19, April 2000 (2000-04), pages 2059-2071, XP004202504 ISSN: 0264-410X page 2065, right-hand column, paragraph 1 page 2066; table 3 page 2068, left-hand column, paragraph 1 page 2069; table 4</p>	<p>1-4,17, 18,20, 26,27, 29,30, 36,37</p>
A	<p>BROSSART P. ET AL.: "Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies" BLOOD, vol. 93, no. 12, 15 June 1999 (1999-06-15), pages 4309-4317, XP002147432 ISSN: 0006-4971 page 4311; table 1</p>	<p>31,32</p>

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-37 all partially

A polypeptide consisting of or comprising at least one amino acid sequence of at most 20 consecutive amino acids defined in SEQ ID NO:1, said polypeptide binding at least one MHC-I glycoprotein, with the proviso that said polypeptide is different from SEQ ID NO:2.

Said polypeptide wherein the amino acid sequence is selected from the group consisting of SEQ ID NO:3 to SEQ ID NO:6, SEQ ID NO:65 and SEQ ID NO:66.

Related polynucleotides, vectors, host cells, compositions, uses, vaccines, products, methods and kits.

2. Claims: 1-37 all partially

As invention 1, wherein the amino acid sequence of the polypeptide is selected from the group consisting of SEQ ID NO:7 to SEQ ID NO:15.

3. Claims: 1-37 all partially

As invention 1, wherein the amino acid sequence of the polypeptide is selected from the group consisting of SEQ ID NO:16 to SEQ ID NO:19.

4. Claims: 1-37 all partially

As invention 1, wherein the amino acid sequence of the polypeptide is selected from the group consisting of SEQ ID NO:19 to SEQ ID NO:21.

5. Claims: 1-37 all partially

As invention 1, wherein the amino acid sequence of the polypeptide is selected from the group consisting of SEQ ID NO:22 to SEQ ID NO:25.

6. Claims: 1-37 all partially

As invention 1, wherein the amino acid sequence of the polypeptide is selected from the group consisting of SEQ ID NO:26 to SEQ ID NO:29.

7. Claims: 1-37 all partially

As invention 1, wherein the amino acid sequence of the

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

polypeptide is selected from the group consisting of SEQ ID  
NO:30 to SEQ ID NO:33.



## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box I.1

Although claims 33 and 34 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Although claim 35 (as far as an in vivo method is concerned) is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

## Continuation of Box I.2

Claims Nos.: 23-25, 28 all totally; 26, 29, 30, 35-37 all partially

Present claim 23 relates to a T cell receptor, or a fragment thereof, present claims 24 and 25 relate to a T cell comprising said T cell receptor, present claim 28 relates to a method employing said T cell receptor or fragment thereof, present claim 36 relates in part to a pharmaceutical composition comprising said T cell.

None of these claims give a true technical characterization of said receptor. Moreover, no specific T cell receptors or T cells comprising said receptors are defined in the application.

Consequently, the scope of said claims is ambiguous and vague, and their subject matter is not sufficiently disclosed or supported (Articles 5 and 6 PCT).

No search can be carried out for such purely speculative claims whose wording is, in fact, a mere recitation of the results to be achieved.

Additionally, present claim 26 relates to a product defined by reference to a desirable characteristic or property, namely its capability to bind the T cell receptor of claim 23.

The claim covers all products having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such products.

In fact, although the T cell receptor of claim 23 is not defined in present application, on pages 21-22 it is specified that the product to which claim 26 refers typically comprises (a) an MHC molecule, comprising a polypeptide (epitope) or analogue of the invention in its peptide groove, or (b) an analogue of (a) which is capable of inhibiting the binding of (a) to a T cell receptor of the invention. No other products having the above specified characteristic or property are defined in present application. Moreover, concerning the analogues of (a) which are capable of inhibiting the binding of (a) to the T cell receptor of the invention, present application recites on page 22 that " (b) is typically a derivative of (a) and, thus, may be made by modifying (a) by any of the modifications mentioned herein ", said modifications being defined in pages 8-11 of present application. Again no specific analogues or derivatives are defined in present application.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

In the present case, the claim so lacks support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claim also lacks clarity (Article 6 PCT). An attempt is made to define the product by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claim which appear to be clear, supported and disclosed, namely those parts relating to (a) an MHC molecule, comprising a polypeptide (epitope) of the invention in its peptide groove, as defined on pages 21-22 of present application.

Moreover, present claim 29 relates in part to a cell comprising the product of claim 26, present claims 30 and 35 relate in part to a method employing said product or said cell, present claim 37 relates in part to a kit comprising said product.

Accordingly, the search has been carried out for those parts of these claims which appear to be clear, supported and disclosed, namely those parts relating to cells, methods and kits comprising (a) an MHC molecule, comprising a polypeptide (epitope) of the invention in its peptide groove.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/08761

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9850527 A	12-11-1998	AU 727863 B AU 7371298 A EP 0986636 A	04-01-2001 27-11-1998 22-03-2000
EP 0369816 A	23-05-1990	CA 2003211 A JP 2273195 A ZA 8908777 A	17-05-1990 07-11-1990 28-12-1990
WO 0006723 A	10-02-2000	AU 5062999 A EP 1100901 A	21-02-2000 23-05-2001

CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
15 March 2001 (15.03.2001)

PCT

(10) International Publication Number  
WO 01/018035 A3

(51) International Patent Classification<sup>7</sup>: C12N 15/12,  
C07K 14/47, 7/06, A61K 38/17, 48/00, G01N 33/50,  
33/53, 33/68

(NL). ACRES, Bruce; 10, rue Jean Hermann, F-67000  
Strasbourg (FR). THOMAS, Mireille; 7, rue du Vieux  
Marché aux Poissons, F-67000 Strasbourg (FR).

(21) International Application Number: PCT/EP00/08761

(74) Agent: VOSSIUS & PARTNER; Siebertstr. 4, 81675  
München, Germany (DE).

(22) International Filing Date:

7 September 2000 (07.09.2000)

(81) Designated States (*national*): AU, CA, JP.

(25) Filing Language:

English

(84) Designated States (*regional*): European patent (AT, BE,  
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,  
NL, PT, SE).

(26) Publication Language:

English

(30) Priority Data:

9921242.5 8 September 1999 (08.09.1999) GB  
99402237.4 10 September 1999 (10.09.1999) EP  
60/187,215 3 March 2000 (03.03.2000) US

Published:

— with international search report

(88) Date of publication of the international search report:  
8 November 2001

(71) Applicants: TRANSGENE S.A. [FR/FR]; 11, rue de  
Molsheim, F-67082 Strasbourg Cedex (FR). IMPE-  
RIAL CANCER RESEARCH TECHNOLOGY, LTD.  
[GB/GB]; Sardinia House, Sardinia Street, London WC2A  
3NL (GB).

(48) Date of publication of this corrected version:  
6 September 2002

(72) Inventors: TAYLOR-PAPADIMITRIOU, Joyce; 9  
Cedar Road, Berkhamstead, Hertfordshire HP4 1BL  
(GB). HEUKAMP, Lukas, Carl; 144 Osborne Road,  
London E7 0PN (GB). OFFRINGA, Rienk; Stieltjesstraat  
63, NL-2313 SJ Leiden (NL). MELIEF, Cornelis, Jo-  
hanna, Maria; Wilhelminapark 33, NL-2012 KC Haarlem

(15) Information about Correction:

see PCT Gazette No. 36/2002 of 6 September 2002, Sec-  
tion II

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: MUC-1 DERIVED PEPTIDES

(57) Abstract: Described are peptides and polypeptides derived from the MUC-1 polypeptide which are able to activate Cyto-  
toxic T Lymphocyte (CTL) response, analogues of such peptides and polypeptides nucleotide sequences encoding such peptides and  
polypeptides and therapeutic uses thereof. Moreover, indications for selecting appropriate minimal antigenic MUC-1 polypeptides  
with reference to the HLA-type of the patient to be treated or tested are described.



WO 01/018035 A3

## MUC-1 derived peptides

The present invention relates to MHC class I restricted epitopes and T cells which can be used to prevent or treat cancer or cause immunosuppression; and to the use of the epitopes to diagnose cancer.

In particular, the present invention relates to antigenic polypeptides of the MUC-1 protein which are able to activate Cytotoxic T Lymphocytes (CTL) response and to nucleotide sequences encoding such polypeptides. Furthermore, the present invention relates to vectors comprising such nucleotide sequences, host cells comprising the same and their use in the production of the antigenic polypeptides. In addition, the present invention relates to compositions comprising the polypeptides, nucleotide sequences, vector or host cells of the present invention and to therapeutic and diagnostic uses of such compositions.

Generally speaking, there are two major types of immune response: the humoral response which is characterized by the production of antibodies by B lymphocytes, and the cell-mediated immune response. Antibodies are able to recognize antigens in their three dimensional form, either soluble or bound to an insoluble support such as a cell, while T cells recognize processed antigen fragments which are bound and presented by glycoproteins encoded by the major histocompatibility complex (MHC) notably MHC-I genes which are expressed at the cell surface of almost all vertebrate cells or MHC-II genes which are expressed on antigen presenting cells (APC).

A cell-mediated immune response usually necessitates the cooperation of helper T lymphocytes and effector cells. This cooperation takes place, in particular, as a result of interleukin-2 and/or various other cytokines which are secreted by helper T lymphocytes after their activation by antigenic fragments presented by APC in association with MHC-II. Cytotoxic T Lymphocytes (CTL) are activated, induced to proliferate and to exert their antigen-specific cytotoxic function upon exposure to antigenic polypeptides complexed with

autologous MHC-I, co-stimulatory molecules on the surface of the APC and cytokines, often derived from helper T cells. T cell derived cytokines can also trigger and drive the proliferation and antigen processing capacity of APC as well as activation and induction of proliferation in other cells, including other T cells.

Thus, cytotoxic T lymphocytes (CTL) recognise epitopes bound to MHC class I molecules on the surface of cells. Recognition of such epitopes on the surface of target cells by CTL leads to the killing of the target cells by the CTL. The epitopes which are displayed on the cell are fragments from proteins which have been processed in the class I antigen processing pathway of the cell. In this pathway proteins (generally from the cytoplasm) are broken down in the cytoplasm into small peptides. The small peptides are then transported through the endoplasmic reticulum (where they bind to the MHC molecules) to the surface of the cell.

Said antigen presentation by MHC-I molecules has been characterized (see for example Groettrup et al., 1996, *Immunology Today* 17, 429-435): a full-sized protein or glycoprotein antigen is digested into shorter antigenic polypeptides (of about 7 to 13 amino acids in length). Said polypeptides are associated with MHC-I molecules and  $\beta$ -2 microglobulin leading to a ternary complex which is further presented on the cell surface.

It is not possible to predict which proteins will enter the antigen processing pathway, which fragments will be produced, or which fragments will bind to MHC molecules and be presented at the surface of the cell. Additionally it is not possible to predict which fragments T cells will recognise and whether the T cells which recognise the fragments will be protective.

MHC-I specificity towards antigens can vary greatly depending on the considered MHC-I molecule (HLA-A, HLA-B, ...) and on the allele (HLA-A2, HLA-A3, HLA-A11, ...) since genes encoding the MHC molecules are greatly variable between individuals among a species (reviewed in George et al., 1995, *Immunology Today*, 16, 209-212).

Most tumor cells express antigens at their surface which differ either qualitatively or quantitatively from the antigens present at the surface of the corresponding normal cells. These antigens are specific when they are expressed only by tumor cells. When they are present on both normal and tumor cells, these antigens are said to be associated with the tumor; in this case, they are present either in larger amounts or in a different form in the tumor cells.

It is now well known that patients suffering from a cancer may develop an immune response to their tumor. This has been revealed, in particular, by demonstrating that the serum of some patients contain anti-tumor antigen antibodies, and that their serum was capable of inhibiting

the growth of cancer cells in vitro. Nevertheless, inasmuch as spontaneous tumor regressions are extremely rare, it appears that the immune response observed in vitro remains ineffective in vivo.

Hellstrom et al. (1969, Adv.Cancer Res.12, 167-223) have shown that antigen-specific CTL can be effective mediators in a tumor-specific immune response. However, this natural immune response is not always effective enough to limit tumor growth. Although an immune response may develop against a tumor, it is not known whether it is of real benefit to the patient. Seemingly uncontrolled tumor growth would suggest that a tumor eludes the body's mechanisms of immune surveillance. Tumor-derived molecules are considered to play a significant part in modifying or diverting the immune response in favor of the tumor rather in favor of the individual.

In the light of the complexity of the immune response against tumors and the modest state of current knowledge in this field, the use of an anticancer vaccine is not obvious. Animal studies have shown that immunization using living or killed cancer cells could lead to rejection of a subsequent tumor graft, however attempts at immunization using acellular products, for example administration of the complete antigenic protein, with polypeptide fragments of such protein DNA fragment encoding all or part of tumor-associated proteins, have generally been less successful.

Recently, Toes et al. (1997, Proc. Natl. Acad. Sci. 94, 14660-14665) have developed an alternative approach based on minimal antigenic polypeptide fragments selection which might be specifically recognized by the CTL. According to said method, the minimal antigenic fragments are expressed in the host cells where they can be associated with MHC-I molecules and then be presented on the cell surface, inducing a specific immune reaction. More specifically, it has been shown that intra-cellular expression of "minigens" encoding very short epitopes (from 7 to 13 amino acids in length) can induce a cellular immune response. Moreover, Whitton et al. (1993, J. of Virology 67, 348-352) have proposed the use of a vector, called "string of beads" construct, which co-expresses several minigens and can induce a synergetic CTL immune response.

Another recent and important use for such polypeptides is in association with soluble complexes of MHC-I,  $\beta$ -2 microglobulin and a fluorescent or otherwise visually detectable reagent. These, so called "Tetramers" ( *eg*, as described in Altman et al, 1996, Science, 274:94-96) can be used to identify by flow cytometry or histology, antigen specific CTL ex vivo.

MUC-1 is a glycosylated mucin polypeptide found on the apical surface of mucin-secreting epithelial cells in various tissues, including breast, lung, pancreas, stomach, ovaries, fallopian tubes, and intestine (Peat et al., 1992, *Cancer Res.* 52:1954-60 - Ho et al., 1993, *Cancer Res.* 53:641-51). Malignant transformation of breast, ovary, pancreas and probably other epithelial tissues, results in over expression of MUC-1 polypeptide in tumor cells (Hareuveni et al., 1990, *Eur. Journ. Biochem.* 189:475-86 ; Layton et al., 1990, *Tumor Biol.* 11:274-86). In addition, abnormal glycosylation of MUC-1 polypeptide in breast, and probably other MUC-1-expressing tumour cells results in the exposure of tumor-associated antigenic epitopes on the protein core of MUC-1 (Burchell et al., 1987, *Cancer Res.* 47:5476-82; Devine et al., 1990, *J. Tumor Marker Oncol.* 5:11-26; Xing et al., 1989, *Immun.Cell Biol.* 67:183-95) as well as on the glycosyl side chains (Samuel et al., 1990, *Cancer Res.* 50:4801-8).

Monoclonal antibodies specific for these epitopes have been described which can identify more than 90% of breast and pancreatic tumors. Non major-histocompatibility-complex (MHC) restricted cytotoxic T cell responses to the MUC-1 tumor specific protein epitope by T cells from breast and pancreatic cancer patients have also been reported (Jerome et al., 1991, *Cancer Res.* 51:2908-16) in addition to MHC restricted, MUC-1-specific CTL (Reddish et al., 1995, *Int. J. Cancer* 10:817-823). Moreover, proliferation of T cells to purified MUC-1 has been seen (Keydar et al., 1989, *Proc.Natl. Acad. Sci. USA* 86:1362-6). These various observations suggest that MUC-1 may be an effective target antigen for active immunotherapy in breast, as well as other cancers. Hareuveni et al. (1991, *Vaccine* 9:618-27) expressed the MUC-1 antigen in vaccinia virus and showed that rat immunized with VV-MUC-1 rejected MUC-1-bearing tumor cells at a rate of 60-80 % (Hareuveni et al., 1990, *Proc. Natl. Acad. Sci. USA* 87:9498-502).

The inventors have now identified epitopes which can be used to induce a MHC class I restricted response which is protective against a tumor challenge. The epitopes are from the MUC1 protein. Since activated T cells express MUC1, these epitopes can also be used to induce an immune response against such T cells or be used to obtain products which are capable of targeting activated T cells.

Thus, the present invention concerns immuno-reactive polypeptides identified from the MUC-1 polypeptide sequence and their uses in cancer therapy and diagnosis. The invention could also be used to follow MUC-1 specific immune responses in patients during the course of disease



and/or treatment. The invention also concerns nucleotide sequences encoding these polypeptides, vectors useful for transferring and expressing said nucleotide sequences into target cells, and uses of said nucleotide sequences in cancer gene therapy vaccination and diagnosis.

Accordingly, in a first aspect the present invention relates to polypeptides consisting of or comprising at least one amino acid sequence of at most 20 consecutive amino-acids defined in SEQ ID NO: 1, wherein said polypeptide is different from SEQ ID NO : 2 and is capable of binding with at least one MHC-I molecule.

"Capable of binding with" means that the considered polypeptide is capable to interact and to bind with MHC-I molecules. In a preferred embodiment of the invention, this binding results in cell surface presentation of these polypeptides by MHC class I molecules in order to elicit a specific immune response or for the detection of a specific immune response, eg, by Tetramer analysis (as described, e.g., in Altman et al., 1996, Science 274:94-96).

According to a preferred embodiment, said amino acid sequence is selected from the group consisting of SEQ ID NO: 3 to SEQ ID NO: 33, SEQ ID NO: 65 and SEQ ID NO: 66. Data to explain why these sequences have been selected are shown in Figures 1 to 7.

According to a preferred embodiment of the invention, said polypeptide presents at least one of the following properties :

- (a) the amino acid sequence is selected from the group consisting of SEQ ID NO:3 to SEQ ID NO:6, SEQ ID NO: 65, SEQ ID NO: 66, and said polypeptide binds the HLA A2 glycoprotein of MHC-I;
- (b) the amino acid sequence is selected from the group consisting of SEQ ID NO:7 to SEQ ID NO: 15, and said polypeptide binds the HLA B7 glycoprotein of MHC-I;
- (c) the amino acid sequence is selected from the group consisting of SEQ ID NO: 16 to SEQ ID NO: 19, and said polypeptide binds the HLA A3 glycoprotein of MHC-I;
- (d) the amino acid sequence is selected from the group consisting of SEQ ID NO: 19 to SEQ ID NO: 21, and said polypeptide binds the HLA A11 glycoprotein of MHC-I;
- (e) the amino acid sequence is selected from the group consisting of SEQ ID NO: 22 to

- SEQ ID NO: 25, and said polypeptide binds the HLA A24 glycoprotein of MHC-I;
- (f) the amino acid sequence is selected from the group consisting of SEQ ID NO: 26 to SEQ ID NO: 29, and said polypeptide binds the HLA A1 glycoprotein of MHC-I; and
- (g) the amino acid sequence is selected from the group consisting of SEQ ID NO: 30 to SEQ ID NO: 33, and said polypeptide binds the HLA B8 glycoprotein of MHC-I.

In a particular preferred embodiment the polypeptide is a peptide that comprises a MHC class I restricted T cell epitope, the epitope being contained in or represented by any one of SEQ ID NO: 1 to 33, 65 or 66, preferably SEQ ID NO: 4, 3, or 5. These latter epitopes lie outside the immunogenic variable non tandem repeat (VNTR) region.

In general, the amino acid sequence present in the polypeptide of the invention may be any stretch of at most 20 contiguous amino acids (such a stretch is in the following referred to as "epitope") of the sequence represented by SEQ ID NO: 1, preferably a sequence represented by any one of SEQ ID NOs: 3 to 33, 65 or 66 below or the amino acid sequence of an epitope present within these sequences (such as the fragments of the sequences shown in the brackets shown below, e.g., for SEQ ID NO: 3 to 5 or for SEQ ID NO: 6, 65 and 66)

SEQ ID NO: 3 - ALGSTAPPV (LGSTAPPV)

SEQ ID NO: 4 - FLSFHISNL (LSFHISNL)

SEQ ID NO: 5 - TLAPATEPA (LAPATEPA)

SEQ ID NO: 6 - SLSYTNPAV (SLSYTNPA or LSYTNPAV)

SEQ ID NO: 65 - LLLTVLTVV (LLLTVLTV or LLTVLTVV)

SEQ ID NO: 66 - ALGSTTPPA (LGSTTPPA)

In one embodiment the polypeptide of the invention has the same sequence as the "epitope". The peptide typically comprises 1, 2, 3 or more copies of each of 1, 2 or more, or all of the above defined "epitopes".

Typically in the polypeptide, a 'linker' sequence may or may not separate the "epitopes" and/or there may or may not be additional (non-"epitope") sequences at the N terminal or C terminal of the polypeptide. Typically the peptide comprises 1, 2, 3 or more linkers. The linkers are typically 1, 2, 3, 4 or more amino acids in length and may comprise amino acid sequence encoded by a polynucleotide sequence that comprises enzyme restriction sites or amino acids

that constitute proteosomal cleavage sites. Thus, in the polypeptide 1, 2 or more, or all of the "epitopes" may be contiguous with each other or separated from each other. The "epitope" sequences may overlap with each other. The polypeptide is typically 8 to 2000 amino acids in length, such as 9 to 1000, 10 to 500, 11 to 200, 12 to 100 or 15 to 50 amino acids.

The peptide may be a natural protein, a fragment thereof, a non-natural protein, or a fusion protein (typically) comprising sequences from different proteins.

The peptide may or may not comprise or be a fragment of MUC1, which fragment may or may not include the MUC1 VNTR. In a preferred embodiment such a fragment only comprises sequences from outside the VNTR. Figure 12 shows a representation of the MUC1 amino acid sequence in which only a single perfect copy of the tandem repeat sequence is shown by amino acids 129 to 148 inclusive. In a particularly preferred embodiment the polypeptide of the invention comprises fragments of the MUC1 sequence shown in Figure 12 or in SEQ ID NO: 2, which fragments do not include any sequence from amino acids 97 to 184, e.g. fragments which do not include sequence from amino acids 90 to 190 (as shown in Figure 12).

SEQ ID NOs: 4, 3 and 5 can be seen at amino acid positions 264 to 272 (inclusive), 167 to 175 (inclusive) and 79 to 87 (inclusive) of Figure 12. In one embodiment the polypeptide only contains a MUC1 sequence that lies close to the epitopes, such as only sequences from or within positions 258 to 276, 253 to 281, 161 to 179, 156 to 184, 72 to 91 or 67 to 96 of Figure 12.

The polypeptide may also comprise a sequence which aids the stimulation of a CTL response directed to the epitope. Such sequence may act as adjuvant or may target the polypeptide to antigen presenting cells (APCs) or to compartments in the antigen processing pathway. The sequence may stimulate a T helper response, such as a Th1 response, and thus may comprise a T helper (e.g. Th1) cell epitope. The polypeptide may also comprise the sequence of any of the proteins mentioned herein.

The polypeptide may be free from modifications. In one embodiment the polypeptide is modified, for example by a natural post-translational modification (e.g. glycosylation) or an artificial modification. Thus, the sequence in the polypeptide may or may not comprise the modification(s) that are present when the sequence is expressed in a normal or cancer cell. The polypeptide may comprise the modifications that occur when it is expressed in a eukaryotic (e.g. human) or prokaryotic (e.g. E. coli) cell. In a further embodiment the polypeptide lacks glycosylation.

The modification may provide a chemical moiety (typically by substitution of a hydrogen, e.g. the hydrogen of a C-H bond), such as an amino, acetyl, hydroxy or halogen (e.g. fluorine) group or carbohydrate group. Typically the modification is present on the N or C terminus.

The present invention also relates to analogues of the polypeptides of the invention which are capable of inhibiting the binding of the polypeptide or of an epitope contained in said polypeptide to a T cell receptor either by directly binding to the same T cell receptor or by binding to the same T cell receptor after being processed.

The analogue of the invention is capable of inhibiting the binding of any of the above-mentioned polypeptides (epitopes) to a T cell receptor, either directly or after the analogue is processed. Therefore, certain analogues of the invention can be processed to provide other analogues (that can bind the T cell receptor directly). The term 'analogue' as used here includes both of these types of analogue.

The term 'processed' refers to being processed by the class I antigen presentation pathway (generally this will be hydrolysis, e.g. proteolysis).

Typically the amount of polypeptide (epitope) which can bind the T cell receptor in the presence of the analogue is decreased. This is because the analogue is able to bind the T cell receptor and therefore competes with the epitope for binding to the T cell receptor. The binding of the analogue to the T cell receptor is a specific binding. Generally during the binding discussed above the polypeptide (epitope) or analogue is bound to an MHC class I molecule, such as HLA-A\*0201.

The inhibition of binding can be determined using techniques known in the art or any of the techniques or under any of the conditions discussed herein. The T cell receptor used binds specifically to the polypeptide (epitope). T cells with such receptors can be produced by stimulating antigen naive T cells with any of the polypeptides (epitopes) of the invention, for example using the stimulation protocol described in Plebanski et al. (Eur. J. Immunol. 25 (1995), 1783-1787).

Typically an analogue is capable of causing antigen specific functional activation of a T cell which recognises the polypeptide (epitope) (which can be measured using any of the techniques discussed herein). Generally the analogue causes such activation when it is presented to the T cell associated with an MHC class I molecule, such as HLA-A\*0201 (for example on the surface of a cell).

The analogue is typically capable of stimulating a MHC class I restricted T cell response directed to the polypeptide (epitope), for example when administered to a human or animal (such as in any of the forms or with any of the adjuvants mentioned herein). Such a response may be protective against a tumor challenge in an animal model or of therapeutic benefit in a human patient.

The analogue typically has a shape, size, flexibility or electronic configuration which is substantially similar to the polypeptide of the invention. It is typically a derivative of the polypeptide.

As well as binding the T cell receptor discussed above the analogue may also be able to bind other specific binding agents that bind the polypeptide (epitope). Such an agent may be HLA-A\*0201. The analogue typically binds to antibodies specific for the polypeptide and, thus, inhibits binding of the polypeptide to such an antibody. The analogue is either a peptide or non-peptide or may comprise both peptide and non-peptide portions. Such a peptide or peptide portion may have homology with the polypeptide of the invention.

The analogue may be at least 30% homologous to the polypeptide, preferably at least 50, 70, 80 or 90% and more preferably at least 95%, 97% or 99% homologous thereto, for example over a region of about 20, preferably at least 30, for instance at least 40, 60 or 100 or more contiguous amino acids. Methods of measuring protein homology are well known in the art and it will be understood by those skilled in the art that in the present context, homology is calculated on the basis of amino acid identity (sometimes referred to as "hard homology"). For example the UWGCG Package provides the BESTFIT program which can be used (e.g. on its default setting) to calculate homology (Devereux et al., Nucl. Acids Res. 12 (1984), 387-395). The homologous peptide typically differs from the epitope present in the polypeptide of the present invention by substitution, insertion or deletion, for example from 1, 2, 3, 4 or more substitutions and/or 1, 2, 3, 4 or more deletions and/or 1, 2, 3, 4 or more insertions over its length. The substitutions are preferably 'conservative'. These are defined according to the following Table. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:

Table 1

ALIPHATIC	Non-polar	G A P
		I L V
	Polar - uncharged	C S T M
		N Q
	Polar - charged	D E
		K R
AROMATIC		H F W Y

Typically the amino acids in an analogue which has homology with the polypeptide which are equivalent to amino acids in the epitope sequence (such as those which contribute to binding the MHC molecule or are responsible for the recognition by the T cell receptor) are the same or are conservatively substituted.

Typically in the analogue the amino acid in position 2 (based on the numbering used for epitopes bound to MHC molecules) is a L or M and/or the amino acid in position 6 is a V and/or the amino acid in position 9 is V or L.

The analogue (including the homologous peptide discussed above) may comprise 1, 2, 3, 4 more non-natural amino acids, for example amino acids with a side chain different from natural amino acids. Generally, the non-natural amino acid will have an N terminus and/or a C terminus. The non-natural amino acid may be an L-amino acid.

Typically the analogue is a peptide which comprises one or more modifications. The sequence of the peptide may be the same as the epitope or homologous peptide discussed above. The modification may be any of the modifications mentioned above which can be present on the polypeptide of the invention.

The modification can be present on any of the amino acids of the polypeptide, such as any of the the amino acids responsible for binding the MHC molecule or which contact the T cell receptor during recognition by a T cell.

The analogue is typically designed or selected by computational means and then synthesised using methods known in the art. Alternatively, the analogue can be selected from a library of compounds. The library may comprise peptides which have an HLA-A\*0201 binding motif. The library may be a combinatorial library or a display library, such as a phage display library. The library of compounds may be expressed in the display library in the form of being bound to a MHC class I molecule, such as HLA-A\*0201.

Analogues can be selected from the library based on any of the characteristics mentioned above, such as their ability to mimic the binding characteristics of the original epitopes. Thus, they may be selected based on the ability to bind a T cell receptor, HLA-A\*0201 or antibody which recognises the epitope. They may be selected based on their ability to cause antigen specific functional activity of a T cell that recognises the epitope (for example using any of the techniques or methods of the invention mentioned herein, e.g. CTL assays, ELISPOT assays or by measuring the production of cytokines inside the T cell).

The analogue which is capable of inhibiting the binding of the polypeptide (epitope) to the T cell receptor after being processed is capable of being processed in the class I antigen processing pathway of a cell to provide a second analogue which can directly inhibit the binding of the polypeptide (epitope) to the T cell receptor.

Such a cell is typically a mammalian or avian cell, such as a human or rodent (e.g. mouse or rat cell). The cell may be a muscle cell or a professional APC (such as a dendritic cell, macrophage, Langerhans cell or B cell). Typically the cell will provide the epitope or analogue on its surface bound to a MHC class I molecule.

The invention also relates to polynucleotides comprising a nucleic acid sequence encoding at least one polypeptide or analogue of the present invention. Based on the amino acid sequences provided with in the present application and by using the genetic code those skilled in the art can easily identify said nucleic acid sequences. According to a preferred embodiment, the nucleic acid sequence of the invention is selected from the group consisting of SEQ ID NO: 34 to SEQ ID NO: 64, and their complementary sequences.

The term "polynucleotide" as used in the scope of the present invention means a DNA and/or RNA fragment, single or double-stranded, linear or circular, natural or synthetic, modified or not (see US-A-5,525,711, US-A-4,711,955, US-A-5,792,608 or EP-A-0 302 175 for modification examples) defining a fragment or a portion of a nucleic acid, without size limitation. It may be, *inter alia*, a genomic DNA, a cDNA, an mRNA. "Polynucleotides" and "nucleic acids" are synonyms with regard to the present invention. The nucleic acid may be in the form of a linear polynucleotide, and preferably in the form of a plasmid. A wide range of plasmids is commercially available and well known by one skilled in the art. These available plasmids are easily modified by the molecular biology techniques (Sambrook et al., 1989, Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York).

Plasmids derived from pBR322 (Gibco BRL), pUC (Gibco BRL), pBluescript (Stratagene), pREP4, pCEP4 (Invitrogen) and also p Poly (Lathe et al., 1987, Gene 57, 193-201) are illustrative of these modifications. According to the invention, the nucleic acid can be a naked polynucleotide (Wolff et al., Science 247 (1990), 1465-1468) or is formulated with at least one compound such as a polypeptide, preferably viral polypeptides, oligonucleotides or cationic lipids, or cationic polymers which can participate in the uptake of the nucleic acid into the cells (see Ledley, Human Gene Therapy 6 (1995), 1129-1144 for a review) or a protic polar compound (examples are provided below in the present specification or in EP-A-0 890362). "Polynucleotide" also designates nucleic acid of viral origin (viral vector) which encodes at least for the polypeptide of the invention. Such viral vector preferably derives from a virus selected among poxvirus (vaccine virus, MVA, canarypox...), adenovirus, retrovirus, herpes virus, alpha virus, foamy virus or adeno associated virus. Said viral vectors and their uses are widely disclosed in gene therapy literature.

Preferably, said nucleic acid includes at least one therapeutically useful gene sequence that can be transcribed and translated to generate a polypeptide of interest and the elements enabling its expression. The genetic information necessary for expression by a target cell comprises all the elements required for transcription of DNA into RNA and, if necessary, for translation of mRNA into a polypeptide. Transcriptional promoters suitable for use in various vertebrate systems are well known. For example, suitable promoters include viral promoters like RSV, MPSV, SV40, CMV or 7.5k, vaccinia promoter, inducible promoters, tissue specific promoters, synthetic promoters, etc or combination thereof. The nucleic acid can also include intron sequences, targeting sequences, transport sequences, sequences involved in replication or integration. Said sequences have been reported in the literature and can be readily obtained by those skilled in the art. The nucleic acid can also be modified in order to be stabilized with specific components as spermine.

The polynucleotide of the invention is capable of expressing 1, 2, 3 or more (different) compounds, each of which is a polypeptide or analogue of the invention (for example any combination of a polypeptide and an analogue). The polynucleotide is typically DNA or RNA, and is single or double stranded. The polynucleotide generally comprises 1, 2, 3 or more coding sequences which may be the same or different. At least one of the coding sequences



encodes a polypeptide or an analogue of the invention. The coding sequence is typically operably linked to a control sequence capable of providing for expression of the polynucleotide. Thus, typically the polynucleotide comprises 5' and 3' to the coding sequence sequences which aid expression, such as aiding transcription and/or translation of the coding sequence. Typically the polynucleotide comprises a promoter, enhancer, transcription terminator, polyadenylation signal, polyA tail, intron, translation initiation codon or translation stop codon.

The polynucleotide may in particular be capable of expressing a polypeptide or analogue of the invention in a mammalian or avian cell, such as in any of the cells discussed herein. The polynucleotide may furthermore be capable of expressing the polypeptide or analogue in the cellular vector discussed below.

The polynucleotide may form or be part of a vector, such as a plasmid or cosmid vector. In one embodiment the polynucleotide is present in a virus or cellular vector, such as a virus which is capable of stimulating a MHC class I restricted T cell response (e.g. a vaccinia virus).

The introduction or transfer process of an anionic substance of interest into a cell is by itself well known. "Introduction or transfer" means that the polynucleotide is transferred into the cell and is located, at the end of the process, inside said cell or within or on its membrane. It is also called "transfection" or "infection" depending of the nature of the vector.

The invention is therefore further directed to a vector, e.g. of viral or plasmid origin, comprising at least a nucleic acid sequence of the invention.

According to a preferred embodiment, the vector of the invention comprises one or more nucleotide sequences selected from the group consisting of:

- the sequences encoding a polypeptide as defined in (a) in addition to one or more of the sequences encoding a polypeptide as defined in (b), (c), (d), (e), (f) or (g),
- the sequences encoding a polypeptide as defined in (b) in addition to one or more of the sequences encoding a polypeptide as defined in (a), (c), (d), (e), (f) or (g),
- the sequences encoding a polypeptide as defined in (c) in addition to one or more of the sequences encoding a polypeptide as defined in (a), (b), (d), (e), (f) or (g),
- the sequences encoding a polypeptide as defined in (d) in addition to one or more of

- the sequences encoding a polypeptide as defined in (a), (b), (c), (e), (f) or (g),
- the sequences encoding a polypeptide as defined in (e) in addition to one or more of the sequences encoding a polypeptide as defined in (a), (b), (c), (d), (f) or (g),
  - the sequences encoding a polypeptide as defined in (f) in addition to one or more of the sequences encoding a polypeptide as defined in (a), (b), (c), (d), (e) or (g), and
  - the sequences encoding a polypeptide as defined in (g) in addition to one or more of the sequences encoding a polypeptide as defined in (a), (b), (c), (d), (e) or (f).

Said constructs are named "string of beads" (Whitton et al. 1993, loc. cit.)

Furthermore, the present invention relates to host cells comprising at least one polynucleotide or at least one vector according to the invention. Preferably such a host cell is a prokaryotic cell or a eukaryotic cell, such as a yeast cell, more preferably an animal cell, most preferably a mammalian cell.

The present invention also relates to a composition (iv) that comprises two or more different compounds wherein each of the compounds is (i) a polypeptide or (ii) an analogue or (iii) a polynucleotide of the invention as defined above.

In the composition (iv) 1, 2, 3, 4, 5 or more different compounds may be present, wherein each of these compounds is (i), (ii) or (iii). Thus, the composition may comprise all the epitopes of the invention (present in the form of the polypeptide of the invention), or instead of any of these epitopes the equivalent analogue. The composition may comprise 1, 2, 3, 4, 5 or more polynucleotides which together are capable of being expressed to provide 1, 2, 3, 4, 5 or more different epitopes, analogues or polypeptides of the invention, or all the epitopes (or instead of any of the epitopes the equivalent analogue) of the invention (e.g. in the form of polypeptide of the invention).

In particular, (i), (ii), (iii) or (iv) are provided for use in a method of vaccination against cancer or for use in a method of immunosuppression. 1, 2, 3, 4, 5, or more different epitopes of the invention (or all of the epitopes of the invention) may be used (or instead of any of these epitopes the equivalent analogue). As discussed above if more than one epitope/analogue is used then the combination of epitopes/analogues may be present in the form of the polypeptide of the invention or in the form of the composition of the invention. Similarly 1, 2, 3, 4, 5 or

more different polynucleotides may be used which together are capable of being expressed to provide any of the combinations of epitopes, analogues, polypeptides or compositions mentioned herein.

However, in one embodiment each epitope/analogue or one or more groups of epitopes/analogues within the combination are administered to the host separately or sequentially. The epitopes/analogues in each group are typically together in the form of a single peptide of the invention or in the form of the composition of the invention. Similarly, different polypeptides or polynucleotides of the invention may be administered separately or sequentially, for example polynucleotides capable of expressing individual or groups of epitopes and/or polypeptides and/or analogues and/or compositions.

Thus, the invention provides a combination of 1, 2, 3, 4, 5 or more different epitopes and/or analogues and/or polypeptides and/or compositions and/or polynucleotides of the invention for simultaneous, separate or sequential use in a method of treatment of the human or animal body by therapy, for example in a method of vaccination against cancer or in a method of immunosuppression.

The method of vaccination against cancer or the method of immunosuppression typically leads to a MHC class I restricted T cell response, the T cells of which are specific for an epitope of the invention.

Thus, (i), (ii), (iii), (iv) can be used in a form or manner in which they stimulate such a MHC class I restricted T cell response. Such methods are known in the art. Generally a MHC class I restricted T cell response can be obtained by vaccinating using an appropriate dose, route of administration, adjuvant or delivery system. Thus, the vaccine of the invention may comprise one or more components (for example, as discussed herein in relation to the vaccine of the invention) in addition to (i), (ii), (iii) or (iv). The components of the vaccine may be administered simultaneously, separately or sequentially to the host.

Thus, the invention also provides a vaccine comprising (i), (ii), (iii) or (iv), which vaccine is capable of stimulating a MHC class I restricted T cell response directed to an epitope (polypeptide) of the invention. Typically such a vaccine comprises an adjuvant or delivery system which stimulates a MHC class I restricted T cell response.

The adjuvant may be capable of causing or augmenting a MHC class II restricted T cell (typically CD4) response which is favourable to the production of a MHC class I restricted T cell response, such as a Th1 response. Thus, the adjuvant may comprise a MHC class II

restricted T cell epitope (or a precursor which can be processed *in vivo* to provide such an epitope). The adjuvant may be a cytokine, such as a cytokine which stimulates a MHC class I restricted T cell response or favourable MHC class II restricted T cell response (e.g. IL-2, IL-7, IL-12 or IFN- $\gamma$ ). The adjuvant may be, for example, CFA (Golding and Scott, Ann. N.Y. Acad. Sci. 754 (1995), 126-137), a muramyl dipeptide (e.g. of a mycobacterial cell wall), monophosphoryl lipid A, lipopolysaccharide (e.g. from *B. abortus*), liposomes, SAF-1 (Golding and Scott, Ann. N.Y. Acad. Sci. 754 (1995), 126-137), a saponin (e.g. Quil A), keyhole limpet hemocyanin, yeast TY particle, beta 2-microglobulin or mannan (e.g. oxidised mannan).

The delivery system is typically capable of providing (i), (ii), (iv) or an epitope or analogue expressed from (iii) or (iv) to an APC, such as a professional APC.

As mentioned above the particular route of administration used may aid the stimulating of a MHC class I restricted T cell response and, thus, (i), (ii), (iii), (iv) or the vaccine of the invention may be provided in a form suitable for administering by such a route. Intraperitoneal or intravenous routes are preferred. In one embodiment these substances are delivered by biolistic means.

Generally a low dose of antigen favours the development of a MHC class I restricted T cell response. Thus, in the method a suitable low dose of a compound of the invention can be given. The vaccine may be provided in an amount and concentration that is suitable for administering to provide an appropriate low dose. In one embodiment (iv) is administered in the form of "naked DNA".

The invention also relates to a composition, preferably a pharmaceutical composition, which is particularly useful for the delivery of polynucleotides of the invention to cells or tissues of a subject in the scope of a gene therapeutic method, especially in case of cancer treatment. The term "gene therapy method" is preferably understood as a method for the introduction of a polynucleotide into cells either *in vivo* or by introduction into cells *in vitro* followed by re-implantation into a subject. "Gene therapy" in particular concerns the case where the polynucleotide is expressed in a target tissue, especially tissue comprising cell expressing MHC-I molecules.

Preferably, the composition, in particular pharmaceutical composition, furthermore comprises

a pharmaceutically acceptable carrier or diluent. The carrier or diluent is non toxic to recipients at the dosages and concentrations employed. Representative examples of carrier or diluent for injectable solutions include water, isotonic saline solutions which are preferably buffered at the physiological pH (such as phosphate buffered saline or Tris-buffered saline), mannitol, dextrose, glycerol and ethanol, as well as polypeptides or protein such as human serum albumin. This carrier or diluent is preferably isotonic, hypotonic or weakly hypertonic and has a relatively low ionic strength. Furthermore, it may contain any relevant solvents, aqueous or partly aqueous liquid carriers comprising sterile, pyrogen-free water, dispersion media, coatings, and equivalents. The pH of the pharmaceutical preparation is suitably adjusted and buffered.

The invention more particularly pertains to a composition, in particular pharmaceutical composition, comprising at least one of the complexes described above and also incorporating at least one adjuvant capable of improving the transfection capacity of said complex. Adjuvants may be selected from the group consisting of a chloroquine, protic polar compounds such as propylene glycol, polyethylene glycol, glycerol, EtOH, 1-methyl L -2-pyrrolidine or their derivatives, or aprotic polar compounds such as dimethylsulfoxide (DMSO), diethylsulfoxide, di-n-propylsulfoxide, dimethylsulfone, sulfolane, dimethylformamide, dimethylacetamide, tetramethylurea, acetonitrile and their derivatives.

In a preferred embodiment, the polynucleotide which is contained in the composition is a DNA. Other particular embodiments of the invention are compositions, in particular pharmaceutical compositions, wherein said polynucleotide is naked, associated with viral polypeptides or complexed with cationic components, more preferably with cationic lipids. In general, the concentration of polynucleotide in such a composition is from about 0.1 µg/ml to about 20 mg/ml.

The composition, in particular pharmaceutical composition, in accordance with the present invention can be administered into a vertebrate tissue. This administration may be made by intradermal, subdermal, intravenous, intramuscular, intranasal, intracerebral, intratracheal, intraarterial, intraperitoneal, intravesical, intrapleural, intracoronary or intratumoral injection, by means of a syringe or other devices. Transdermal administration is also contemplated, as

are inhalation, aerosol routes, instillation or topical application.

According to the present invention, the composition, in particular pharmaceutical composition, can be administered into target tissues of the vertebrate body including those of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, connective tissue, blood, etc. In a preferred embodiment, said composition will be administered into tumor.

Administration of such a composition to a patient allows to elicit an immune response based on the activation of cytotoxic lymphocytes by the polypeptides encoded by said nucleotide sequences. The composition of the invention is particularly suitable for the treatment or prevention of MUC-1-expressing cancers, such as breast cancer, ovary cancer, pancreas or lung cancer.

According to a special embodiment, the compositions of the present invention, i.e. containing polypeptide or polynucleotide sequences of the instant invention (see above), is suitable for the treatment or prevention of MUC1-expressing cancers, wherein said treatment or prevention comprises:

- a step a) consisting in administering to a patient a composition of the present invention,
- a step b) consisting in administering to the same patient in need a second composition, wherein said composition is either a composition of the present invention, or a composition containing a MUC-1 polypeptide, or a polynucleotide encoding such a MUC-1 polypeptide, wherein said MUC-1 polypeptide is the full length MUC-1 polypeptide of SEQ ID NO: 2, or a MUC-1 polypeptide as disclosed in US 4,963,848, US 5,053,489, WO 8805054 or US 5,861,381 corresponding to MUC-1 polypeptide presenting varying tandem repeat sequence.

According to this special embodiment, both administration steps a) and b) can be made independently of each other or in the same time. This special embodiment can result in boosting the immune response developed by the treated patient.

According to the invention, the term "cells" includes prokaryote cells and eukaryote cells, yeast cells, plant cells, human or animal cells, in particular mammalian cells. In particular, cancer cells should be mentioned. The invention can be applied *in vivo* to the interstitial or

luminal space of tissues in the lungs, the trachea, the skin, the muscles, the brain, the liver, the heart, the spleen, the bone marrow, the thymus, the bladder, the lymphatic system, the blood, the pancreas, the stomach, the kidneys, the ovaries, the testicles, the rectum, the peripheral or central nervous system, the eyes, the lymphoid organs, the cartilage, the endothelium. In preferred embodiments, the cell will be a muscle cell, a haematopoietic system stem cell or an airways cell, a tracheal or pulmonary cell, or a tumor cell.

The present invention also relates to a process for transferring a nucleic acid into cells wherein said process comprises contacting said cells with at least one polynucleotide according to the invention. This process may be applied by direct administration of said polynucleotide to cells of the animal *in vivo*, or by *in vitro* treatment of cells which were recovered from the animal and then re-introduced into the animal body (*ex vivo* process). In *in vitro* application, cells cultivated on an appropriate medium are placed in contact with a suspension consisting of polynucleotide of the invention. After an incubation time, the cells are washed and recovered. Introduction of the polynucleotide can be verified (eventually after lysis of the cells) by any appropriate method.

In the case of *in vivo* treatment according to the invention, in order to improve the transfection rate, the patient may undergo a macrophage depletion treatment prior to administration of the pharmaceutical preparations described above. Such a technique is described in the literature (refer particularly to Van Rooijen et al., 1997, TibTech 15, 178-184).

The present invention further concerns the use of a polypeptide or analogue or a polynucleotide, a vector or a host cell as defined above for the preparation of a composition intended for diagnostic, curative, preventive or vaccination treatment of man or animals, and more specifically for the treatment of cancer.

Moreover, the present invention relates to a diagnostic composition comprising at least one polypeptide as defined above. The use of a polypeptide of the invention in a diagnostic composition is illustrated by the following processes:

- a process which enables the detection and eventually the quantification of an antibody directed against said polypeptide consists in (i) contacting with said polypeptide a biological sample susceptible to containing said antibody and (ii) detecting the

formation of an immune complex between said antibody and said polypeptide.

- a process which enables the detection and eventually the quantification of MUC-1-specific T lymphocytes according to the ELISPOT technique (Scheibenbogen et al., 1997, Clinical Cancer Research 3, 221-226); Tetramer analysis (e.g., as described in Altman et al., 1996, Science 274:94-96) or other techniques which allow the identification of specific T cells by virtue of specificity of their T cell receptor for the polypeptides of this invention.

The methods, compositions, uses of the invention can be used for the treatment of all kinds of cancer the treatment and/or diagnostic of which being related to or dependent on the immune properties of the polypeptides of the invention. The compositions, and uses of the present invention may be desirably employed in humans, although animal treatment is also encompassed by the uses described herein.

The present invention also relates to a T cell receptor which recognizes a polypeptide (epitope) of the invention or a fragment thereof which can recognize the polypeptide (epitope).

The T cell receptor of the invention recognises a polypeptide (epitope) of the invention. The fragment of the T cell receptor typically comprises the extracellular domain. The fragment may be a soluble fragment or a fragment capable of binding to a cell membrane. The T cell receptor or fragment may be modified, such as by any of the modifications described herein in relation to the polypeptide of the invention. The T cell receptor or fragment may be part of a fusion protein.

The T cell receptor or fragment is able to bind an MHC molecule (e.g. HLA-A\*0201) that comprises the polypeptide (epitope) in its peptide binding groove. Typically the MHC molecule will be present on the surface of a cell. The T cell receptor or fragment may or may not be able to cause antigen specific functional activity of a T cell upon which they are present. This activity may include cytotoxic activity (such as the killing of the cell that bears the MHC/epitope complex which is recognised) or the secretion of substance (such as IFN- $\gamma$ ) from the T cell. The activity may be measured by CTL assay, ELISPOT assay or by measuring the production of cytokine inside the T cell.

The T cell receptor may be present in a population (or composition) which comprises 2, 3, 4,



5 or more different T cell receptors of the invention which together recognise any of the combinations of a polypeptide or analogue of the invention.

Furthermore, the present invention relates to a T cell which comprises a T cell receptor according to the invention.

Such a T cell is preferably a MHC class I restricted cell, and is typically a CD8 T cell, although in one embodiment it is a MHC class I restricted CD4 cell. Generally when the T cell receptor of the T cell recognises the epitope antigen specific functional activity of the cell occurs (such as the functional activity mentioned above). The T cell may be an antigen naive or antigen experienced T cell. The T cell may be of a cell line, such as an immortalised cell line. The T cell may have been fused with another cell, which may or may not be a T cell.

The T cell is typically obtained from a host, such as a naive host, a host that has cancer or a host that has been immunised with a MUC1 based immunogen, such as any of the polypeptides, analogues or polynucleotides mentioned herein. The T cell may be replicated *in vitro* in an antigen specific (typically by contacting with an epitope or analogue of the invention) or a non-antigen specific manner. Thus, the invention provides a T cell of the invention that has been produced by replication *in vitro*.

The invention also provides a product that selectively binds a T cell receptor of the invention, typically in a reversible manner. Such a product is generally able to inhibit the binding of a polypeptide (epitope) of the invention (e.g. bound to an MHC molecule) to the T cell receptor. The product is typically able to cause antigen specific functional activity of a T cell with the T cell receptor of the invention.

The product typically comprises (a) an MHC molecule, or fragment thereof, comprising a polypeptide (epitope) or analogue of the invention in its peptide binding groove, or (b) an analogue of (a) which is capable of inhibiting the binding of (a) to a T cell receptor of the invention.

The MHC molecule of (a) is generally a class I molecule (e.g. HLA-A\*0201). Such molecules comprise an  $\alpha$  chain and a  $\beta$  chain. The fragment may comprise only the extracellular domain of the MHC molecule. The fragment may or may not be capable of binding a cell membrane. (b) may comprise a protein which has homology with a naturally occurring  $\alpha$  chain (or a fragment thereof) and/or a protein which has homology with a naturally occurring  $\beta$  chain (or a fragment thereof). The naturally occurring  $\alpha$  or  $\beta$  chain may be of an HLA-A molecule (e.g.

HLA-A\*0201). Any of the above homologous proteins or fragments may be present as part of fusion proteins.

(b) is typically a derivative of (a) and, thus, may be made by modifying (a) by any of the modifications mentioned herein.

The product may be designed, made or identified using methods known in the art. Thus, the invention provides use of a polypeptide (epitope or epitope sequence) of the invention to design or identify the product. The product may be designed by computational means or may be identified from a library of compounds.

Thus, the invention also provides a method of identifying a product of the invention comprising contacting a candidate substance with a T cell receptor or fragment of the invention and determining whether the candidate substance binds to the T cell receptor or fragment, the binding of the candidate substance to the T cell receptor or fragment indicating that the substance is such a product.

In the method the product may be present on the surface of a cell, such as a professional APC. The binding may be measured by contacting the candidate substance with a T cell of the invention and determining whether the candidate substance causes antigen specific functional activity of the T cell (such as by any means mentioned herein).

The product may be linked to a cytotoxic agent. In one embodiment the product is an antibody. In one embodiment 2, 3, 4 or more products are linked together in a multimer and, thus, the invention provides a multimer comprising 2 or more products of the invention. Such a multimer may be used in the same manner as the product is used in the different aspects of the invention and, thus, the term 'product' as used in the context of the other aspects of the invention includes the multimer.

The products in the multimer may be linked by a covalent bond or by non-covalent means. In a preferred embodiment the products are linked by a streptavidin - biotin interaction and, thus, typically the products comprise a biotin portion (typically chemically linked to or in a fusion protein with the product) which allows the products to be linked together by streptavidin.

The multimer generally has a higher binding affinity to the T cell receptor of the invention than the product, and in one embodiment is able to cause more antigen specific functional activity than the product. The multimer may also comprise a detectable label, such as a radioactive or a light detectable (e.g. fluorescent) label. The label may allow the multimer to be sorted by

flow cytometry (e.g. when the multimer is bound to a T cell receptor which is present on a T cell of the invention).

The multimer may be a soluble multimer or may be capable of associating with a cell membrane. In one embodiment the multimer is attached to a solid support, such as a microtitre plate.

The invention also provides a cell comprising a product of the invention. The cell may be any of the types of cells mentioned herein, such as a professional APC or T cell. The cell may be capable of stimulating antigen specific functional activation of a T cell of the invention. Thus, the cell may be used to stimulate a MHC class I restricted T cell response *in vitro* or *in vivo*, which response is directed to a polypeptide (epitope) of the invention. The cell may, therefore, be used in a method of treatment of the human or animal body by therapy, particularly in a method of treating or preventing cancer.

In one embodiment the cell may be made by providing a polypeptide, analogue, polynucleotide or composition of the invention to a cell which is able to process the polypeptide, analogue, polynucleotide or composition and present them on its surface (under conditions in which such processing occurs).

The invention furthermore provides a method of causing the replication of MHC class I restricted T cells which are specific for a cancer epitope comprising contacting a population of cells which comprises MHC class I restricted T cells with a polypeptide or analogue of the invention under conditions in which the polypeptide or analogue are presented to T cells in the population, or with a product or cell of the invention.

The invention includes use of a T cell of the invention (including a T cell replicated by the above method) *in vitro* or *in vivo* to kill a cell which presents the polypeptide (epitope) of the invention. Such a cell is typically a cancer cell, but in one embodiment is a T cell (typically a MUC1 expressing activated T cell). Thus, the invention provides a T cell of the invention, or a cell which has been replicated in the method of the invention for use in a method of treatment of the human or animal body by therapy. In particular for use in a method of preventing or treating cancer or a disease caused by an immune response, such as an inflammatory disorder, autoimmune disease, organ transplant rejection or graft versus host disease.

As mentioned above, the invention also provides a method of identifying a MHC class I restricted T cell response which is based on determining whether MHC class I restricted T cells from a host recognise a polypeptide or analogue of the invention (either of which may be provided by a polynucleotide of the invention), or a product or cell of the invention. In the method the polypeptide or analogue may be in the form of the composition of the invention. In one embodiment the determination of whether the T cells recognise the polypeptide or analogue is done by detecting a change in the state of the T cells in the presence of the polypeptide or analogue or determining whether the T cells bind the polypeptide or the analogue. The change in state is generally caused by antigen specific functional activity of the T cell after the T cell receptor binds the polypeptide or the analogue. Generally, when binding the T cell receptor the polypeptide or the analogue is bound to an MHC class I molecule, which is typically present on the surface of an APC.

The change in state of the T cell may be the start of or increase in the expression of a substance in the T cells and/or secretion of a substance from the T cell, such as a cytokine (e.g. IFN- $\gamma$ , IL-2 or TNF- $\alpha$ ). Determination of IFN- $\gamma$  expression or secretion is particularly preferred. The substance can typically be detected by allowing it to bind to a specific binding agent and then measuring the presence of the specific binding agent/substance complex. The specific binding agent is typically an antibody, such as polyclonal or monoclonal antibodies. Antibodies to cytokines are commercially available, or can be made using standard techniques.

Typically the specific binding agent is immobilised on a solid support (and thus the method may be based on the ELISPOT assay to detect secretion of the substance). After the substance is allowed to bind the solid support can optionally be washed to remove material which is not specifically bound to the agent. The agent/substance complex may be detected by using a second binding agent which will bind the complex. Typically the second agent binds the substance at a site which is different from the site which binds the first agent. The second agent is preferably an antibody and is labelled directly or indirectly by a detectable label.

Thus, the second agent may be detected by a third agent which is typically labelled directly or indirectly by a detectable label. For example, the second agent may comprise a biotin moiety, allowing detection by a third agent which comprises a streptavidin moiety and typically alkaline phosphatase as a detectable label.

Alternatively, the change in state of the T cell which can be measured may be the increase in

the uptake of substances by the T cell, such as the uptake of thymidine. The change in state may be an increase in the size of the T cells, or proliferation of the T cells, or a change in cell surface markers on the T cell.

The change in state may be the killing (by the T cell) of a cell which presents the polypeptide, the analogue or the product of the invention to the T cell (e.g. the killing of the cell of the invention). Thus, the determination of whether the T cells recognise the peptide may be carried out using a CTL assay.

In one embodiment the T cells which are contacted in the method are taken from the host in a blood sample, although other types of samples which contain T cells can be used. The sample may be added directly to the assay or may be processed first. Typically the processing may comprise diluting of the sample, for example with water or buffer. Typically the sample is diluted from 1.5 to 100 fold, for example 2 to 50 or 5 to 10 fold.

The processing may comprise separation of components of the sample. Typically mononuclear cells (MCs) are separated from the sample. The MCs will comprise the T cells and APCs. Thus, in the method the APCs present in the separated MCs can present the peptide to the T cells. In another embodiment only T cells, (in one embodiment only CD8 T cells), can be purified from the sample. PBMCs, MCs and T cells can be separated from the sample using techniques known in the art.

The T cells used in the assay can be in the form of unprocessed or diluted samples, or are freshly isolated T cells (such as in the form of freshly isolated MCs or PBMCs) which are used directly *ex vivo*, i.e. they are not cultured before being used in the method. However, more typically the T cells are cultured before use, for example in the presence of the polypeptide or the analogue of the invention and, generally, also exogenous growth promoting cytokines. During culturing the polypeptide or the analogue are typically present on the surface of APCs, such as the APC used in the method. Pre-culturing of the T cells may lead to an increase in the sensitivity of the method.

The APC which is typically used in the method is from the same host as the T cell or from a different host. The APC can be a non-professional APC, but is typically a professional APC, such as any of the APCs mentioned herein. The APC may be an artificial APC. The APC is a cell which is capable of presenting the peptide to a T cell. It is typically separated from the same sample as the T cell and is typically co-purified with the T cell. Thus, the APC may be present in MCs or PBMCs. The APC is typically a freshly isolated *ex vivo* cell or a cultured

cell. It may be in the form of a cell line, such as a short term or immortalised cell line. The APC may express empty MHC class I molecules on its surface.

In one embodiment the method identifies a MHC class I restricted T cell response to any of the combinations of a polypeptide or an analogue of the invention discussed above in relation to the composition of the invention. Thus, in the method the T cells can be placed into an assay with the composition of the invention (which comprises the combination of the polypeptide or the analogue which are to be tested). Alternatively, the T cells can be divided and placed into separate assays each of which contains a group of polypeptides or analogues within the combination.

In one embodiment a polypeptide or an analogue *per se* is added directly to an assay comprising T cells and APCs. As discussed above the T cells and APCs in such an assay could be in the form of MCs.

In one embodiment the polypeptide or the analogue are provided to the APC in the absence of the T cell. The APC is then provided to the T cell, typically after being allowed to present the polypeptide or the analogue on its surface. The polypeptide or the analogue may have been taken up inside the APC and presented, or simply be taken up onto the surface without entering inside the APC.

The duration for which the polypeptide or the analogue are contacted with the T cells will vary depending on the method used for determining recognition of the peptide. Typically the concentration of T cells used is  $10^3/\text{ml}$  to  $10^9/\text{ml}$ , preferably  $10^5/\text{ml}$  to  $10^7/\text{ml}$ . In the case where peptide is added directly to the assay its concentration is typically from 0.1 to 1000  $\mu\text{g}/\text{ml}$ , preferably 10 to 100  $\mu\text{g}/\text{ml}$ .

Typically the length of time for which the T cells are incubated with the polypeptide or the analogue is from 4 to 24 hours, preferably 6 to 16 hours.

The determination of the recognition of the polypeptide or the analogue by the T cells may be done by measuring the binding the polypeptide or the analogue to the T cells. Typically, T cells which bind the polypeptide can be sorted based on this binding, for example using a FACS machine. The presence of T cells which recognise the polypeptide will be deemed to occur if the frequency of cells sorted using the polypeptide is above a 'control' value (i.e. above the frequency of antigen naive T cells which recognise the polypeptide or the analogue). The frequency of antigen-experienced T cells during a disease state can be up to 2.5% of the total CD8 T cells.

The polypeptide, the analogue, the polynucleotide, the composition, the product or the cell of the invention can be used to detect a MHC class I restricted T cell response to a polypeptide (epitope) of the invention *in vitro* (such as in a sample from a host) or *in vivo*. This can be done, for example, by using the method discussed above. The presence of a response generally indicates the presence of a cell which is expressing MUC1, such as a cancer cell or an activated T cell. Thus, the detection of the response may be used to diagnose cancer. Measurement of the level of the response may be used to monitor the severity of the cancer (i.e. the number of cancer cells present in the host), a larger response indicating a more severe cancer.

In the method of diagnosis of the invention the presence or absence of the MHC class I restricted T cell response is typically determined by the method of identifying a MHC class I restricted T cell response discussed above.

The antibodies mentioned herein may be produced by raising antibody in a host animal. Such antibodies will be specific to the peptide or to the substances mentioned above which bind antibodies. The peptide or substances are referred to as the 'immunogen' below. Methods of producing monoclonal and polyclonal antibodies are well-known. A method for producing a polyclonal antibody comprises immunising a suitable host animal, for example an experimental animal, with the immunogen and isolating immunoglobulins from the serum. The animal may therefore be inoculated with the immunogen, blood subsequently removed from the animal and the IgG fraction purified. A method for producing a monoclonal antibody comprises immortalising cells which produce the desired antibody. Hybridoma cells may be produced by fusing spleen cells from an inoculated experimental animal with tumour cells, for example as described in Köhler and Milstein (Nature 256 (1975), 495-497).

An immortalized cell producing the desired antibody may be selected by a conventional procedure. The hybridomas may be grown in culture or injected intraperitoneally for formation of ascites fluid or into the blood stream of an allogenic host or immunocompromised host. Human antibody may be prepared by *in vitro* immunisation of human lymphocytes, followed by transformation of the lymphocytes with Epstein-Barr virus.

For the production of both monoclonal and polyclonal antibodies, the experimental animal is suitably a goat, rabbit, rat or mouse. If desired, the immunogen may be administered as a conjugate in which the immunogen is coupled, for example via a side chain of one of the amino acid residues, to a suitable carrier. The carrier molecule is typically a physiologically

acceptable carrier. The antibody obtained may be isolated and, if desired, purified.

### Administration

Any of the polypeptides, analogues or polynucleotides discussed above in any form or in association with any other agent discussed above is included in the termed "vaccination agent" below. An effective non-toxic amount of such a vaccination agent may be given to a human or non-human patient in need thereof. The condition of a patient suffering from a cancer can therefore be improved by administration of such a vaccination agent. The vaccination agent may be administered prophylactically to an individual who does not have a cancer in order to prevent the individual developing cancer.

Thus, the present invention provides the vaccination agent for use in a method of treating the human or animal body by therapy. The invention provides the use of the vaccination agent in the manufacture of a medicament for vaccinating against cancer. Thus, the invention provides a method of vaccinating an individual comprising administering the vaccination agent to the individual.

The vaccination agent is typically administered by any standard technique used for administering vaccines, such as by injection.

Typically after the initial administration of the vaccination agent a booster of the same or a different vaccination agent of the invention can be given. In one embodiment the subject is given 1, 2, 3 or more separate administrations, each of which is separated by at least 12 hours, 1 day, 2, days, 7 days, 14 days, 1 month or more.

The vaccination agent may be in the form of a pharmaceutical composition which comprises the vaccination agent and a pharmaceutically acceptable carrier or diluent. Suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline. Typically the composition is formulated for parenteral, intravenous, intramuscular, subcutaneous, transdermal, intradermal, oral, intranasal, intravaginal, or intrarectal administration.

The dose of vaccination may be determined according to various parameters, especially according to the substance used; the age, weight and condition of the patient to be treated; the route of administration; and the required regimen. A physician will be able to determine the required route of administration and dosage for any particular patient. A suitable dose may however be from 10 $\mu$ g to 10g, for example from 100  $\mu$ g to 1g of the vaccination agent. These values may represent the total amount administered in the complete treatment regimen or may represent each separate administration in the regimen.



In the case of vaccination agents which are polynucleotides transfection agents may also be administered to enhance the uptake of the polynucleotides by cells. Examples of suitable transfection agents include cationic agents (for example calcium phosphate and DEAE-dextran) and lipofectants (for example lipofectam<sup>TM</sup> and transfectam<sup>TM</sup>).

When the vaccination agent is a polynucleotide which is in the form of a viral vector the amount of virus administered is in the range of from  $10^4$  to  $10^{12}$  pfu, preferably from  $10^7$  to  $10^{10}$  pfu (for example for adenoviral vectors), more preferably about  $10^8$  pfu for herpes viral vectors. A pox virus vector may also be used (e.g. vaccinia virus), typically at any of the above dosages. When injected, typically 1-2 ml of virus in a pharmaceutically acceptable suitable carrier or diluent is administered.

These and other embodiments are disclosed or are obvious from and encompassed by the description and examples of the present invention. Further literature concerning any one of the methods, uses and compounds to be employed in accordance with the present invention may be retrieved from public libraries, using for example electronic devices. For example the public database "Medline" may be utilized which is available on Internet, e.g. under <http://www.ncbi.nlm.nih.gov/PubMed/medline.html>. Further databases and addresses, such as <http://www.ncbi.nlm.nih.gov/>, <http://www.infobiogen.fr/>, [http://www.fmi.ch/biology/research\\_tools.html](http://www.fmi.ch/biology/research_tools.html), <http://www.tigr.org/>, are known to the person skilled in the art and can also be obtained using, e.g., <http://www.lycos.com>. An overview of patent information in biotechnology and a survey of relevant sources of patent information useful for retrospective searching and for current awareness is given in Berks, TIBTECH 12 (1994), 352-364.

The invention has been described in an illustrative manner, and it is to be understood that the terminology which has been used is intended to be in the nature of words of description rather than of limitation. Obviously, many modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that within the scope of the appended claims, the invention may be practised otherwise than as specifically described. Accordingly, those skilled in the art will recognize, or able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described specifically herein. Such equivalents are intended to be encompassed in

the scope of the following claims.

All of the above cited disclosures of patents, publications and database entries are specifically incorporated herein by reference in their entirety to the same extent as if each such individual patent, publication or entry were specifically and individually indicated to be incorporated by reference.

**Figures 1 to 7** show competition binding data from polypeptides whose sequences are from within the sequence of human MUC-1. Experiments were performed according to the method described in *van der Burg et al.* (1995, Hum. Immunol. 44:189-198). Polypeptides described as 'pp x' correspond to the SEQ ID NO. For example, pp 27 corresponds to SEQ ID NO 27. In some Figures the competition binding curves of some negative (therefore not claimed) polypeptide sequences are shown to demonstrate the specificity of the competition binding assay.

**Figures 8, 9 and 10** show ELISpot data from three experiments performed with PBMC, from patients immunized with VV-MUC-1-IL2, exposed to polypeptides from this invention. Spots per 10e6 PBMC indicate the number of CD8+ (CTL) T lymphocytes, per million PBMC, which are specific for that polypeptide. Black histograms represent the ELISpot responses of PBMC drawn from the patient 1 weeks after the injection of VV-MUC-1-IL2 (Figure 8) , 4 weeks after injection (Figure 9) or 4 weeks after the second injection (Figure 10). The white bars correspond to the ELISpot response of patient PBMC taken before VV-MUC-1 administration (Figure 8) 5 months after injection (Figure 9) or before the second injection (Figure 10).

**Figure 11** shows that MUC1 derived HLA-A\*0201 binding peptides induce peptide specific cytotoxic CTL responses. A2K<sup>b</sup> mice were immunised twice with 100µg of MUC1 peptide in IFA and 140µg of Th peptide on day -28 and -14. On day 0 single cell splenocyte suspensions were restimulated *in vitro* for one week with peptide loaded syngeneic LPS-elicited lymphoblasts and tested for cytotoxicity of peptide loaded Jurkat-A\*0201K<sup>b</sup>. Groups of A2K<sup>b</sup> mice were immunised with MUC1 peptides MUC1<sup>264-272</sup> (FLSFHISNL), MUC1<sup>460-468</sup> (SLSYTNPAV), MUC1<sup>13-21</sup> (LLLTVLTVV), MUC1<sup>167-175</sup> (ALGSTAPPV) or MUC1<sup>79-87</sup>

(TLAPATEPA). CTL bulk cultures were tested against Jurkat-A\*0201K<sup>b</sup> cells loaded with the cognate peptide (filled triangles) or irrelevant influenza matrix control peptide (open circles). Three representative graphs for each peptide are shown. The vertical axis shows % specific lysis.

**Figure 12** shows the amino acid sequence of one version of the MUC-1 protein.

The following examples serve to further illustrate the invention.

These examples show:

- 1) The identification of MUC-1 polypeptides which bind specifically to molecules of the human Major Histocompatibility Complex I (MHC-I); and
- 2) The utility of these polypeptides in a functional bioassay, known as ELISpot (Enzyme Linked Immuno Spot) assay.

### **Example 1**

#### **Competition Binding Assay**

**INTRODUCTION:** Polypeptide fragments 8 - 13 amino acids long, of proteins produced within a nucleated, vertebrate cell are associated with newly formed cellular proteins of the MHC-I complex. The complex of MHC-I protein and polypeptide fragment are further associated with a protein known as Beta-2 microglobulin. This trimolecular complex is then transported to the cell surface, anchored to the cell membrane and exposed to the extracellular milieu. Thymus-derived, or T lymphocytes of the CD8 category have specific 'antigen' receptors on their cell surface, which recognise the MHC-I-Beta-2-microglobulin-peptide complex. Individual CD8+ T cells or clonal progeny of an individual T cell precursor express on their cell surface antigen receptors which recognise only one (or very few) such polypeptides within the context of the MHC-I-Beta-2-microglobulin-peptide complex. This is known as 'Antigen Specificity' of T lymphocytes. If the polypeptide is derived from a normal or 'self' protein, T lymphocytes are not 'stimulated' due either to the deletion of self-specific T cells from the immune repertoire or due to negative regulation of self-specific immune responses. If, however, the polypeptide is from a pathogenic organism, such as a virus, then specific T cells are activated to proliferate and to become cytotoxic such that CD8 'cytotoxic

effector cells' or CTL specifically recognise the infected cell and eliminate that cell in an effort to contain the pathogenic condition. Tumours can also produce 'tumour-specific' protein molecules or modifications of cellular proteins. In those cases, specific CD8 T cells can recognise a tumour cell as pathogenic and eliminate these cells by the same mechanism as is used to eliminate virus-infected cells. Often, the tumour-specific modification of a protein is merely quantitative in that a protein is over-produced in tumour cells. It has been shown that such proteins can also be recognised by specific Cytotoxic T Lymphocytes (CTL). For example see Disis *et al.*, Cancer Research, 54: 1071-1076 (1994); or Barnd *et al.*, Proc Natl Acad Sci USA, 86: 7159-7163 (1989).

It has been shown in numerous publications that the binding of said polypeptides to MHC-I molecules depends upon certain 'motifs' of amino acids at defined positions within the polypeptides. For example, the amino acids Leucine at position 2 and Valine at position 9 of a nine amino acid polypeptide will result in the binding of that polypeptide to HLA-A2. For a review, see Rammensee *et al.*, Immunogenetics, 41: 178-228 (1995). The knowledge of the required amino acid positions had been acquired by the extraction of polypeptides from MHC-I molecules and sequencing them. In addition to the 'anchoring' residues there are various other 'preferred' flanking amino acids, such that a polypeptide can be given a 'rank' of likelihood that it will bind to a particular MHC-I molecule, depending on its sequence. Such ranking of predicted binding of polypeptides can be determined by one of several computer programs. In accordance with the invention, the program 'BIMAS' has been consulted (BioInformatics & Molecular Analysis Section) 'HLA POLYPEPTIDE Binding Predictions' ([http://bimas.dcrt.nih.gov/molbio/hla\\_bind/](http://bimas.dcrt.nih.gov/molbio/hla_bind/)) for predictions of which polypeptides from the human MUC-1 sequence are likely to bind to various HLA types. This, of course, is only a computer prediction and binding must be ascertained with a biochemical assay. Then, whether the polypeptides selected by the binding assay must be tested in a biological assay.

About 200 of the top ranking MUC-1 polypeptides, as predicted by the BIMAS program, predicted to bind to HLA-A1, A2, A3, A11, A24, B7 and B8 were produced (NeoSytem, Strasbourg, France) and were screened for HLA binding by a competitive binding assay. This assay is described in van der Burg *et al.*, Human Immunology, 44:189-198 (1995). Briefly, EBV-transformed B lymphocyte cell lines, of a known HLA-type, are exposed to a polypeptide known to bind to that HLA type. Binding of the polypeptide is determined by flow cytometry

using a Fluorescence Activated Cell Sorter. Binding can be envisioned with this apparatus since the polypeptide known to bind is tagged with a fluorescence molecule. Thus cells binding the polypeptide become fluorescent. Each polypeptide to be screened for binding is mixed together with the reference fluorescent polypeptide, which is at a constant concentration of 150 nM. The test polypeptide is added at various concentrations and the mixture exposed to the same cells. A test polypeptide is considered 'positive' if the binding of the reference polypeptide is inhibited by 50 % at 20 µg/ml or less of the test polypeptide. In Figures 1 - 7 are shown data for the competitive binding of polypeptides deemed, by this assay, to be positive for binding to HLA-A2, B7, A3, A11, A24, A1, and B8 respectively. In each case, binding is compared to a negative control polypeptide, known not to bind to that HLA type and a positive control polypeptide, known to bind to that HLA type. For example, the positive control 'Flu' is a polypeptide with the sequence GILGFVFTL from the influenza virus matrix protein (Scheibenbogen et al. International Journal of Cancer, 71: 932-936 (1997)).

#### **MATERIALS:**

EBV-B cell lines were derived by cultivating human Peripheral Blood Mononuclear Cells (PBMC) in filtered culture supernatant which had been used to grow cells from the marmoset line B-958. These cells produce the Epstein Barr Virus. PBMC are cultured for 2-3 days in the presence of 1 µg/ml Cyclosporin A (to inhibit T cell reactivity to the virus) in the B-958 supernatant, then thereafter cultured in fresh culture medium. HLA-typed EBV-transformed human B cell lines were used for all tests. HLA types are described in Table 2.

Culture medium was Dulbecco's Modified Eagle's Medium (DMEM) +  $5 \times 10^{-5}$  M Beta-Mercaptoethanol (with the addition of 25 mM HEPES buffer for the step of polypeptide detachment and cell washing) plus either 2% or 10% Fetal bovine Serum. All tests were performed in 96 well, V-bottom microtitre plates (PS micro plate).  $\beta$ -2 microglobulin was purchased from Sigma. The buffer for the polypeptide detachment used was:

13.76 g citric acid (M MUC-1 210.14 g/L)

5.43 g Na<sub>2</sub>HPO<sub>4</sub> · 2H<sub>2</sub>O (MMUC-1 177.9 g/L)

in 500 ml distilled H<sub>2</sub>O

pH initially adjusted to pH 4.0, but pH then re-adjusted depending upon which HLA type is

being tested (see Table 2).

Dulbecco's Phosphate Buffered Saline (PBS) was purchased as a powder from Sigma. Reference polypeptides labelled with fluorescence at the cysteine residue (Table 2) were prepared according to Van de Burg et al., 1995, Hum. Immunol., 44, 189-198. Test polypeptides were purchased from NeoSystem, Strasbourg or prepared according to standard methods. Positive control polypeptides were purchased from NeoSystem (Strasbourg, France). Details of the polypeptides used are described in Table 2.

Plastics, unless otherwise indicated, were purchased from Corning.

## **METHODS:**

Cells were cultivated in Corning T175 flasks in 20 of culture medium (10% FBS). The night before the assay, cells were re-suspended and 10 ml of fresh medium added. The day of the test cells were resuspended, counted, pelleted by centrifugation and resuspended in 5 ml complete medium with 10% FBS. Distribute cells into a 6 well plate,  $10^5$  cells per well in 5 ml culture medium. Cells were then cultured for 4 hours at 37°, 5% CO<sub>2</sub>. During that time polypeptides were prepared by dilution in 600 µg/ml in PBS. Two-fold serial dilutions from 600 - 4.68 (to have a final dilution of 100 to 0.78 µg/ml in the test plate) were first prepared in a separate 96 well 'polypeptide dilution' plate.

The test plate (96 well, V-bottom) was prepared as follows:

- negative control (no polypeptide): 50 µl PBS
- positive control (reference polypeptide only): 25 µl PBS + 25 µl Fl-reference polypeptide
- tests: 25 µl Fl-reference polypeptide at 150 nM (final) then 25 µl of test polypeptides (including positive and negative control polypeptides) at their various dilutions were added. Plates were then placed in a refrigerator in the dark.

After the 4 hour incubation of cells, the following were prepared, on ice:

- Two 15 ml conical bottom test tubes containing culture medium with 2% FBS.
- One 15 ml conical bottom test tube containing 10 ml culture medium with 2% FBS and

including 1.5 µg/ml β-2 microglobulin

- One 15 ml conical bottom test tube containing 2 ml acid 'peptide detachment' buffer at the pH for the particular HLA type as indicated in Table 2.

Cells in the 5 ml culture medium in the 6 well plate were resuspended and transferred to a 15 ml conical bottom test tube and then centrifuged for 5 minutes at 1500 rpm (500g). Resuspend the cells in PBS and centrifuge a second time (500g). Supernatant was removed and 2 ml detachment buffer while on ice. Cells were resuspended by gentle pipetting during the first 30 seconds of this 2 minute period. After 2 minutes, 14 ml culture medium with 2% FBS was added. Cells are mixed by inverting the tube twice, then centrifuged at 2000 rpm (800g) for 3 minutes at 4°C. Supernatant was removed and cells resuspended in 14 ml cold culture medium with 2% FBS and centrifugation repeated (3 minutes at 800g). Supernatant was removed and cells gently resuspended in 14 ml culture medium, 2 % FBS and 1.5 µg/ml β-2 microglobulin. One hundred µl cells from this suspension were added to each well of the 96 well plate, which already contained the polypeptides. The plate was wrapped in Saran Wrap and left 24 hours at 4°C. The next day, plates were centrifuged at 1000 rpm (200g), supernatant removed and cells resuspended in 100 µl PBS containing 0.1% Bovine Serum Albumin (BSA) and 0.02% sodium azide and cells pelleted by centrifugation at 200g. This step was repeated once more, then cells were resuspended in 1% paraformaldehyde and analysed for fluorescence by a FACScan (Becton Dickinson, Mountainview California).

The mean fluorescence intensity (MFI) of cells with the fluorescent reference polypeptide but with no competitor polypeptide (positive control) was taken as 0% inhibition. Similarly, the MFI of cells without the fluorescent reference polypeptide (negative control) was taken to be equal to 100 % inhibition. Percentage inhibition was calculated as:

$$\% \text{ inhibition} = \left( 1 - \frac{(\text{MFI with test polypeptide}) - (\text{MFI negative control})}{(\text{MFI with test polypeptide}) - (\text{MFI positive control})} \right) \times 100$$

High Affinity Binding was taken to be 50 % inhibition at  $\leq 10$  µM polypeptide ( $\sim 10$  µg/ml)

TABLE 2: Reference and Positive Control polypeptides used in the Competition Binding assay

Allele tested	elution pH	Reference Polypeptide			Positive Control Polypeptide	B-EBV Line	HLA Type
		sequence (origin)	Conc. pmol/ $\mu$ l	Final Conc. nM			
A1	pH 3.1	YLEPAC*AKY	183	150	CTELKLSDY (Influenza NP 44-52)	MAR	A01, A02, B08, B27, C01, C07
A2	pH 3.1	FLPSCD*FPSV (HBV core 18-27)	250	150	GILGFVFTL (Influenza matrix 58-66)	JY	A02, B07, C07
A3	pH 3	KVFPC*ALINK	28 et 20	150	QVPLRPMTYK (HIV nef 73-82)	FRE	A03, A24, B35, B08, C04, C07
A11	pH 3	KVFPC*ALINK	28 et 20	150		BVR	A11, B35, C04
A24	pH 3.1	RYLKC*QQLL (HIV gp41 583-591)	66 et 20	150	AYGLDFYIL (melanoma p15 10-18)	YT2	A24, B54, C01
B7	pH 3.1	APAPAPC*WPL (human p53 84-93)	29 et 20	150	RPPIFIRL (EBNA-3A 379-387)	JY	A02, B07, C07
B8	pH 3.1	FLGRAC*GI (EBNA-3 339-347)	20	150	YLKDQQLL (HIV gp41 591-598)	MAR	A01, A02, B08, B27, C01, C07

Where polypeptide origin is not indicated, HLA-A consensus sequences, as described in Sette *et al.*, Molecular Immunology, 31: 813-822 (1994) were used. C\* indicates that the fluorescent molecule is coupled to a cysteine residue (as described in van der Burg *et al.*, Human Immunology, 44: 189-198 (1995)).

Positive control polypeptides are published in Rammensee *et al.*, 'MHC Ligands and polypeptide Motifs' Springer, New York (1995)



**RESULTS:**

The competition for binding to selected HLA types between serial dilutions of selected peptides and the reference peptides (as described in Table 2) are shown in Figures 1-7. Binding of polypeptides, from the sequence of human MUC-1, to HLA -A2, B7,A3, A11, A24, A1 and B8 are shown in Figures 1,2,3,4,5,6, and 7 respectively. High affinity binding sequences were often, but not always, within the top 20 predicted binding polypeptide sequences as predicted by the BIMAS HLA Peptide Motif program (as described above).

**Example 2****ELISpot**

The ELISpot is a technique which allows the identification of antigen-specific (in this case, MUC-1-specific) T cell recognician by the detection of antigen induced production of cytokines (IFN $\gamma$ , TNF $\alpha$ , IL-4, etc...) following an antigenic stimulation *in vitro*. More particularly, ELISpot allows the determination of the number of antigen specific T lymphocytes in a population of peripheral blood mononuclear cells (PBMC) (Scheibenbogen et al., 1997, Int. J. Cancer 71-1). In this case, the production of IFN $\gamma$  produced by CD8+ T cells (CTL) in responses to polypeptides as presented by autologous HLA molecules were examined.

Briefly, in an ELISpot, the cytokines are captured between two specific antibodies. The first antibody, specific for human IFN $\gamma$ , is adsorbed on a nitrocellulose membrane. Lymphocytes from human blood samples are added to the microtitre wells containing the attached antibody. Antigen, in the form of polypeptides, is also added to the wells. The principal is that polypeptides will attach to cell surface HLA molecules (together with  $\beta$ -2 microglobulin). Polypeptide specific T cells will recognize the complex of the polypeptide:HLA: $\beta$ -2 $\mu$ globulin. Upon recognition of antigen, the T cells become 'activated' to produce cytokines such as IFN $\gamma$ . Secreted IFN $\gamma$  is then captured by the antibody which is attached to the nitrocellulose. Cells are washed away leaving behind the areas of secreted IFN $\gamma$ . These areas are revealed by the second antibody (coupled to biotin) and then by a streptavidin-alkaline phosphatase conjugate. The enzyme substrate hydrolysis by the enzyme leads to a spot appearance. Thus each spot

represents the 'fingerprint' of a cytokine producing cell. The tests described below were performed using a commercially available kit (MABTECH, Nacka, Sweden)

## MATERIALS

### *Peripheral blood mononuclear cells :*

In Figures 8 and 9 patient PBMC (Peripheral Blood Mononuclear Cells) were obtained from breast cancer patients who had participated in a Phase I clinical trial carried out in the Institut Curie, Paris. In Figure 10, patient PBMC came from prostate cancer patients who had participated in a similar immunotherapy Phase I trial in Los Angeles, USA. In these trials, patients were immunized with a Vaccinia virus construct which expresses, upon infection, the both MUC-1 and IL2. The goal was to generate an immune response to MUC-1 which is an antigen over-expressed on both types of cancers. PBMC were isolated from peripheral blood by Hypaque-Ficol density centrifugation and resulting mononuclear cells frozen in aliquotes of 2 to 4x10<sup>6</sup> cells in a 1 ml volume of culture medium containing 10% DMSO and stored in the vapour phase of liquid nitrogen until use.

**TABLE 3**

Patient Identification Code	Cancer	HLA-Type
Pt#4 SOM	Advanced Breast	HLA-A 01/02; B 44/08
Pt#5 LEC	Advanced Breast	HLA-A 02/24; B 07/44
A002	Prostate	HLA-A01/26; B38/08

### *Tissue typing :*

Breast cancer patient PBMC was HLA typed by serology and PCR at the Etablissement de Transfusion Sanguine, Strasbourg. Prostate cancer patients' PBMC were HLA typed by PCR at Transgene using the 'One Lamda' HLA typing kit (One Lamda, Canoga Park, CA, USA)

*Polypeptides :*

Polypeptides were produced at NeoSytem (Strasbourg, France)

*ELISPOT :*

The ELISPOT kit was purchased from and used according the instructions of MABTECH (Nacka, Sweden). The technique was carried out according to the manufacturer's instructions. Briefly, PBMC were cultured in 96 well microtitre plates for 48 hours in the presence of test or control polypeptides at 5 µg/ml and recombinant IL-2 at 30 units/ml. IFN $\gamma$  spots were revealed with a second antibody reagent, also specific for Human Interferon gamma, according to the manufacturer's instructions.

**RESULTS:**

The results from three experiments are shown in Figures 8, 9 and 10. Patient PBMC were taken from liquid nitrogen and thawed the day before the ELISpot assay. The controls and the polypeptides (numbered according to their SEQ ID N°) were added as described above. Duplicate or triplicate wells containing 1- 2 x 10<sup>5</sup> PBMC were used. The number of spots was determined and is represented as the number of spots per 10<sup>6</sup> cells.

These data shown in Figure 8 show that PBMC from patient #4 (who is HLA-A2) are able to respond to the polypeptide of SEQ ID NO: 4 in that PBMC from this patient are stimulated to produce IFN $\gamma$  in response to the presence of this polypeptide but not in the presence of the negative control polypeptide or polypeptide SEQ ID N° 3. The response is seen after vaccination (black histograms), but not before (white histograms). In Figure 9 is shown the results of an experiment in which PBMC from patient #5 (HLA-A2 and B7) are stimulated to produce IFN $\gamma$  ELISpots upon exposure to polypeptide 4 (SEQ ID N° 4) and polypeptide 10 (SEQ ID N° 10) but not to the negative control or to polypeptides 3 or 7. No PBMC from prior to vaccination were available, but the patient's T cell response, as determined by *in vitro* CD4+ T cell proliferation assay, to a longer (24 aa) MUC-1 polypeptide was discernable only in the weeks following vaccination but was undetectable 5 months afterwards. The transient nature of the T cell responses is verified in Figure 9 in that only PBMC taken 28 days after

vaccination (black histograms) were able to produce ELISpots over background, whereas PBMC taken 5 months after injection produced no ELISpot response to these peptide (white histograms).

These examples demonstrate the value of the invention in the diagnosis of a CD8+T cell immune response to MUC-1.

The invention could also be used in other diagnostic applications such as Tetramer analysis in which soluble MHC-I, beta-2-microglobulin and polypeptides of this invention are complexed together with a fluorescent reagent. The complex is then used to fluorescently tag T cells with an antigen receptor specific for that polypeptide. The quantification of the specific T cells is accomplished with a fluorescence activated flow cytometer and can be done by one practised in the art.

The polypeptides of the invention could also be used in therapeutic or vaccine composition in order to prevent or treat MUC-1-expressing cancers. Polypeptides could be administered alone or complexed with MHC-I and beta-2-microglobulin to stimulate a MUC-1-specific CD8+ (CTL) T cell immune response. The invention could also be used as a DNA-based vector in which oligonucleotide sequences coding for the polypeptides of this invention, incorporated into viral or synthetic vector, are used to vaccinate a patient for the treatment or prevention of MUC-1-expressing cancers.

### **Example 3**

#### **Prediction of peptides that bind HLA-A\*0201**

A computer program (D'Amaro et al., Hum. Immunol. 43 (1995), 13-18) was used to scan the MUC1 sequence with two tandem repeats for nine amino acid long peptides complying with the anchor residue motifs for HLA-A\*0201. A full set of ninemers with an eight amino acid overlap covering the tandem repeat as well as ninemers in the top 10% of the scoring data for HLA-A\*0201 were synthesised (90 peptides in total) by fmoc chemistry with a yield of 5-15 mg.

### Example 4

#### Testing the synthesised peptides in a binding assay

Peptide binding to HLA-A\*0201 was analysed using HLA-A\*0201<sup>+</sup> B lymphoblastoid JY cells in a semi-quantitative competition assay (van der Burg et al. (J. Immunol. 156 (1996), 3308-3314)). The assay is based on competitive binding of two peptides to acid stripped MHC class I molecules on a B cell line (JY). A test peptide competes with a fluorescently labelled reference peptide for the empty class I molecules on the cell surface. Mild-acid-treated JY cells were incubated with 150nM fluorescein (FL)-labelled reference peptide FLPSDC(-FL)FPSV and with several concentrations of competitor peptide for 24 hours at 37°C in the presence of 1.0µg/ml β2-microglobulin. Subsequently, the cells were washed, fixed with paraformaldehyde and analysed by flow cytometry. The mean fluorescence (MF) obtained in the absence of competitor peptide was regarded as maximal binding and equated to 0%; the MF obtained without reference peptide was equated to 100% inhibition. The percentage inhibition was calculated using the formula:

$$\{1 - (\text{MF 150nM reference and competitor peptide} - \text{MF no reference peptide}) / (\text{MF 150nM reference peptide} - \text{MF no reference peptide})\} \times 100\%$$

The binding capacity of competitor peptides is expressed as the concentration needed to inhibit 50% of binding of the FL-labelled reference peptide (IC<sub>50</sub>). All peptides were tested several times in two fold dilutions starting with a concentration of 100µM. The six peptides that showed any significant binding were further analysed. The IC<sub>50</sub> values of these peptides are shown in the table below together with the value for a flu peptide.

The peptides are defined in terms of the amino acid numbering used in Figure 12. The tandem repeat can be defined using the restriction enzyme SmaI which cuts at CCCGGG three times in the MUC1 sequence, once either side of the tandem repeat and once in the C-terminus. This leads to the tandem repeat being defined as amino acids 129 to 148 in Figure 12. The six peptides were analysed further as described below.

Peptide Position	Amino Acid Sequence	Motif Score *	IC <sub>50</sub> mM/ml
Flu Matrix <sup>58-66</sup>	GILGVVFTL	54	<5
MUC1 <sup>264-272</sup>	FLSFHISNL	59	3-5
MUC1 <sup>460-468</sup>	SLSYTNPAV	62	5-10
MUC1 <sup>13-21</sup>	LLLTVLTVV	63	6-10
MUC1 <sup>167-175</sup>	ALGSTAPPV	64	10
MUC1 <sup>79-87</sup>	TLAPATEPA	58	10-15
MUC1 <sup>107-115</sup>	ALGSTTPPA	56	25

\* The algorithm used to define the motif score is described in (D'Amaro et al. (loc. cit.)).

### Example 5

#### Testing the peptides in a cytotoxic T lymphocyte (CTL) assay

##### Summary of assay

To show that the six peptides were functional *in vivo*, transgenic mice expressing the chimeric protein A\*0201K<sup>b</sup> (Vitiello et al. (J. Exp. Med. 173 (1991), 1007-1015)) underwent an immunization protocol with a MUC1-derived peptide and T helper epitope formulated with adjuvant. The mice were then sacrificed and the splenocytes restimulated by culturing with peptide-loaded, irradiated LPS-elicited B lymphoblasts. The restimulated cells were separated from the lymphoblasts and used in a CTL assay as effector cells. Effector cells were incubated with Na<sup>51</sup>CrO<sub>4</sub> loaded target cells at various E:T ratios and cell killing estimated by measuring the amount of <sup>51</sup>Cr released into the cell supernatant using a gamma radiation counter.

##### Immunisation of mice with MUC1-derived peptides

Transgenic mice expressing the chimeric protein A\*0201K<sup>b</sup> (Vitiello et al., loc. cit.) were immunised subcutaneously in the base of the tail with 100µg of MUC1-derived peptide and 140µg of H-2 I-A<sup>b</sup>-restricted HBV core antigen-derived T helper epitope (amino acid sequence; TPPAYRPPNAPIL) (Milich et al., Proc. Natl. Acad. Sci. USA 85 (1988), 1610-1614) emulsified in a 1:1 ratio with Incomplete Freund's Adjuvant (IFA) in a total volume of 200 µl. After a minimum of two weeks, the mice were boosted using the same protocol.

##### Preparation of LPS-elicited B lymphoblasts

Splenocytes from (unimmunized) transgenic mice expressing the chimeric protein A\*0201K<sup>b</sup> (Vitiello et al., loc. cit.) were prepared 72h prior to use as stimulator cells. The cells of several mice were pooled and resuspended in IMDM N medium (IMDM (Biowhittaker) supplemented with 2mM L-glutamine, 8% (v/v) heat inactivated foetal calf serum (FCS), 20µM 2-mercaptoethanol and 100 IU/ml penicillin) containing 25µg/ml LPS (Sigma) and 7µg/ml dextran sulphate (Pharmacia). A 30 ml culture of cellular concentration,  $1.5 \times 10^6$  cells per ml was incubated at 37°C for 72h.

Cells were then collected, resuspended in IMDM N, separated on a Ficoll gradient and adjusted to a cellular concentration of  $5 \times 10^6$  cells/ml. Cells were then irradiated for 8 min (the equivalent of 2500 RAD). Cells were then washed once and resuspended in IMDM to a cellular concentration of  $40 \times 10^6$  cells/ml.

Each MUC1 derived peptide, at a concentration of 100µg/ml, was incubated for 1h at 37°C with 1 ml LPS-elicited B lymphoblasts. The cells were then washed once and resuspended in IMDM N at a concentration of  $10 \times 10^6$  cells/ml.

#### Restimulation of splenocytes from peptide-immunized mice

Two weeks after the final immunization, the mice were sacrificed and the spleens removed. Splenocytes ( $30 \times 10^6$  cells in a 9 ml volume of IMDM N medium) were restimulated by incubation in complete medium with a 1ml volume of syngeneic, irradiated LPS-elicited B cell lymphoblasts (such that the ratio of splenocytes to blast cells is 3:1). On day 7 of culture the cells were separated on a Ficoll gradient, resuspended in IMDM N medium and counted to generate a preparation of effector cells of known concentration.

#### Preparation of target cells

The Jurkat-A\*0201K<sup>b</sup> cell line which is a stable transfectant of a human T cell leukaemia line expressing the product of the HLA-A\*0201K<sup>b</sup> chimeric gene construct was used as a source of target cells.

Cells growing in log phase were harvested, washed once, counted and  $10^6$  cells transferred to a microfuge tube. The cells were pelleted and resuspended in a 100µl volume of 1 mCi/ml Na<sup>51</sup>CrO<sub>4</sub> solution (Amersham) followed immediately by the addition of a 5µl volume of 1M HEPES pH 7.0 and gentle mixing of the cell suspension by pipetting. The tubes were incubated

for 1h at 37°C. The cells were then washed four times in IMDM N medium and resuspended in a 25 ml volume of IMDM N medium containing the relevant peptide. After a 20 min incubation the cells were plated out into wells already containing effector CTLs. The final concentration of peptide in each well was 2µg/ml.

#### <sup>51</sup>Cr release assay

Effector cells, prepared as above, were added in triplicate to wells of a 96 well plate (round bottom wells) such that the resulting ratio of Effector:Target cells was a range from 5:1 to 100:1. For each target cell line tested, six wells containing IMDM N or PBS with 2% (v/v) triton X-100 were prepared as controls to measure the spontaneous and maximal release of <sup>51</sup>Cr respectively.

A 50µl volume of the preparation of target cells (1000 or 2000 cells depending on preparation and number of effector cells) was then added to each well and the 96 well plates centrifuged for 2 min at 1200rpm. The plates were then incubated for 6 h at 37°C. The culture supernatants from each well were then harvested using Skatron harvesting frames according to the manufacturer's instructions and the <sup>51</sup>Cr in each supernatant measured using a Wallac gamma counter.

The data was presented as %age specific <sup>51</sup>Cr release which is defined as 100 x ([experimental cpm - spontaneous cpm]/[total cpm - spontaneous cpm]) where the experimental value was the average of three test wells, the spontaneous value, the average of six wells containing IMDM N and target cells and the total value is the average of six wells containing 2% (v/v) triton X-100 and target cells. Data is shown for peptides MUC1<sup>79-87</sup>, MUC1<sup>167-175</sup>, MUC1<sup>264-272</sup>, MUC1<sup>460-468</sup> and MUC1<sup>13-21</sup> in Figure 11.

### **Example 6**

#### **Protection assay**

Mice were inoculated subcutaneously with 10<sup>5</sup>, 5x10<sup>5</sup> and 10<sup>6</sup> B16-MUC1-A2K<sup>b</sup> cells (a melanoma cell line constitutively expressing MUC1 and the chimeric gene product HLA-A\*0201K<sup>b</sup>). Tumour growth was observed 20 days post inoculation and continued until sacrifice of the animal. An inoculation of 5x10<sup>5</sup> B16-MUC1-A2K<sup>b</sup> was defined as the optimal



dose for tumour challenge experiments.

To test whether the HLA-A\*0201 binding peptides that were previously identified could protect A2K<sup>b</sup> transgenic mice (Vitiello et al., loc. cit.) against subsequent tumour challenge with B16-MUC1-A2K<sup>b</sup>, groups of 6-8 animals were immunised with 100µg of peptide in IFA in the presence of 140µg of the H-2 I-A<sup>b</sup>-restricted HBV core antigen-derived T helper epitope (128-140; sequence TPPAYRPPNAPIL)(Milich et al., loc. cit.), on day -28, boosted on day -14 and challenged with 5x10<sup>5</sup> B16-MUC1-A2K<sup>b</sup> cells on day 0. Control mice were given IFA or PBS. A measurable tumour was defined as having a volume greater than 36 mm<sup>3</sup>.

Results from these experiments are shown in the tables below in the form of the percentage of mice surviving at a given day. For experiments 2 and 3 results using a vaccinia construct that expresses MUC1 (VV-MUC1) are also shown. In other experiments immunising with MUC1<sup>167-175</sup> and boosting with MUC1<sup>79-87</sup> or immunising with MUC1<sup>79-87</sup> and boosting with MUC1<sup>167-175</sup> gave a percentage survival of between 60 and 70% at day 30. Experiment 3 shows results from an experiment in which the mice were inoculated with 8x10<sup>5</sup> A2K<sup>b</sup> dendritic cells (DC) which had been pulsed with the peptides.

### Experiment 1

Day	0	21	22	23	26	32	34
IFA	100	38	0	0	0	0	0
MUC1 <sup>264-272</sup>	100	75	75	75	63	63	63
MUC1 <sup>167-175</sup>	100	63	63	63	63	63	63
MUC1 <sup>79-87</sup>	100	100	75	75	75	75	63
MUC1 <sup>460-468</sup>	100	25	25	25	25	25	25
MUC1 <sup>13-21</sup>	100	25	13	13	0	0	0
VV-MUC1	100	75	75	75	63	63	38

### Experiment 2

Day	0	13	24	26	28	33	38	46	52	53
IFA	100	100	70	50	50	40	40	30	30	30

MUC1 <sup>264-272</sup>	100	100	100	88	88	75	75	63	63	63
MUC1 <sup>167-175</sup>	100	100	88	63	63	63	63	38	38	38
MUC1 <sup>79-87</sup>	100	100	100	100	100	88	88	75	75	75
MUC1 <sup>460-468</sup>	100	100	100	75	75	50	50	38	38	38
MUC1 <sup>13-21</sup>	100	100	50	25	25	25	25	25	25	25
VV-MUC1	100	100	90	80	80	80	80	60	60	60

**Experiment 3**

Day	0	15	21	24	27	32	39	40	42	45	72
PBS	100	89	56	11	11	11	11	11	11	11	0
DC + Flu Matrix <sup>58-66</sup>	100	88	63	50	50	38	38	38	38	38	38
DC + MUC1 <sup>264-272</sup>	100	100	88	88	88	88	88	88	88	88	88
DC + MUC1 <sup>167-175</sup>	100	100	78	78	78	78	78	78	67	67	67
DC + MUC1 <sup>79-87</sup>	100	100	89	89	89	67	67	67	67	67	67
DC + MUC1 <sup>460-468</sup>	100	100	75	63	38	38	25	25	25	13	13
DC + MUC1 <sup>13-21</sup>	100	100	67	56	56	44	22	22	22	22	22

**CLAIMS**

1. A polypeptide consisting of or comprising at least one amino acid sequence of at most 20 consecutive amino-acids defined in SEQ ID NO: 1, said polypeptide binding at least one MHC-I glycoprotein, with the proviso that said polypeptide is different from SEQ ID NO: 2.
2. The polypeptide of claim 1, wherein the amino acid sequence is selected from the group consisting of the amino acid sequences shown in SEQ ID NO: 3 to SEQ ID NO: 33, SEQ ID NO: 65 and SEQ ID NO: 66.
3. The polypeptide of claim 1 or 2, wherein the amino acid sequence is selected from the group consisting of:
  - (a) SEQ ID NO: 3 to SEQ ID NO: 6 and SEQ ID NO: 65 and SEQ ID NO: 66, and said polypeptide binds the HLA A2 glycoproteins of MHC-I;
  - (b) SEQ ID NO: 7 to SEQ ID NO: 15, and said polypeptide binds the HLA B7 glycoproteins of MHC-I;
  - (c) SEQ ID NO: 16 to SEQ ID NO: 19, and said polypeptide binds the HLA A3 glycoprotein of MHC-I;
  - (d) SEQ ID NO: 19 to SEQ ID NO: 21, and said polypeptide binds the HLA A11 glycoproteins of MHC-I;
  - (e) SEQ ID NO: 22 to SEQ ID NO: 25, and said polypeptide binds the HLA A24 glycoproteins of MHC-I;
  - (f) SEQ ID NO: 26 to SEQ ID NO: 29, and said polypeptide binds the HLA A1 glycoproteins of MHC-I; and
  - (g) SEQ ID NO: 30 to SEQ ID NO: 33, and said polypeptide binds the HLA B8 glycoproteins of MHC-I.
4. An analogue of the polypeptide of any one of claims 1 to 3, which is capable of inhibiting the binding of the polypeptide or of an epitope contained in said polypeptide to a T cell receptor either by directly binding to the same T cell receptor or by binding to the same T cell receptor after being processed.

5. A polynucleotide encoding the polypeptide of any one of claims 1 to 3.
6. The polynucleotide of claim 5, comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 34 to SEQ ID NO: 64, and their complementary sequences.
7. A polynucleotide encoding the analogue of claim 4.
8. The polynucleotide of any one of claims 5 to 7, further containing elements allowing the expression of the polypeptide or analogue in a host cell.
9. The polynucleotide of claim 8, wherein said element for expression in a host cell is a promoter.
10. The polynucleotide of any one of claims 5 to 9, wherein said polynucleotide is associated with one or more compounds selected from the group consisting of transfecting agents, stabilizing agents and targeting agents.
11. A vector comprising at least one polynucleotide of any one of claims 5 to 10.
12. The vector of claim 11 comprising at least two different nucleotide sequences encoding at least two polypeptides as defined in claim 3.
13. The vector of claim 11 or 12 which is a plasmid.
14. The vector of claim 11 or 12, which is a viral vector.
15. A host cell comprising a polynucleotide of any one of claims 5 to 10 or a vector of any one of claims 11 to 14.
16. The host cell of claim 15, which is a prokaryotic cell, a yeast cell, or an animal cell, such as a mammalian cell.

17. A composition comprising a polypeptide of any one of claims 1 to 3, an analogue of claim 4, a polynucleotide of any one of claims 5 to 10, a vector of any one of claims 11 to 14, or a host cell of claim 15 or 16 or a combination of two or more of these different compounds.
18. The composition of claim 17, further comprising a pharmaceutical carrier.
19. Use of a polypeptide of any one of claims 1 to 3, of an analogue of claim 4, of a polynucleotide of any one of claims 5 to 10, of a vector of any one of claims 11 to 14, of a host cell of claim 15 or 16 or of a composition of claim 17 for the preparation of a medicament for effecting a CTL response in a subject.
20. A diagnostic composition comprising a polypeptide of any one of claims 1 to 3.
21. A vaccine comprising a polypeptide of any one of claims 1 to 3, an analogue of claim 4, a polynucleotide of any one of claims 5 to 10, a vector of any one of claims 11 to 14 or a host cell of claim 15 or 16, which vaccine is capable of stimulating a MHC class I restricted T cell response directed to an epitope as contained in a polypeptide of any one of claims 1 to 3.
22. The vaccine of claim 21 which comprises an adjuvant or a delivery system, which adjuvant or delivery system stimulates a MHC class I restricted response.
23. A T cell receptor which recognizes an epitope contained in a polypeptide of any one of claims 1 to 3 or a fragment of said T cell receptor which can recognize the epitope.
24. A T cell comprising the T cell receptor of claim 23.
25. The T cell of claim 24, which has been produced by replication *in vitro*.
26. A product that selectively binds a T cell receptor of claim 23.

27. The product of claim 26 which product comprises (a) an HLA molecule, or a fragment thereof, comprising a polypeptide of any one of claims 1 to 3 or an analogue of claim 4 in its peptide binding groove, or (b) an analogue of (a) which is capable of inhibiting the binding of (a) to a T cell receptor of claim 23.
28. A method of identifying a product of claim 26 or 27 comprising contacting a candidate substance with a T cell receptor or fragment of claim 23 and determining whether the candidate substance binds to the T cell receptor or fragment, the binding of the candidate substance to the T cell receptor or fragment indicating that the candidate substance is such a product.
29. A cell comprising a product of claim 26 or 27.
30. A method of identifying a MHC class I restricted T cell response, said method comprising contacting a population of cells comprising MHC class I restricted T cells with:  
the polypeptide of any one of claims 1 to 3 or with the analogue of claim 4 under conditions suitable for the presentation of the polypeptide or analogue to the T cells,  
or  
a product of claim 26 or 27 or cells of claim 29; and  
determining whether the CD8 T cells recognize the polypeptide, analogue, the product or the cell, recognition by the T cells indicating the presence of a MHC class I restricted T cell response.
31. The method of claim 30, in which the determination of the T cell recognition is done by detecting the expression of a substance by the T cells, the expression of the substance indicating that the T cells have recognized the polypeptide, the analogue, the product or the cell.
32. The method of claim 31, in which the substance which is detected is IFN- $\gamma$ .
33. A method of diagnosing cancer in a host said method comprising determining the presence or absence in the host of a MHC class I restricted T cell response to a

polypeptide of any one of claims 1 to 3, the presence of the MHC class I restricted T cell response indicating that the host has cancer.

34. The method of claim 33, in which the presence or absence of the MHC class I restricted T cell response is determined by the method of any one of claims 30 to 32.
35. A method of causing the replication of MHC class I restricted T cells which recognize an epitope of a cancer cell or an activated T cell, said method comprising contacting a population of cells which comprises MHC class I restricted T cells with the polypeptide of any one of claims 1 to 3 or with the analogue of claim 4 under conditions in which the polypeptide or the analogue are presented to T cells in the population, or with a product of claim 26 or 27 or with a cell of claim 29.
36. A pharmaceutical composition comprising a product of claim 26 or 27, a cell of claim 28, the T cell of claim 24 or 25, or a cell which has been replicated in the method of claim 35.
37. A kit for carrying out a method of any one of claims 30 to 35 comprising a polypeptide of any one of claims 1 to 3, an analogue of claim 4, a polynucleotide of any one of claims 5 to 10, a composition of claim 17 and/or a product of claim 26 or 27.

**HLA-A2:  
MUC1 Polypeptide Competition  
Binding Assay**




Fig. 1






Fig. 2

**HLA-A3:  
MUC1 Polypeptide  
Competition Binding Assay**




Fig. 3

**HLA-A11:  
MUC1 Polypeptide  
Competition Binding Assay:**




Fig. 4

**HLA-A24 :  
MUC1 Polypeptide  
Competition Binding Assay**




Fig. 5

**HLA-A1:  
MUC1 Polypeptide Competition  
Binding Assay:**




Fig. 6




Fig. 7




Fig. 8




Fig. 9







Fig. 10



E:T

Fig. 11

```

Met Thr Pro Gly Thr Gln Ser Pro Phe Phe Leu Leu Leu Leu Leu Thr
 1           5           10           15
Val Leu Thr Val Val Thr Gly Ser Gly His Ala Ser Ser Thr Pro Gly
          20          25          30
Gly Glu Lys Glu Thr Ser Ala Thr Gln Arg Ser Ser Val Pro Ser Ser
          35          40          45
Thr Glu Lys Asn Ala Val Ser Met Thr Ser Ser Val Leu Ser Ser His
          50          55          60
Ser Pro Gly Ser Gly Ser Ser Thr Thr Gln Gly Gln Asp Val Thr Leu
          65          70          75          80
Ala Pro Ala Thr Glu Pro Ala Ser Gly Ser Ala Ala Thr Trp Gly Gln
          85          90          95
Asp Val Thr Ser Val Pro Val Thr Arg Pro Ala Leu Gly Ser Thr Thr
          100          105          110
Pro Pro Ala His Asp Val Thr Ser Ala Pro Asp Asn Lys Pro Ala Pro
          115          120          125
Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr
          130          135          140
Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser
          145          150          155          160
Ala Pro Asp Asn Arg Pro Ala Leu Gly Ser Thr Ala Pro Pro Val His
          165          170          175
Asn Val Thr Ser Ala Ser Gly Ser Ala Ser Gly Ser Ala Ser Thr Leu
          180          185          190
Val His Asn Gly Thr Ser Ala Arg Ala Thr Thr Thr Pro Ala Ser Lys
          195          200          205
Ser Thr Pro Phe Ser Ile Pro Ser His His Ser Asp Thr Pro Thr Thr
          210          215          220
Leu Ala Ser His Ser Thr Lys Thr Asp Ala Ser Ser Thr His His Ser
          225          230          235          240
Thr Val Pro Pro Leu Thr Ser Ser Asn His Ser Thr Ser Pro Gln Leu
          245          250          255
Ser Thr Gly Val Ser Phe Phe Phe Leu Ser Phe His Ile Ser Asn Leu
          260          265          270
Gln Phe Asn Ser Ser Leu Glu Asp Pro Ser Thr Asp Tyr Tyr Gln Glu
          275          280          285

```

Fig. 12

```

Leu Gln Arg Asp Ile Ser Glu Met Phe Leu Gln Ile Tyr Lys Gln Gly
  290                      295                      300
Gly Phe Leu Gly Leu Ser Asn Ile Lys Phe Arg Pro Gly Ser Val Val
 305                      310                      315                      320
Val Gln Leu Thr Leu Ala Phe Arg Glu Gly Thr Ile Asn Val His Asp
                      325                      330                      335
Val Glu Thr Gln Phe Asn Gln Tyr Lys Thr Glu Ala Ala Ser Arg Tyr
                      340                      345                      350
Asn Leu Thr Ile Ser Asp Val Ser Val Ser Asp Val Pro Phe Pro Phe
                      355                      360                      365
Ser Ala Gln Ser Gly Ala Gly Val Pro Gly Trp Gly Ile Ala Leu Leu
                      370                      375                      380
Val Leu Val Cys Val Leu Val Ala Leu Ala Ile Val Tyr Leu Ile Ala
 385                      390                      395                      400
Leu Ala Val Cys Gln Cys Arg Arg Lys Asn Tyr Gly Gln Leu Asp Ile
                      405                      410                      415
Phe Pro Ala Arg Asp Thr Tyr His Pro Met Ser Glu Tyr Pro Thr Tyr
                      420                      425                      430
His Thr His Gly Arg Tyr Val Pro Pro Ser Ser Thr Asp Arg Ser Pro
                      435                      440                      445
Tyr Glu Lys Val Ser Ala Gly Asn Gly Gly Ser Ser Leu Ser Tyr Thr
                      450                      455                      460
Asn Pro Ala Val Ala Ala Thr Ser Ala Asn Leu
 465                      470

```

Fig. 12 (continued)

## SEQUENCE LISTING

&lt;110&gt; TRANSGENE SA et al.

&lt;120&gt; MUC-1 derived peptides

&lt;130&gt; D 2195 PCT

&lt;140&gt;

&lt;141&gt;

&lt;160&gt; 67

&lt;170&gt; PatentIn Ver. 2.1

&lt;210&gt; 1

&lt;211&gt; 1572

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (58)..(1542)

&lt;400&gt; 1

```

gaattccctg gctgcttgaa tctgttctgc cccctcccca cccatttcac caccacc      57

atg aca ccg ggc acc cag tct cct ttc ttc ctg ctg ctg ctc ctc aca      105
Met Thr Pro Gly Thr Gln Ser Pro Phe Phe Leu Leu Leu Leu Leu Thr
  1              5              10              15

gtg ctt aca gtt gtt aca ggt tct ggt cat gca agc tct acc cca ggt      153
Val Leu Thr Val Val Thr Gly Ser Gly His Ala Ser Ser Thr Pro Gly
              20              25              30

gga gaa aag gag act tcg gct acc cag aga agt tca gtg ccc agc tct      201
Gly Glu Lys Glu Thr Ser Ala Thr Gln Arg Ser Ser Val Pro Ser Ser
              35              40              45

act gag aag aat gct gtg agt atg acc agc agc gta ctc tcc agc cac      249
Thr Glu Lys Asn Ala Val Ser Met Thr Ser Ser Val Leu Ser Ser His
              50              55              60

agc ccc ggt tca ggc tcc tcc acc act cag gga cag gat gtc act ctg      297
Ser Pro Gly Ser Gly Ser Ser Thr Thr Gln Gly Gln Asp Val Thr Leu
              65              70              75              80

gcc ccg gcc acg gaa cca gct tca ggt tca gct gcc acc tgg gga cag      345
Ala Pro Ala Thr Glu Pro Ala Ser Gly Ser Ala Ala Thr Trp Gly Gln
              85              90              95

gat gtc acc tcg gtc cca gtc acc agg cca gcc ctg ggc tcc acc acc      393
Asp Val Thr Ser Val Pro Val Thr Arg Pro Ala Leu Gly Ser Thr Thr
              100              105              110

ccg cca gcc cac gat gtc acc tca gcc ccg gac aac aag cca gcc ccg      441
Pro Pro Ala His Asp Val Thr Ser Ala Pro Asp Asn Lys Pro Ala Pro
              115              120              125

ggc tcc acc gcc ccc ccg gcc cac ggt gtc acc tcg gcc ccg gac acc      489

```

2

Gly	Ser	Thr	Ala	Pro	Pro	Ala	His	Gly	Val	Thr	Ser	Ala	Pro	Asp	Thr	
130						135					140					
agg	ccg	ccc	ccg	ggc	tcc	acc	gcc	ccc	gcc	gcc	cac	ggg	gtc	acc	tcg	537
Arg	Pro	Pro	Pro	Gly	Ser	Thr	Ala	Pro	Ala	Ala	His	Gly	Val	Thr	Ser	
145					150					155					160	
gcc	ccg	gac	acc	agg	ccg	gcc	ccg	ggc	tcc	acc	gcc	ccc	ccg	gcc	cac	585
Ala	Pro	Asp	Thr	Arg	Pro	Ala	Pro	Gly	Ser	Thr	Ala	Pro	Pro	Ala	His	
				165					170						175	
ggg	gtc	acc	tcg	gcc	ccg	gac	aac	agg	ccg	gcc	ttg	ggc	tcc	acc	gcc	633
Gly	Val	Thr	Ser	Ala	Pro	Asp	Asn	Arg	Pro	Ala	Leu	Gly	Ser	Thr	Ala	
				180				185						190		
cct	cca	gtc	cac	aat	gtc	acc	tcg	gcc	tca	ggc	tct	gca	tca	ggc	tca	681
Pro	Pro	Val	His	Asn	Val	Thr	Ser	Ala	Ser	Gly	Ser	Ala	Ser	Gly	Ser	
		195					200					205				
gct	tct	act	ctg	gtg	cac	aac	ggc	acc	tct	gcc	agg	gct	acc	aca	acc	729
Ala	Ser	Thr	Leu	Val	His	Asn	Gly	Thr	Ser	Ala	Arg	Ala	Thr	Thr	Thr	
	210					215				220						
cca	gcc	agc	aag	agc	act	cca	ccc	agc	att	ccc	agc	cac	cac	tct	gat	777
Pro	Ala	Ser	Lys	Ser	Thr	Pro	Pro	Ser	Ile	Pro	Ser	His	His	Ser	Asp	
225					230					235					240	
act	cct	acc	acc	ctt	gcc	agc	cat	agc	acc	aag	act	gat	gcc	agt	agc	825
Thr	Pro	Thr	Thr	Leu	Ala	Ser	His	Ser	Thr	Lys	Thr	Asp	Ala	Ser	Ser	
				245					250						255	
act	cac	cat	agc	acg	gta	cct	cct	ctc	acc	tcc	tcc	aat	cac	agc	act	873
Thr	His	His	Ser	Thr	Val	Pro	Pro	Leu	Thr	Ser	Ser	Asn	His	Ser	Thr	
			260					265						270		
tct	ccc	cag	ttg	tct	act	ggg	gtc	tct	ttc	ttt	ttc	ctg	tct	ttt	cac	921
Ser	Pro	Gln	Leu	Ser	Thr	Gly	Val	Ser	Phe	Phe	Phe	Leu	Ser	Phe	His	
		275					280						285			
att	tca	aac	ctc	cag	ttt	aat	tcc	tct	ctg	gaa	gat	ccc	agc	acc	gac	969
Ile	Ser	Asn	Leu	Gln	Phe	Asn	Ser	Ser	Leu	Glu	Asp	Pro	Ser	Thr	Asp	
	290					295					300					
tac	tac	caa	gag	ctg	cag	aga	gac	att	tct	gaa	atg	ttt	ttg	cag	att	1017
Tyr	Tyr	Gln	Glu	Leu	Gln	Arg	Asp	Ile	Ser	Glu	Met	Phe	Leu	Gln	Ile	
305					310					315					320	
tat	aaa	caa	ggg	ggg	ttt	ctg	ggc	ctc	tcc	aat	att	aag	ttc	agg	cca	1065
Tyr	Lys	Gln	Gly	Gly	Phe	Leu	Gly	Leu	Ser	Asn	Ile	Lys	Phe	Arg	Pro	
				325					330					335		
gga	tct	gtg	gtg	gta	caa	ttg	act	ctg	gcc	ttc	cga	gaa	ggg	acc	atc	1113
Gly	Ser	Val	Val	Val	Gln	Leu	Thr	Leu	Ala	Phe	Arg	Glu	Gly	Thr	Ile	
			340					345					350			
aat	gtc	cac	gac	gtg	gag	aca	cag	ttc	aat	cag	tat	aaa	acg	gaa	gca	1161
Asn	Val	His	Asp	Val	Glu	Thr	Gln	Phe	Asn	Gln	Tyr	Lys	Thr	Glu	Ala	
		355					360				365					
gcc	tct	cga	tat	aac	ctg	acg	atc	tca	gac	gtc	agc	gtg	agt	cat	gtg	1209

Ala	Ser	Arg	Tyr	Asn	Leu	Thr	Ile	Ser	Asp	Val	Ser	Val	Ser	His	Val	
370						375					380					
cca	ttt	cct	ttc	tct	gcc	cag	tct	ggg	gct	ggg	gtg	cca	ggc	tgg	ggc	1257
Pro	Phe	Pro	Phe	Ser	Ala	Gln	Ser	Gly	Ala	Gly	Val	Pro	Gly	Trp	Gly	
385					390					395					400	
atc	gcg	ctg	ctg	gtg	ctg	gtc	tgt	ggt	ctg	ggt	gcg	ctg	gcc	att	gtc	1305
Ile	Ala	Leu	Leu	Val	Leu	Val	Cys	Val	Leu	Val	Ala	Leu	Ala	Ile	Val	
				405					410					415		
tat	ctc	att	gcc	ttg	gct	gtc	tgt	cag	tgc	cgc	cga	aag	aac	tac	ggg	1353
Tyr	Leu	Ile	Ala	Leu	Ala	Val	Cys	Gln	Cys	Arg	Arg	Lys	Asn	Tyr	Gly	
			420					425					430			
cag	ctg	gac	atc	ttt	cca	gcc	cgg	gat	acc	tac	cat	cct	atg	agc	gag	1401
Gln	Leu	Asp	Ile	Phe	Pro	Ala	Arg	Asp	Thr	Tyr	His	Pro	Met	Ser	Glu	
		435					440					445				
tac	ccc	acc	tac	cac	acc	cat	ggg	cgc	tat	gtg	ccc	cct	agc	agt	acc	1449
Tyr	Pro	Thr	Tyr	His	Thr	His	Gly	Arg	Tyr	Val	Pro	Pro	Ser	Ser	Thr	
	450					455					460					
gat	cgt	agc	ccc	tat	gag	aag	ggt	tct	gca	ggt	aat	ggt	ggc	agc	agc	1497
Asp	Arg	Ser	Pro	Tyr	Glu	Lys	Val	Ser	Ala	Gly	Asn	Gly	Gly	Ser	Ser	
465					470				475						480	
ctc	tct	tac	aca	aac	cca	gca	gtg	gca	gcc	act	tct	gcc	aac	ttg		1542
Leu	Ser	Tyr	Thr	Asn	Pro	Ala	Val	Ala	Ala	Thr	Ser	Ala	Asn	Leu		
				485				490						495		
taggggacg	tcgccctctg	agctgagtgg														1572

&lt;210&gt; 2

&lt;211&gt; 495

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

Met	Thr	Pro	Gly	Thr	Gln	Ser	Pro	Phe	Phe	Leu	Leu	Leu	Leu	Leu	Thr	
1				5					10						15	
Val	Leu	Thr	Val	Val	Thr	Gly	Ser	Gly	His	Ala	Ser	Ser	Thr	Pro	Gly	
			20					25					30			
Gly	Glu	Lys	Glu	Thr	Ser	Ala	Thr	Gln	Arg	Ser	Ser	Val	Pro	Ser	Ser	
		35					40					45				
Thr	Glu	Lys	Asn	Ala	Val	Ser	Met	Thr	Ser	Ser	Val	Leu	Ser	Ser	His	
	50					55					60					
Ser	Pro	Gly	Ser	Gly	Ser	Ser	Thr	Thr	Gln	Gly	Gln	Asp	Val	Thr	Leu	
65					70					75					80	
Ala	Pro	Ala	Thr	Glu	Pro	Ala	Ser	Gly	Ser	Ala	Ala	Thr	Trp	Gly	Gln	
				85					90					95		
Asp	Val	Thr	Ser	Val	Pro	Val	Thr	Arg	Pro	Ala	Leu	Gly	Ser	Thr	Thr	
			100					105					110			

Pro Pro Ala His Asp Val Thr Ser Ala Pro Asp Asn Lys Pro Ala Pro  
 115 120 125  
 Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr  
 130 135 140  
 Arg Pro Pro Pro Gly Ser Thr Ala Pro Ala Ala His Gly Val Thr Ser  
 145 150 155 160  
 Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His  
 165 170 175  
 Gly Val Thr Ser Ala Pro Asp Asn Arg Pro Ala Leu Gly Ser Thr Ala  
 180 185 190  
 Pro Pro Val His Asn Val Thr Ser Ala Ser Gly Ser Ala Ser Gly Ser  
 195 200 205  
 Ala Ser Thr Leu Val His Asn Gly Thr Ser Ala Arg Ala Thr Thr Thr  
 210 215 220  
 Pro Ala Ser Lys Ser Thr Pro Pro Ser Ile Pro Ser His His Ser Asp  
 225 230 235 240  
 Thr Pro Thr Thr Leu Ala Ser His Ser Thr Lys Thr Asp Ala Ser Ser  
 245 250 255  
 Thr His His Ser Thr Val Pro Pro Leu Thr Ser Ser Asn His Ser Thr  
 260 265 270  
 Ser Pro Gln Leu Ser Thr Gly Val Ser Phe Phe Phe Leu Ser Phe His  
 275 280 285  
 Ile Ser Asn Leu Gln Phe Asn Ser Ser Leu Glu Asp Pro Ser Thr Asp  
 290 295 300  
 Tyr Tyr Gln Glu Leu Gln Arg Asp Ile Ser Glu Met Phe Leu Gln Ile  
 305 310 315 320  
 Tyr Lys Gln Gly Gly Phe Leu Gly Leu Ser Asn Ile Lys Phe Arg Pro  
 325 330 335  
 Gly Ser Val Val Val Gln Leu Thr Leu Ala Phe Arg Glu Gly Thr Ile  
 340 345 350  
 Asn Val His Asp Val Glu Thr Gln Phe Asn Gln Tyr Lys Thr Glu Ala  
 355 360 365  
 Ala Ser Arg Tyr Asn Leu Thr Ile Ser Asp Val Ser Val Ser His Val  
 370 375 380  
 Pro Phe Pro Phe Ser Ala Gln Ser Gly Ala Gly Val Pro Gly Trp Gly  
 385 390 395 400  
 Ile Ala Leu Leu Val Leu Val Cys Val Leu Val Ala Leu Ala Ile Val  
 405 410 415  
 Tyr Leu Ile Ala Leu Ala Val Cys Gln Cys Arg Arg Lys Asn Tyr Gly  
 420 425 430



Gln Leu Asp Ile Phe Pro Ala Arg Asp Thr Tyr His Pro Met Ser Glu  
 435 440 445

Tyr Pro Thr Tyr His Thr His Gly Arg Tyr Val Pro Pro Ser Ser Thr  
 450 455 460

Asp Arg Ser Pro Tyr Glu Lys Val Ser Ala Gly Asn Gly Gly Ser Ser  
 465 470 475 480

Leu Ser Tyr Thr Asn Pro Ala Val Ala Ala Thr Ser Ala Asn Leu  
 485 490 495

<210> 3

<211> 9

<212> PRT

<213> Homo sapiens

<220>

<221> CDS

<222> (58)..(1542)

<400> 3

Ala Leu Gly Ser Thr Ala Pro Pro Val  
 1 5

<210> 4

<211> 9

<212> PRT

<213> Homo sapiens

<400> 4

Phe Leu Ser Phe His Ile Ser Asn Leu  
 1 5

<210> 5

<211> 9

<212> PRT

<213> Homo sapiens

<400> 5

Thr Leu Ala Pro Ala Thr Glu Pro Ala  
 1 5

<210> 6

<211> 9

<212> PRT

<213> Homo sapiens

<400> 6

Ser Leu Ser Tyr Thr Asn Pro Ala Val  
 1 5

<210> 7  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 7  
Ser Val Pro Val Thr Arg Pro Ala Leu  
1 5

<210> 8  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 8  
Gly Val Pro Gly Trp Gly Ile Ala Leu  
1 5

<210> 9  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 9  
Ala Pro Gly Ser Thr Ala Pro Pro Ala  
1 5

<210> 10  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 10  
Ala Val Ser Met Thr Ser Ser Val Leu  
1 5

<210> 11  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 11  
Ala Val Ala Ala Thr Ser Ala Asn Leu  
1 5

<210> 12  
<211> 9

<212> PRT  
<213> Homo sapiens

<400> 12  
Arg Pro Gly Ser Val Val Val Gln Leu  
1 5

<210> 13  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 13  
Val Pro Gly Trp Gly Ile Ala Leu Leu  
1 5

<210> 14  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 14  
Ser Ala Ser Gly Ser Ala Ser Thr Leu  
1 5

<210> 15  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 15  
Ser Ala Gly Asn Gly Gly Ser Ser Leu  
1 5

<210> 16  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 16  
Ala Leu Ala Val Cys Gln Cys Arg Arg  
1 5

<210> 17  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 17  
Gly Gln Leu Asp Ile Phe Pro Ala Arg

8

1 5

<210> 18  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 18  
Thr Leu Val His Asn Gly Thr Ser Ala Arg  
1 5 10

<210> 19  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 19  
Thr Thr Leu Ala Ser His Ser Thr Lys  
1 5

<210> 20  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 20  
Gly Val Thr Ser Ala Pro Asp Thr Arg  
1 5

<210> 21  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 21  
Gly Val Thr Ser Ala Pro Asp Asn Arg  
1 5

<210> 22  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 22  
Ile Tyr Lys Gln Gly Gly Phe Leu Gly Leu  
1 5 10

&lt;210&gt; 23

<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 23  
Phe Phe Leu Ser Phe His Ile Ser Asn Leu  
1 5 10

<210> 24  
<211> 10  
<212> PRT  
<213> Homo sapiens

<220>  
<221> CDS  
<222> (58)..(1542)

<400> 24  
Gly Phe Leu Gly Leu Ser Asn Ile Lys Phe  
1 5 10

<210> 25  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 25  
Tyr Tyr Gln Glu Leu Gln Arg Asp Ile Ser  
1 5 10

<210> 26  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 26  
Ile Ser Glu Met Phe Leu Gln Ile Tyr  
1 5

<210> 27  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 27  
Asp Val Glu Thr Gln Phe Asn Gln Tyr  
1 5

<210> 28  
<211> 10

10

<212> PRT  
<213> Homo sapiens

<400> 28  
Ser Leu Glu Asp Pro Ser Thr Asp Tyr Tyr  
1 5 10

<210> 29  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 29  
Ile Ser Glu Met Phe Leu Gln Ile Tyr Lys  
1 5 10

<210> 30  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 30  
Asn Ile Lys Phe Arg Pro Gly Ser Val  
1 5

<210> 31  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 31  
Thr Leu Ala Phe Arg Glu Gly Thr Ile  
1 5

<210> 32  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 32  
Gln Cys Arg Arg Lys Asn Tyr Gly Gln Leu  
1 5 10

<210> 33  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 33  
Glu Ala Ala Ser Arg Tyr Asn Leu Thr

1

5

<210> 34  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 34  
gccttgggct ccaccgccc tccagtc

27

<210> 35  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 35  
ttcctgtctt ttcacatttc aaacctc

27

<210> 36  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 36  
actctggccc cggccacgga accagct

27

<210> 37  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 37  
agcctctctt acacaaaccc agcagtg

27

<210> 38  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 38  
tcggtcccag tcaccaggcc agccctg

27

<210> 39  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 39  
ggggtgccag gctggggcat cgcgctg

27

<210> 40  
<211> 27

<212> DNA  
<213> Homo sapiens

<400> 40  
gccccgggct ccaccgcccc cccggcc 27

<210> 41  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 41  
gctgtgagta tgaccagcag cgtactc 27

<210> 42  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 42  
gcagtggcag ccacttctgc caacttg 27

<210> 43  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 43  
aggccaggat ctgtggtggt acaattg 27

<210> 44  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 44  
gtgccaggct ggggcatcgc gctgctg 27

<210> 45  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 45  
tctgcatcag gctcagcttc tactctg 27

<210> 46  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 46  
tctgcaggta atggtggcag cagcctc 27



<210> 47  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 47  
gccttggtg tctgtcagtg ccgccga 27

<210> 48  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 48  
gggcagctgg acatctttcc agcccgg 27

<210> 49  
<211> 30  
<212> DNA  
<213> Homo sapiens

<400> 49  
actctggtgc acaacggcac ctctgccagg 30

<210> 50  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 50  
accacccttg ccagccatag caccaag 27

<210> 51  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 51  
ggtgtcacct cggccccgga caccagg 27

<210> 52  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 52  
ggtgtcacct cggccccgga caacagg 27

<210> 53  
<211> 30  
<212> DNA  
<213> Homo sapiens

<400> 53  
atttataaac aaggggggttt tctgggcctc 30

<210> 54  
<211> 30  
<212> DNA  
<213> Homo sapiens

<400> 54  
tttttctctgt cttttcacat ttcaaacctc 30

<210> 55  
<211> 30  
<212> DNA  
<213> Homo sapiens

<400> 55  
ggttttcttgg gcctctccaa tattaagtcc 30

<210> 56  
<211> 30  
<212> DNA  
<213> Homo sapiens

<400> 56  
tactaccaag agctgcagag agacatttct 30

<210> 57  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 57  
atttctgaaa tgtttttgca gatttat 27

<210> 58  
<211> 30  
<212> DNA  
<213> Homo sapiens

<400> 58  
atttctgaaa tgtttttgca gatttataaa 30

<210> 59  
<211> 30  
<212> DNA  
<213> Homo sapiens

<400> 59  
tctctggaag atcccagcac cgactactac 30

<210> 60  
<211> 27

15

<212> DNA  
 <213> Homo sapiens

<400> 60  
 gacgtggaga cacagttcaa tcagtat 27

<210> 61  
 <211> 27  
 <212> DNA  
 <213> Homo sapiens

<400> 61  
 aatattaagt tcaggccagg atctgtg 27

<210> 62  
 <211> 27  
 <212> DNA  
 <213> Homo sapiens

<400> 62  
 actctggcct tccgagaagg taccatc 27

<210> 63  
 <211> 30  
 <212> DNA  
 <213> Homo sapiens

<400> 63  
 cagtgccgcc gaaagaacta cgggcagctg 30

<210> 64  
 <211> 27  
 <212> DNA  
 <213> Homo sapiens

<400> 64  
 gaagcagcct ctcgatataa cctgacg 27

<210> 65  
 <211> 9  
 <212> PRT  
 <213> Homo sapiens

<400> 65  
 Leu Leu Leu Thr Val Leu Thr Val Val  
 1 5

<210> 66  
 <211> 9  
 <212> PRT  
 <213> Homo sapiens

<400> 66  
 Ala Leu Gly Ser Thr Thr Pro Pro Ala  
 1 5

<210> 67  
 <211> 475  
 <212> PRT  
 <213> Homo sapiens

<400> 1

```

Met Thr Pro Gly Thr Gln Ser Pro Phe Phe Leu Leu Leu Leu Leu Thr
  1           5           10           15
Val Leu Thr Val Val Thr Gly Ser Gly His Ala Ser Ser Thr Pro Gly
      20           25           30
Gly Glu Lys Glu Thr Ser Ala Thr Gln Arg Ser Ser Val Pro Ser Ser
      35           40           45
Thr Glu Lys Asn Ala Val Ser Met Thr Ser Ser Val Leu Ser Ser His
      50           55           60
Ser Pro Gly Ser Gly Ser Ser Thr Thr Gln Gly Gln Asp Val Thr Leu
      65           70           75           80
Ala Pro Ala Thr Glu Pro Ala Ser Gly Ser Ala Ala Thr Trp Gly Gln
      85           90           95
Asp Val Thr Ser Val Pro Val Thr Arg Pro Ala Leu Gly Ser Thr Thr
      100           105           110
Pro Pro Ala His Asp Val Thr Ser Ala Pro Asp Asn Lys Pro Ala Pro
      115           120           125
Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr
      130           135           140
Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser
      145           150           155           160
Ala Pro Asp Asn Arg Pro Ala Leu Gly Ser Thr Ala Pro Pro Val His
      165           170           175
Asn Val Thr Ser Ala Ser Gly Ser Ala Ser Gly Ser Ala Ser Thr Leu
      180           185           190
Val His Asn Gly Thr Ser Ala Arg Ala Thr Thr Thr Pro Ala Ser Lys
      195           200           205
Ser Thr Pro Phe Ser Ile Pro Ser His His Ser Asp Thr Pro Thr Thr
      210           215           220
Leu Ala Ser His Ser Thr Lys Thr Asp Ala Ser Ser Thr His His Ser
      225           230           235           240
Thr Val Pro Pro Leu Thr Ser Ser Asn His Ser Thr Ser Pro Gln Leu
      245           250           255
Ser Thr Gly Val Ser Phe Phe Phe Leu Ser Phe His Ile Ser Asn Leu
      260           265           270
Gln Phe Asn Ser Ser Leu Glu Asp Pro Ser Thr Asp Tyr Tyr Gln Glu

```

275		280		285
Leu Gln Arg Asp Ile Ser Glu Met Phe Leu Gln Ile Tyr Lys Gln Gly				
290		295		300
Gly Phe Leu Gly Leu Ser Asn Ile Lys Phe Arg Pro Gly Ser Val Val				
305		310		315
Val Gln Leu Thr Leu Ala Phe Arg Glu Gly Thr Ile Asn Val His Asp				
		325		330
Val Glu Thr Gln Phe Asn Gln Tyr Lys Thr Glu Ala Ala Ser Arg Tyr				
		340		345
Asn Leu Thr Ile Ser Asp Val Ser Val Ser Asp Val Pro Phe Pro Phe				
		355		360
Ser Ala Gln Ser Gly Ala Gly Val Pro Gly Trp Gly Ile Ala Leu Leu				
		370		375
Val Leu Val Cys Val Leu Val Ala Leu Ala Ile Val Tyr Leu Ile Ala				
		385		390
Leu Ala Val Cys Gln Cys Arg Arg Lys Asn Tyr Gly Gln Leu Asp Ile				
		405		410
Phe Pro Ala Arg Asp Thr Tyr His Pro Met Ser Glu Tyr Pro Thr Tyr				
		420		425
His Thr His Gly Arg Tyr Val Pro Pro Ser Ser Thr Asp Arg Ser Pro				
		435		440
Tyr Glu Lys Val Ser Ala Gly Asn Gly Gly Ser Ser Leu Ser Tyr Thr				
		450		455
Asn Pro Ala Val Ala Ala Thr Ser Ala Asn Leu				
		465		470
				475

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 00/08761

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/47 C07K7/06 A61K38/17 A61K48/00  
G01N33/50 G01N33/53 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 50527 A (BIOMIRA INC (CA); AGRAWAL B; KRANTZ M.J; REDDISH M.A; LONGENECKER B.M.) 12 November 1998 (1998-11-12)	1-11, 13-22, 26,27, 29,30, 35-37
Y	page 8, line 9,10; figure 12A page 11, line 23,24 page 43; table III page 45, line 17; figure 9 page 47, line 5-18 claim 14 --- -/--	31,32

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

9 July 2001

Date of mailing of the international search report

23/07/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Macchia, G

## INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/EP 00/08761

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	AGRAWAL B. ET AL.: "In vitro induction of MUC-1 peptide-specific type 1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors" JOURNAL OF IMMUNOLOGY, vol. 157, no. 5, 1 September 1996 (1996-09-01), pages 2089-2095, XP002078857 ISSN: 0022-1767 page 2090	31,32
X	KAM J.L. ET AL.: "MUC1 synthetic peptide inhibition of intercellular adhesion molecule-1 and MUC1 binding requires six tandem repeats" CANCER RESEARCH, vol. 58, 1 December 1998 (1998-12-01), pages 5577-5581, XP002171171 page 5578; table 1 page 5580; figure 3B	1-7,17, 18,20,37
X	AGRAWAL B. ET AL.: "The anti-MUC1 monoclonal antibody BCP8 can be used to isolate and identify putative major histocompatibility complex class I associated amino acid sequences" CANCER RESEARCH, vol. 58, 15 November 1998 (1998-11-15), pages 5151-5156, XP002171172 page 5152; table 1 page 5155 -page 5156	1-7,17, 18,20,37
A		19
X	APOSTOLOPOULOS V. ET AL.: "MUC1 peptide epitopes associated with five different H-2 class I molecules" EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 27, October 1997 (1997-10), pages 2579-2587, XP001009768 page 2582 -page 2583; figures 2B,4A,5B,6A; table 1 page 2585; table 3 page 2587	1-7, 17-22, 26,27, 29,30, 35-37
X	APOSTOLOPOULOS V. ET AL.: "Anti-MUC1 antibodies react directly with MUC1 peptides presented by class I H2 and HLA molecules" THE JOURNAL OF IMMUNOLOGY, vol. 161, 1998, pages 767-775, XP002171173 page 768, right-hand column -page 769; figure 1B	1-7,17, 18,20, 26,27, 29,30, 35-37
	--- -/--	

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/08761

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	APOSTOLOPOULOS V. ET AL.: "Induction of HLA-A2-restricted CTLs to the Mucin 1 human breast cancer antigen" THE JOURNAL OF IMMUNOLOGY, vol. 159, 1997, pages 5211-5218, XP002171238 page 5213, right-hand column, paragraph 2 page 5215; figure 3A ---	1-7, 17-22, 26,27, 29,30, 35-37
X	EP 0 369 816 A (UNIV MELBOURNE (AU); XING PEI-XIANG; MCKENZIE IAN FARQUHAR CAMPBELL) 23 May 1990 (1990-05-23) page 10, line 24-49, paragraph 2.4 page 15; table 2 page 4, column 37 -page 5, column 18 page 20; claims 22,24,25 ---	1-7, 17-22,37
X	XING PEI-XIANG ET AL.: "Synthetic peptides reactive with anti-human milk fat globule membrane monoclonal antibodies" CANCER RESEARCH, vol. 50, no. 1, 1 January 1990 (1990-01-01), pages 89-96, XP001010017 page 90; table 1 page 93, right-hand column -page 94; figures 5,6 page 93 -page 94; figures 5,6 ---	1-7,17, 18,20,37
X	DOMÉNECH N. ET AL.: "Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen Mucin" THE JOURNAL OF IMMUNOLOGY, vol. 155, 1995, pages 4766-4774, XP002171174 page 4767; figure 1 page 4770; table I ---	1-7,17, 18,20, 26,27, 29,30,37
X	NISHIMORI I. ET AL.: "N-Acetylgalactosamine glycosylation of MUC1 tandem repeat peptides by pancreatic tumor cell extracts" CANCER RESEARCH, vol. 54, 15 July 1994 (1994-07-15), pages 3738-3744, XP002171175 page 3741 -page 3742; figures 3,5 --- -/--	1-7,17, 20



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/08761

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>WO 00 06723 A (YEDA RES DEV CO LTD WEIZMANN INST SCI (IL) BIO-TECHNOLOGY GEN CORP (US) 10 February 2000 (2000-02-10)</p> <p>SEQ ID NO:43,44,47 page 4, line 35,36 page 40, line 9 -page 42, line 38; figures 18-22; example 4 page 54 -page 59; claims</p>	<p>1-4, 17-22, 26,27, 29,30, 35-37</p>
P, X	<p>CARMON L. ET AL.: "Novel breast-tumor-associated Muc1-derived peptides: characterization in Db-/- X beta2 microglobulin (beta2m) null mice transgenic for a chimeric HLA-A2.1/Db-beta2 microglobulin single chain" INTERNATIONAL JOURNAL OF CANCER, vol. 85, no. 3, 1 February 2000 (2000-02-01), pages 391-397, XP001009767 page 393, left-hand column; table I</p>	<p>1-4, 17-22, 26,27, 29,30, 35-37</p>
P, X	<p>PIETERSZ G.A. ET AL.: "Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1" VACCINE, vol. 18, no. 19, April 2000 (2000-04), pages 2059-2071, XP004202504 ISSN: 0264-410X page 2065, right-hand column, paragraph 1 page 2066; table 3 page 2068, left-hand column, paragraph 1 page 2069; table 4</p>	<p>1-4,17, 18,20, 26,27, 29,30, 36,37</p>
A	<p>BROSSART P. ET AL.: "Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies" BLOOD, vol. 93, no. 12, 15 June 1999 (1999-06-15), pages 4309-4317, XP002147432 ISSN: 0006-4971 page 4311; table 1</p>	<p>31,32</p>

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/08761

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9850527 A	12-11-1998	AU 727863 B AU 7371298 A EP 0986636 A	04-01-2001 27-11-1998 22-03-2000
EP 0369816 A	23-05-1990	CA 2003211 A JP 2273195 A ZA 8908777 A	17-05-1990 07-11-1990 28-12-1990
WO 0006723 A	10-02-2000	AU 5062999 A EP 1100901 A	21-02-2000 23-05-2001